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Abstract 
 
The use of cationic liposomes to deliver nucleic acids has shown great promise; 
however, their therapeutic potential is greatly limited by their in vivo instability. Upon 
systemic administration, cationic liposomes are prone to plasma protein adsorption, 
leading to RES recognition and rapid clearance from blood circulation. Surface 
modification using hydrophilic polymers, usually PEG, is known to prolong the 
circulation half-lives of liposomes in vivo. PEG is required for increased liposome 
stability, but it is undesirable once at a target tissue since its presence significantly 
inhibits the release of the encapsulated agent. The development of cleavable PEG that 
can be removed in response to a specific trigger once at the target site may be one 
strategy to overcome this problem.      
 
Here, we report the development of PEGylated peptide-lipid conjugates sensitive to the 
proteolytic enzymes found in tumour cells, HLE and MMP-2. The synthesis was carried 
out by conjugating an enzyme substrate peptide between PEG and a lipid, enabling a 
series of enzyme-sensitive PEGylated peptide-lipid conjugates to be used for liposomal 
nucleic acid delivery. Although enzymatic degradation of the peptide linker resulting in 
the detachment of PEG was not observed with the analytical techniques used, the in 
vitro result showed enhanced pDNA transfection efficiency by the nanoparticles 
containing the PEGylated peptide-lipid conjugates in response to the enzymes, 
compared to the controls. Physicochemical characterisation showed the nanoparticles 
have small diameters and high nucleic acid encapsulation efficiency. The nanoparticles 
with lower zeta potential were found to exhibit enhanced stability in serum and 
minimum toxicity.    
 
Further investigation in a siRNA system revealed the ability of the PEGylated peptide-
lipid nanoparticles to significantly knockdown the target protein in response to 
enzymatic activation. Thus, the results from these studies demonstrated the possibility 
of using the enzyme-sensitive PEGylated peptide-lipid conjugates to improve nucleic 
acid delivery.  
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1.1 Gene therapy 
 
Gene therapy is defined as the delivery of genetic material into cells for therapeutic 
purposes, either by replacing an existing defective gene with a therapeutic one, or by 
knockdown of disease-associated proteins. Gene therapy was initially aimed at treating 
inheritable diseases such as cystic fibrosis, adenosine deaminase deficiency, 
Gaucher’s disease, and Duchenne muscular dystrophy.1 However, as the field has 
grown, its potential for treating acquired diseases – in particular, cancer – has been 
realised and has gained increasing attention over the past two decades. Cancer is a 
term for diseases in which abnormal cells proliferate in an uncontrollable manner and 
have the ability to invade other tissues and spread to distant sites through the 
bloodstream (metastasis) (http://www.cancerresearchuk.org/). It is a leading cause of 
death worldwide. According to the World Health Organisation (WHO), 13% of all deaths 
in 2007 were caused by cancer; in that same year, the American Cancer Society 
reported total global deaths due to cancer of 7.6 million 
(http://www.cancer.org/Research/CancerFactsFigures/index). For several decades, 
chemotherapy has been a predominant option for cancer treatment; however, it is 
associated with a number of drawbacks, including toxicity and poor bioavailability of 
anticancer agents. Non-specific distribution of chemotherapeutic drugs causes 
undesirable side effects on healthy tissues and also results in reduced quantities of 
drug accumulating at tumour sites, often to below therapeutic concentrations. 
Degradation of anticancer drugs before arriving at tumour sites, and drug resistance 
developed by the tumour cells, decreases their therapeutic efficiency. To increase 
bioavailability, administration of drugs in larger doses is required, which can further 
increase toxicity. In addition, the repeated use of chemotherapeutic agents is limited by 
toxicity. Doxorubicin is one of the most well-known anticancer drugs which has limited 
application due to its toxic side effects on the heart (cardiotoxicity) and on bone marrow 
activity (myelosuppression).2, 3 To improve its safety profile, this has led to the 
development of PEGylated liposomal doxorubicin in which doxorubicin is contained in 
PEGylated liposomes (Doxil/Caelyx). Doxil has shown better accumulation in tumours 
than in normal cells and reduced toxicity compared to free doxorubicin.4, 5 Abraxane, 
albumin-bound nanoparticles of paclitaxel (a highly hydrophobic anticancer drug), was 
approved by the US Food and Drug Administration (FDA) in 2005 for treating 
metastatic breast cancer, showing higher efficiency in breast cancer treatment with 
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fewer toxic effects compared to paclitaxel on its own.6 These examples highlight the 
need to develop suitable delivery systems for efficient cancer treatments that enhance 
drug integrity, improve their bioavailability, and minimise their side effects and toxicity. 
 
Cancer arises as a result of abnormalities or mutations occurred in the DNA sequence. 
The Cancer Genome Project’s success in identifying a large number of cancer genes 
(oncogenes) provides insight into the origins of cancer and suggests potential new 
avenues for treatment.7, 8 Cancer gene therapy, referring to the use of therapeutic 
nucleic acids to enhance the expression of tumour suppressors or to knockdown the 
expression of oncogenic proteins, may provide an effective and specific treatment, 
attacking the disease at its root cause. The use of RNA interference (RNAi) technology, 
including small interfering ribonucleic acid (siRNA) and microRNA (miRNA), to silence 
gene expression has recently gained the attention of many researchers. Its ability to 
render specific gene knockdown has led to the possibility of its use as a cancer 
therapy. siRNA-based formulations have been intensively studied and some are being 
investigated in clinical trials. ALN-VSP02, a stable nucleic acid lipid particle (SNALP) 
formulation containing two siRNAs directed against kinesin spindle protein (KSP) and 
vascular endothelial growth factor (VEGF), is currently being employed by Alnylam in a 
phase I clinical trial for the treatment of hepatocellular carcinoma (HCC) 
(http://clinicaltrials.gov).  CALAA-01, cyclodextrin-based nanoparticles, has been 
developed by Calando to deliver the M2 subunit of the ribonucleotide reductase 
(RRM2) siRNA to solid tumours. RRM2 is involved in DNA replication process and 
inhibition of its activity has shown to reduce the growth of cancer cells.9 These 
nanoparticles are currently being studied in a phase I clinical trial.10 Finally, the 
restoration of metastasis suppressor miRNA-126 in human breast cancer in vivo was 
shown to reduce tumour growth and proliferation.11         
 
Systemic administration of nucleic acids into blood circulation usually results in low 
efficiency of gene transfer due to the rapid degradation of nucleic acids by serum 
nucleases and their clearance by the mononuclear phagocyte system. The 
development of carriers that can selectively and efficiently deliver the nucleic acid 
therapeutics to target cells has been key to the success of genetic therapies. The types 
of carriers currently being studied fall into two categories: viral and nonviral. Viral 
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carriers have been the most effective delivery method for gene therapy due to their 
inherent ability to efficiently infect and transfer genetic material into host cells. To 
ensure safe gene transfer and avoid subsequent pathogenic effects, viral vectors 
derived from microorganisms (known as ‘wild type’) must have been modified by 
deleting their pathogenic genes, which are critical for viral replication, and replacing 
them with therapeutic foreign genes. Examples of viruses that have been developed for 
gene therapy include retroviruses12, adenoviruses13, adeno-associated viruses14 and 
herpes simplex viruses15. These carriers are currently the most studied vectors in gene 
therapy clinical trials owing to their efficient gene transfer into a wide variety of cells 
(Figure 1-1).  
  
 
   
 
Figure 1-1: Overview of vectors used in gene therapy clinical trials worldwide. Updated 
information available from The Journal of Gene Medicine Clinical Trial Database: 
http://www.wiley.com/legacy/wileychi/genmed/clinical/ 
 
Despite the success of viral vectors, many hurdles remain to be overcome before they 
can be extensively used in gene therapy applications. The major obstacles associated 
with viral carriers include toxicity and immunogenicity16, random integration into host 
genomes and oncogenic effects17, long-termed transgene expression16, size limitations 
for transgene insertion18, and ease of carrier preparation. These limitations, safety 
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concerns in particular, have led to the increased development of alternative carriers. 
Nonviral carriers, referring to the delivery of genes using either physical or chemical 
approaches, have advantages over viral vectors: low toxicity, ease of large-scale 
production, and simplicity of use. In the gene delivery history, nonviral vectors can be 
divided into two broad categories: delivery of nucleic acids by physical methods, such 
as gene guns and electroporation; and delivery of nucleic acids by chemical methods, 
such as protein-based, polymer-based, and liposome-based carriers. 
  
1.2 Nonviral carriers 
 
1.2.1 Delivery of nucleic acids by physical methods    
 
1.2.1.1 Gene guns 
 
Particle-mediated gene delivery, called “gene guns”, involves the bombardment of 
tissues or cells by DNA-coated gold particles which are accelerated either by a high 
voltage electric discharge or pressurised helium pulse.19 These gold particles are 
typically 0.5-2.0 m in diameter. Owing to their small sizes, this approach allows the 
direct penetration of the microcarriers into cytoplasm, bypassing the 
endosomal/lysosomal membrane, thus diminishing the degradation of DNA by nuclease 
enzymes. Successful transfection in subcutaneous tumours and muscles has been 
demonstrated using this delivery method, without apparent toxicity.19 Although the 
technique has demonstrated advantages in gene therapy applications – such as ease 
of DNA microparticle production, controllable dosing of delivered DNA, and no 
observable toxicity – it is limited by short-term gene expression, low efficiency of 
transfection, and ability to deliver DNA to only small areas. 
 
1.2.1.2 Electroporation 
 
Electroporation, also known as electropermeabilisation, is the combination of naked 
DNA injection along with a pulsed, controlled electric field that facilitates nucleic acid 
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uptake into cells.20 Applied electric pulses open pores in the cell membrane, permitting 
macromolecules to pass through the membrane into the cell interior. The pores close 
after initial permeabilisation, and DNA is trapped inside the cells. Compared to injection 
of naked DNA without electric pulses, this technique increases gene expression in 
melanoma cells up to 21- to 42-fold.21 Transfection of the p53 gene by electroporation 
was able to suppress tumour growth.22 The gene expression, however, was limited to 
only the central part of the xenografts and multiple electroporations were therefore 
required in order to obtain apparent retardation of the tumour growth. Although the 
technique has shown great promise in nucleic acid delivery, the conditions of delivery, 
such as DNA dose, physical arrangement of electrodes, electrical field strength, and 
duration of electrical pulses, need to be well-optimised in order to achieve high 
transfection efficiency and long-term gene expression with minimum damage to target 
tissues and low toxicity.  
 
Other techniques, such as hydrodynamic injection23 and ultrasound24 has also shown 
an improvement in gene expression compared to the delivery of naked DNA. The 
physical methods may be efficient in local delivery of nucleic acids but they are limited 
to target cells that are at remote sites, such as metastasised tumours. The use of 
synthetic carriers may provide a more viable approach toward effective cancer 
treatment. 
   
1.2.2   Delivery of nucleic acids by chemical methods 
 
1.2.2.1 Protein-based carriers 
 
One example of a protein-based carrier is atelocollagen, a pepsin-digested product of 
type I collagen from which a telopeptide, an amino acid sequence attributed to 
collagen’s antigenicity, is removed (Scheme 1-1).25 Atelocollagen therefore possesses 
low immunogenicity. Generally, atellocolagen is obtained from pepsin digestion of 
bovine demis. Due to its isoelectric point (pI) above 8, atellocollagen possesses 
positive charge at physiological pH, and can electrostatically interact with nucleic acids, 
such as plasmid DNA, antisense oligonucleotides (antisense ODNs), and short 
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interfering RNA (siRNA). At low temperature, atellocollagen is in liquid state and can 
easily mix with nucleic acids; however, at physiological temperature, it becomes fibrous 
and solid, protecting nucleic acids from nuclease digestion and thereby enhancing 
circulation times in vivo. Delivery of anti-VEGF siRNA by atelocollagen showed 
suppression of both tumour angiogenesis and tumour growth.26 In addition, effective 
gene silencing in bone-metastatic tumours using atelocollagen-mediated siRNA 
delivery has been demonstrated with no observable side effects.27  
 
 
 
Scheme 1-1: Atelocollagen production, resulting from triple helix collagen, with 
immunogenic telopeptides removed by enzyme reaction. Modified from Sano et al., 
Adv. Drug Deliv. Rev., 2003, 55, 1651-1677.  
 
Protein-based carriers have been a preferred option for gene delivery due to their low 
immunogenicity, biocompatibility, and biodegradability. However, chemical 
manipulations of the proteins are not easy, limiting their potential for functionalisation, 
such as the incorporation of targeting ligands, which could improve the efficacy of this 
delivery system. The vectors capable of chemical modifications – for example, 
polymers and liposomes – are more widely used for gene therapy applications.  
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1.2.2.2 Polymer-based carriers 
 
Polymers exhibit good potential as gene delivery vectors owing to their ease of 
preparation and chemical modification, providing flexibility for development according to 
their application. Polymer-based vectors are made to carry positive charge, which 
allows them to interact electrostatically with negatively charged nucleic acids and form 
stable nanoparticles known as polyplexes. One of the first polymers employed for gene 
therapy was poly (L-lysine) (PLL) (Figure 1-2). PLL is a linear polypeptide with a 
repeating unit of amino acid lysine, thus possessing biodegradable properties, which is 
an advantage for in vivo applications. However, PLL vectors have limited use as 
transfection agents due to their relatively poor level of gene expression and cytotoxic 
side effects. The inclusion of additional agents, or further synthetic modification, is 
usually required to improve transfection efficiency and reduce cytotoxicity.28, 29  
 
 
 
Figure 1-2: Structure of poly (L-lysine) (PLL) 
 
A more versatile polymeric vector is poly (ethylene imine) (PEI) (Figure 1-3), which is a 
synthetic linear or branched polymer with varying molecular weight.30 It bears a high 
cationic charge density, which allows for strong binding to nucleic acids. Low molecular 
weight PEI (5-25 kDa) is considered the most suitable for gene transfer as it has been 
shown to be less toxic compared to higher molecular weight PEI, and is yet still capable 
of transfection.31 The increased cytotoxicity associated with high molecular weight is 
probably due to the precipitation of cationic polymers in huge clusters that adhere to the 
outer cell membrane, which leads to necrosis.32, 33 PEI (22 kDa) coupled to targeting-
ligand transferin (Tf) showed enhanced gene expression in tumours and lowered 
toxicity compared to 800 kDa PEI.34 Linear PEI of low molecular weight is already 
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commercially available as transfection agents, including ExGen500 (Fermentas) and 
jetPEI (Polyplus Transfection).  
 
 
 
Figure 1-3: Structure of linear poly (ethylene imine) (PEI) 
 
Although the toxicity of PEI appears to decrease with decreasing polymer size, total 
lack of toxicity would be an ideal characteristic for gene delivery vectors. The recent 
development of analogous biodegradable polymers has gained much attention. Unlike 
non-biodegradable PEI, degradable polymers decompose to low molecular weight 
constituents in cytosol and hence facilitate the release of nucleic acids, resulting in 
lower toxicity and higher transfection efficiency. Forrest et al. reported that 
biodegradable PEI derivatives, synthesised by coupling 800 Da PEIs via short 
diacrylate linkages, of which ester bonds are susceptible to hydrolysis at physiological 
condition and in acidic environment of endosomes, to form conjugates of 14-30 kDa. 
The degradable PEI enhanced gene expression 2- to 16-fold (depending on cell lines) 
compared to 25 kDa, nondegradable PEI, and showed minimal toxicity.35 siRNA 
delivery using a biodegradable poly (amido ethyleneimine), containing multiple disulfide 
bonds which can be cleaved by cytosolic glutathione, demonstrated higher gene 
suppression than that of 25-kDa PEI, with a more favourable toxicity profile.36  
 
Another well-characterised polymer is cyclodextrin-containing polymer. Cyclodextrins 
are cup-shaped, cyclic oligosaccharides comprising 6, 7 or 8 glucose units (Figure 1-4), 
obtained by degradation of starch by mean of enzymatic conversion.37 They have 
several characteristics that are beneficial for gene delivery including low toxicity, lack of 
immune stimulation, and biocompatibility. The cyclodextrin-based polymer is a short 
polycation that can assemble with nucleic acids via electrostatic interactions, resulting 
in the encapsulation of nucleic acids within their hydrophilic cores. In addition, via van 
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de Waal’s interactions, the cavities within cyclodextrins can form inclusion complexes 
with small hydrophobic molecules, such as adamantane (AD). Davis et al. utilized this 
feature to develop a new class of cyclodextrin-based polymer in that the cyclodextrin 
was part of the linear polymer backbone and the cores within cyclodextrins that reside 
on the nanoparticle surface were used for inclusion of AD-PEG and AD-PEG-Tf 
conjugate for steric stabilisation and tumour-targeting effect (Figure 1-5). 38  The 
surface modified cyclodextrin-containing polymer was shown to be an effective and 
versatile method of both DNA and siRNA delivery in vitro.39 The efficacy of the 
cyclodextrin-containing polycations for siRNA delivery was also demonstrated in vivo, 
showing efficient silencing of oncogenes, inhibition of tumour growth, and the possibility 
of multiple dose administration.38, 40, 41 In addition, the particles were well-tolerated in 
non-human primates and no sign of immune response was observed. A targeted, 
cyclodextrin polymer-based nanoparticle formulation of siRNA, known as CALAA-01, 
developed by Calando Pharmaceuticals has recently reached phase I clinical trial.41 
The interim results of this trial demonstrate that systemic administration of anti-RRM2 
siRNA in patients with melanomas can produce specific gene silencing, shown by a 
reduction in both RRM2 (the M2 subunit of ribonucleotide reductase) mRNA and the 
translated protein.10 This finding is the first to provide mechanistic evidence of RNAi in 
humans by the detection of mRNA fragments as a result of siRNA-mediated specific 
mRNA cleavage.    
 
 
 
Figure 1-4: Representation of cyclodextrin and its cup-shaped structure 
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a) 
 
 
b) 
 
 
 
Figure 1-5: Illustration of cyclodextrin-based delivery system developed by Davis et al. 
a) chemical structure of cyclodextrin-containing polymer (CDP) in which cyclodextrin is 
conjugated as part of the linear polymer backbone (n = 5-6).42 b) (left) delivery 
components including CDP, siRNA, Adamantane (AD)-PEG conjugate (AD-PEG), and 
AD-PEG conjugated to targeting-ligand transferin (Tf) (AD-PEG-Tf), (middle) self-
assembled nanoparticles containing siRNA and (right) nanoparticles entering the cell 
via receptor-mediated endocytosis.41 
 
The natural origin polymer chitosan is gaining increasing interest as a gene delivery 
vector due to its biodegradability, biocompatibility, and non-toxicity. It is a natural, linear 
polysaccharide produced by the deacetylation of chitin, a polysaccharide found in the 
exoskeletons of crustaceans and insects (Figure 1-6).30 It possesses a high cationic 
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charge, providing a strong electrostatic interaction with nucleic acids. Numerous reports 
have demonstrated efficient gene delivery using chitosan/DNA nanoparticles.43-45 The 
potential of chitosan-mediated siRNA delivery highlighted by the work of Howard et al. 
showed effective gene silencing both in vitro and in vivo.46 However, transfection 
efficiency seems to depend on several factors: for example, the molecular weight of 
chitosan, the charge ratio of chitosan to nucleic acids, and transfection conditions.44, 47 
Optimisation of these factors is different for different types of cells. 
 
 
 
Figure 1-6: Structure of chitosan 
 
Other polymers, such as block copolymers and dendrimers, are also being investigated 
as efficient vehicles for gene delivery. One example of a block copolymer is poly (lactic-
co-glycolic acid) (PLGA), which has been approved by the FDA as safe for human 
use48 (Figure 1-7). PLGA is a biodegradable copolymer obtained by the co-
polymerisation of two different monomers, lactic acid and glycolic acid, which are linked 
together by ester bonds. PLGA-mediated delivery has shown increased in vitro 
transfection efficiency as well as sustained release of DNA.49 Murata et al. recently 
demonstrated suppression of tumour growth and sustained suppressive effect after 
intratumoural injection by PLGA microspheres encapsulating anti-VEGF siRNA.50 
Administration of PLGA nanoparticles loaded with siRNA to the reproductive tracts of 
female mice has also shown a significant level of gene knockdown and sustained gene 
silencing for at least 14 days.51 
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Figure 1-7: Structure of poly (lactic-co-glycolic acid) (PLGA), where m= number of units 
of lactic acid, n= number of units of glycolic acid. 
 
Dendrimers are spherical, highly branched polymers. One of the most commonly used 
dendrimers for nucleic acid delivery is polyamidoamine (PAMAM). PAMAM contains a 
high density of amine, enabling electrostatic condensation of nucleic acids. 
Transfection efficiency appears to depend on the size and shape of the dendrimers.52 
The modified dendrimers have been shown to enhance transfection efficiency and gene 
silencing in mammalian cell lines.53, 54 
 
1.2.2.3 Liposome-based carriers 
 
Liposomes are composed of amphiphilic lipids that, upon hydration, self-assemble into 
spherical bilayers enclosing an aqueous compartment. Amphiphilic lipids have both 
hydrophilic and hydrophobic regions in the same molecules. In an aqueous 
environment, lipids arrange themselves in order to minimise hydrophobic interaction 
and maximise hydrophilic interaction with aqueous phase, resulting in a variety of self-
assemblies depending on geometrical structures and the concentration of the lipids in 
solution. Lipids involved in liposome preparation usually have a cationic head group on 
the hydrophilic region, allowing for nucleic acid encapsulation within the inner core of 
the liposome via electrostatic interaction (Figure 1-8). Liposomes, like polymer-based 
vectors, are capable of condensing nucleic acids; however, they have several 
advantages over cationic polymers as gene delivery carriers. The physical properties of 
liposomes, such as their size, surface charge, and the rigidity of bilayers, can be simply 
manipulated by adding and tuning lipid compositions according to their application. In 
addition, functionalisation of liposomes – including incorporation of stealth layers, 
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targeting ligands, fluorescent probes, and metallic-lipid amphiphiles, for stabilisation, 
targeting, tracking, and imaging purposes – can be easily performed. The organisation 
of all these functional molecules is feasible on a liposome and the resulting assembly is 
usually a nanoparticle. These features allow greater flexibility of nanoparticle design 
compared to polymers. Another attractive advantage of liposomes is their low toxicity 
and immunogenicity. Since liposomes are composed of lipid or amphiphile constituents 
which resemble cell membranes, they are biocompatible and easily cleared from cells 
after cellular uptake.55 Liposomes have been shown to be more versatile as carriers for 
nucleic acid delivery compared to the other delivery systems described above. 
 
 
 
Figure 1-8: Representation of liposome formation and nucleic acid encapsulation. 
Amphiphilic lipids self-assemble into liposomes and nucleic acids can then be 
electrostatically entrapped within the aqueous compartment of liposomes.   
 
Liposomes are typically categorised by their size and the number of lamellars or 
bilayers. Liposomes composed of multiple bilayers are termed multilamellar vesicles 
(MLV) and are typically larger than 500 nm in diameter. Liposomes that consist of a 
single bilayer are termed unilamellar vesicles (ULV). Their size ranges between 50-500 
nm for large unilamellar vesicles (LUV) and 20-50 nm for small unilamellar vesicles 
(SUV).56 Diameters of liposomes are typically determined using dynamic light 
scattering.  
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Traditionally, liposomes have been used as drug carriers by encapsulating hydrophilic 
drugs in their core in order to improve drug pharmacokinetics.57-59 A numbers of 
liposomal drugs have been approved and some are in clinical trials. The potential of 
liposomes as efficient carriers for nucleic acid delivery was first recognised when 
Felgner et al. published their study in 1987.60 The authors demonstrated successful in 
vitro DNA transfection with the use of cationic lipid 1,2-di-O-octadecenyl-3-
trimethylammonium propane hydrochloride (DOTMA) and neutral phospholipid 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) in a 1:1 molar ratio. Following its 
success in DNA delivery, this lipid formulation became commercially available under 
the trade name Lipofectin.61, 62 A more recently developed liposome-based 
transfection agent is Lipofectamine, which has been widely used in several biological 
protocols. Cationic liposomes composed of cationic lipid 1,2-dioleoyl-3-
trimethylammonium propane (DOTAP) and neutral lipid cholesterol has also shown 
efficient transgene expression in tumour cells both in vitro and in vivo.63 Liposome-
based delivery systems have been extensively studied and some formulations of 
cationic liposome/DNA nanoparticles – for example, Allovectin-7 – are being 
investigated in phase II clinical trials in patients with metastatic melanomas.64 The use 
of liposomes to mediate siRNA delivery has shown great promise for cancer gene 
therapy in recent years. Many publications have reported successful inhibition of 
tumour growth by siRNA-containing nanoparticles.65-69 Currently being investigated in 
phase I clinical trial is Atu-027, a liposomal formulated 2’-O-methyl modified siRNA 
directed against protein kinase N3 (PKN3), which has been identified as a downstream 
effector of the phosphoinositide-3-kinase (PI3K) signalling pathway, and is involved in 
tumour angiogenesis and development.70 Preclinical data regarding the use of this 
formulation in mouse models of prostate and pancreatic tumours showed significant 
inhibition of tumour growth and reduction of lymph node metastasis.71 
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1.3 Barriers to liposome delivery to tumours 
 
One major problem associated with the delivery of nanoparticles is that they are treated 
as foreign molecules by the body and subsequently cleared out of circulation before 
they can complete their therapeutic function. Understanding biological barriers 
encountered in the delivery process is essential for the design of viable nanocarriers. 
The hurdles to successful delivery of therapeutic nucleic acids in vivo can be divided 
into two categories: extracellular barriers and intracellular barriers. Extracellular barriers 
describe the obstacles that nanoparticles meet after administration into blood 
circulation, up to their arrival at the tumour site. Intracellular barriers refer to obstacles 
faced after cellular internalisation, up to the release of the encapsulated agent inside 
the cell. The details of these biological barriers are described below. 
. 
1.3.1 Extracellular barriers   
 
One of the unique anatomical and pathophysiological characteristics of tumours is their 
abnormal vasculature. Unlike normal blood vessels, tumour vasculatures are not 
uniform: they are leaky and their endothelial cells are disorganised with large 
fenestrations (Figure 1-9).72, 73 These defective architectures are a result of 
angiogenesis, the formation of new blood vessels from the existing microvascular beds 
due to elevated levels of vascular mediators such as vascular endothelial growth factor 
(VEGF). Angiogenesis occurs when the tumour reaches a size of 2-3 mm, supplying 
nutrients and oxygen to the growing tumour.74 The leaky vasculatures allow passive 
transport of circulating nanoparticles, a process termed extravasation, into tumour 
interstitium. This, combined with impaired lymphatic drainage in tumours, allows 
enhanced accumulation and retention of nanoparticles in solid tumours, and is known 
as the enhanced permeability and retention (EPR) effect73, 75, which was initially 
described by Maeda et al. in 1986.76  It was found that the maximum nanoparticle size 
that can cross vasculature fenestrations in tumours is around 400 nm 77, so only 
nanoparticles with diameters up to 400 nm can extravasate into tumour tissues. 
Nanoparticles less than 200 nm in diameter were shown to effectively accumulate in 
tumours.78-81 Nanoparticles less than 100 nm in diameter were susceptible to uptake by 
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hepatocytes due to their ability to penetrate through hepatic fenestrations and interact 
with hepatocytes.78, 82 This established the significance of nanoparticle diameter in 
tumour accumulation: nanoparticle size is a key consideration of optimal design.  
 
 
 
Figure 1-9: A schematic representation of nanoparticles’ localisation to tumour tissues 
by the enhanced permeability and retention (EPR) effect. Nanoparticles are unable to 
diffuse through normal vasculature due to the tight junction of endothelial cells, while 
leaky vasculatures in tumours enhance extravasation and increase accumulation of 
nanoparticles, contributing to the EPR effect. Modified from Lyer et al., Drug Discov. 
Today, 2006, 11 (17-18), 812-818.  
 
In biological fluids, nanoparticles are exposed to high concentrations of salt and various 
plasma proteins in the bloodstream. Such conditions can dramatically alter the stability 
of the nanoparticles. Adsorption of plasma protein on the surface of the nanoparticles, 
specifically high-charge particles, leads to charge neutralisation, which induces 
nanoparticle aggregation. The increase in nanoparticle diameter as a result of 
nanoparticle aggregation reduces the opportunity for nanoparticles to diffuse into 
tumour sites, as extravasation of large macromolecules is limited to the size of tumour-
vasculature fenestrations. In addition, the deposition of opsonins, plasma proteins 
involved in immune response of the reticuloendothelial system (RES), marks the 
positively charged nanoparticles for recognition by the cells of the mononuclear 
phagocyte system, which is mainly localised in the liver (specifically the Kupffer cells) 
and spleen.83, 84 Identification by mononuclear phagocytes results in rapid removal of 
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the nanoparticles from circulation, preventing them from localising in tumour cells. 
Furthermore, this opsonisation can activate the complement system which in turn 
initiates an inflammatory response against the charged nanoparticles. To reduce their 
clearance rate, the surface characteristics of the nanoparticles are some of the most 
crucial factors to be considered in the nanoparticle design. According to the Derjaguin-
Landau-Verwey-Overbeek (DLVO) theory 85, the stability of colloidal particles in solution 
is explained by two types of interparticle interaction forces: repulsive forces generated 
by electrostatic and/or steric repulsion, and van der Waals attractive forces. To 
maintain dispersion of particles, the repulsive forces must be greater than the attractive 
forces in order to prevent nanoparticles from coming into contact and aggregating. In 
biological system, steric stabilisation is more crucial than electrostatic stabilisation since 
highly charged nanoparticles are prone to the RES recognition and rapidly cleared from 
circulation. Steric stabilisation is generally achieved by the the introduction of a stealth 
layer (Figure 1-10), which is a layer of hydrophilic polymers such as polyethylene glycol 
(PEG).86-88 A PEG layer provides stability to nanoparticles by increasing repulsive 
forces between nanoparticles, preventing them from coming into close contact with one 
another. In addition, PEG creates a hydrophilic layer on the nanoparticle surface, which 
repels plasma proteins and slows down RES uptake. 
 
To overcome extracellular barriers posed by systemic delivery and be able to 
accumulate in tumours, nanoparticles must resist aggregation in blood in order to 
maintain a small diameter and also resist plasma protein adsorption in order to avoid 
recognition by RES and clearance from circulation. After arriving at tumour cells via the 
circulation, nanoparticles encounter further challenges in the form of intracellular 
barriers. 
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Figure 1-10: According to DLVO theory, colloidal stability of nanoparticles is 
maintained when repulsive force is greater than attractive force. Stabilisation of 
nanoparticles in solution can be achived by electrostatic repulsion, the nanoparticles 
are surrounded by a highly charged double layer, (left) or by steric repulsion, the 
surface of the nanoparticles is functionalised with polymer, (right). Adapted from 
http://www.malvern.com/LabEng/industry/colloids/dlvo_theory.htm 
 
1.3.2 Intracellular barriers 
 
Once at the tumour site, cellular entry of the nanoparticles is generally achieved by 
endocytosis. Endocytosis is the cellular uptake mechanism by which a cell membrane 
invaginates and pinches off to engulf extracellular substances into the cell. Cellular 
internalisation of non-targeted nanoparticles mainly relies on electrostatic interactions 
between cationic nanoparticles and anionic glycoproteins, such as proteoglycans, 
present on the cell surface, followed by the clathrin-coated pit mechanism (Figure 
1-11).89, 90 For receptor-targeted nanoparticles, their internalisation occurs by receptor-
mediated endocytosis.91 Clathrin is a cytosolic coat protein that plays a critical role in 
the formation of membrane-bounded vesicles for endocytosis. After being internalised, 
clathrin-coated vesicles become uncoated (depolymerisation), resulting in early 
endosomes. These endosomes can recycle their contents, such as plasma proteins or 
nanoparticles, back to the cell surface, or they can progress to late endosomes and 
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eventually fuse with lysosomes for degradation of endocytosed materials. In late 
endosomes, the acidity of the compartment increases from neutral to pH 5-6 due to 
ATPase proton-pump enzyme on the membrane transporting protons into the vesicles. 
The internalised macromolecules that are destined for the lysosome – a membrane-
bounded vesicle, pH 5-5.5, containing various hydrolytic enzymes – are digested and 
unable to produce a therapeutic effect. Therefore, endosomal disruption of the 
endocytosed nanoparticles is essential to avoid lysosomal degradation and also 
transportation back to the cell surface.  
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Figure 1-11: Schematic representation of intracellular hurdles encountered by 
nanoparticles. Cationic nanoparticles first interact with anionic glycoproteins, such as 
proteoglycans, found on the cell surface. This leads to accumulation of clathrin proteins 
at the binding site for endocytosis. After internalisation, the clathrin coat depolymerises, 
resulting in early endosomes. The plasma proteins then recycle back to the cell 
surface. Endocytosed nanoparticles must escape from endosomes to be able to 
release their contents into the cytoplasm. The released DNA must then traffic through 
the cytoplasm and cross the nuclear membrane to perform their therapeutic effects in 
the nucleus, whereas siRNA functions in the cytoplasm. Internalised macromolecules 
that fail to escape from endosomes will degrade in lysosomes. 
 
Endosomal disruption of liposomal nanoparticles was proposed to occur as a result of 
lipid mixing, the so-called flip-flop mechanism (Figure 1-12a).92 According to this 
mechanism, internalised cationic nanoparticles electrostatically induce lateral diffusion 
of anionic lipids, predominantly located on the cytoplasmic side, to form charge-
neutralised ion pairs with cationic lipids in the liposomes. The ion pairing leads to 
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destabilisation of the endosomal membrane, allowing for the penetration of DNA into 
the cytoplasm. Unlike liposomal nanoparticles, polyplexes such as PEI are believed to 
escape from the endosomes through a different mechanism, termed the proton-sponge 
mechanism (Figure 1-12b).93  PEI possesses a high buffering capacity as it contains a 
large number of amine groups. This hypothesis suggests that at the low pH in 
endosomes, PEI becomes more protonated, causing ATPase to transport more protons 
to maintain the pH in the vesicles. The excessive accumulation of protons leads to an 
influx of chloride counter ions, causing osmotic swelling and eventually rupturing of the 
endosomal membrane, releasing the polyplexes into the cytoplasm. 
 
a)                                                                       b) 
 
  
Figure 1-12: Representation of hypothesis of endosomal escape of a) lipoplexes and 
b) polyplexes.30  
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After endosomal escape, DNA must traffic to the nucleus through the cytoplasm. 
Several proteins and organelles in cytoplasm restrict the mobility of DNA, constituting 
another significant barrier for efficient DNA delivery. In addition, due to their small pore 
sizes ( 55 Å), nuclear pores in the nuclear envelope permit the passive transport of 
molecules up to a molecular weight of 70 kDa or a diameter of  10 nm.94 This size limit 
is much smaller than the size of DNA (e.g. a 5 kb DNA has a molecular weight of 
approximately 3.3 million Da), providing it little chance of entering the nucleus. It is 
widely accepted that the nuclear translocation can occur either via cell division during 
mitosis, when the nuclear membrane loses its integrity, allowing the entry of DNA, or 
via an active transport mechanism, requiring the use of nuclear localisation sequences 
(NLS) to facilitate DNA transportation by binding to cytosolic receptors – importins.89, 94 
Unlike pDNA, the interference mechanism of siRNA molecules occurs in cytoplasm, 
eliminating the obstacle associated with nuclear entry. However, siRNA still needs to 
escape the endosomal barrier. 
        
1.4 Components of liposomal nanoparticles 
 
In order to overcome the delivery barriers previously described, liposomal nanoparticles 
are generally composed of three main layers: the nucleic acid core (A), lipid envelope 
layer (B), and stealth layer (C) (Figure 1-13). Nucleic acids (A) are condensed within a 
lipid envelope (B) in order to protect them from the undesirable effects of external 
conditions. AB nanoparticles are themselves capable of nucleic acid delivery; however, 
their instability under physiological conditions usually results in aggregation and 
subsequent loss of their therapeutic function. A stealth layer (C), commonly made of a 
hydrophilic polymer such as PEG, is therefore required for ultimate protection of the 
nanoparticles. To enhance specificity of the delivery system, targeting ligands (D) 
having high affinity to receptors expressed on tumour cells can be incorporated on the 
external layer of the ABC nanoparticles.  
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Figure 1-13: Schematic representation of ABCD nanoparticle paradigm. Nucleic acids 
(A) are condensed and protected within lipid bilayers (B). A stealth layer (C) is 
necessary for nanoparticles’ stability and long circulation in vivo. Targeting ligands (D) 
can be included on the exterior layer of the nanoparticles for selective delivery and 
enhanced cell internalisation.  
 
1.4.1 Nucleic acids (A)  
 
Nucleic acids employed in cancer gene therapy can be either DNA or RNA, with the 
aim of altering the production of specific proteins for therapeutic benefits, either by 
augmentation of tumour suppressor genes or inhibition of dominant oncogenes. 
Delivery of DNA is intended to enhance the expression of proteins involved in tumour 
growth suppression – the so-called tumour suppressors. One example of a tumour 
suppressor gene is p53, which encodes for a transcription factor that regulates the cell 
cycle and induces programmed cell death (apoptosis).95-97 In patients with cancer, p53 
genes have been found to be mutated, leading to uncontrollable cell growth and 
tumourigenesis. Restoration of the gene function might re-establish the balance 
between cell cycle and apoptosis. The p53 gene has therefore gained much interest 
from many researchers as an attractive target for cancer therapy. The use of a p53-
based adenoviral vector (Gendicine) has been approved for the treatment of head and 
neck cancer in combination with radiotherapy.98 
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Emerging antisense technology has led to increasing focus on the use of antisense 
oligodeoxynucleotides (AS-ODNs) and RNA molecules for therapeutic purposes. Unlike 
DNA, antisense molecules are designed to inhibit the translation and expression of 
proteins that are involved in cancer growth – the so-called oncogenic proteins. 
Antisense oligodeoxynucleotides (AS-ODNs) are short, synthetic, single-stranded 
deoxynucleotide (DNA) molecules, usually composed of 12-25 nucleotides.99, 100 They 
can stably complex to complementary sequences of messenger ribonucleic acids 
(mRNA), preventing mRNA from being translated to specific proteins. Fomivirsen 
(Vitravene) was the first antisense drug to be approved by the FDA for the treatment of 
viral infections of the eye caused by cytomegalovirus (CMV).99, 101   Oblimersen is one 
of the antisense drugs that are being investigated in clinical trials. It is designed to 
target B-cell lymphoma protein 2 (Bcl2), which inhibits apoptosis. Overexpression of the 
BCL2 gene, found in many kinds of tumours, and the chemotherapy resistance of 
tumours is thought to be correlated.101 Despite significant progress in clinical trials, the 
use of ODNs has been reported to be associated with non-antisense effects, such as 
binding to non-targeted mRNA, receptors, or other proteins, which impairs their 
therapeutic effect and may cause un-intended consequences.102, 103   
 
The use of short interference ribonucleic acid (siRNA) as a powerful tool in silencing 
specific gene expression has held great promise in cancer research since the discovery 
of the RNA interference (RNAi) pathway in 1998.104, 105 siRNA is a short sequence of 
double stranded RNA, usually 21-23 nucleotides long. Similar to AS-ODNs, siRNA is 
able to bind to complementary mRNA sequences and inhibit the expression of coded 
proteins. However, siRNA has shown to be more stable in physiological fluids and more 
efficient in gene silencing than AS-ODNs.106 Once inside the cells, siRNA is 
incorporated within the RNA-induced silencing complex (RISC). The activated RISC 
then binds to and cleaves perfectly matched mRNA sequences, preventing protein from 
being translated.107 Like siRNA, micro RNA (miRNA) is capable of inducing RNAi-
mediated gene suppression.108 When incorporated into RISC, the activated complex 
can bind to corresponding mRNA sequences. mRNA is cleaved and subsequently 
degraded if the complex is fully complementary to the mRNA target 109, whereas 
incomplete base pairing leads to inhibiting mRNA translation.110  Due to their ability to 
prevent specific proteins from being translated, the technology has been extensively 
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used for silencing of the oncogenic proteins being expressed. Vascular endothelial 
growth factor (VEGF) is an example of a widely studied oncogenic protein for RNAi-
induced therapeutics. It is a tumour-secreted growth factor protein that plays a key role 
in angiogenesis, the process necessary for tumour growth. Blockade of the protein 
expression mediated by VEGF siRNA has been shown to result in inhibition of tumour 
growth.26, 111, 112 In one recent study, delivery of siRNA targeting the E6/7 oncogenes, 
which is found to bind and degrade p53 tumour suppressors, resulted in inhibition of 
tumour growth with a 50% reduction in tumour size.66 
 
All nucleic acids contain anionic phosphodiester bonds, which are highly sensitive to 
nucleases. Systemic administration of nucleic acids on their own (so-called naked 
nucleic acids) is therefore vulnerable to enzyme degradation, resulting in inefficient 
gene expression at target cells. In addition, phosphate backbones in their structure give 
nucleic acids negative charge, causing poor interaction with the anionic cell membrane. 
Nucleic acids therefore need to be packaged in a suitable carrier in order to increase 
their nuclease resistance and ultimately improve their interaction with the cell.  
 
1.4.2  Lipid envelope layer (B) 
 
In order to enhance cellular interaction with the negatively charged cell membrane, 
liposomes bearing positive charge are typically employed. Cationic liposomes generally 
consist of cationic lipids and neutral helper lipids. Cationic lipids are made of a cationic 
polar head group (usually polyamines) linked to a hydrophobic moiety (typically 
hydrocarbon chains or cholesterol), and are therefore positively charged amphiphiles. 
The cationic head groups are necessary for interaction with the negatively charged 
phosphate backbone of nucleic acids. This characteristic also provides electrostatic 
interaction with the anionic cell surface, resulting in enhanced cellular uptake of 
nanoparticles. Cationic lipids may be either monovalent lipids, containing a single 
amine functional group, or multivalent lipids, containing several amine functions. 
Examples of cationic lipids commonly employed for liposomal formulation are 
presented in Table 1-1. 
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Cationic 
lipid 
Structure Maximum 
charge 
 
 
 
DOTAP 
 
 
 
 
 
+1 
   
 
 
DOGS 
 
 
 
+4 
   
 
 
DC-Chol 
 
 
 
+1 
 
 
 
CDAN 
 
 
 
 
 
 
+3 
 
Table 1-1: Examples of most commonly used cationic lipids113 
 
In addition to the commonly used cationic lipids shown in Table 1-1, design and 
synthesis of cationic lipids has been substantially conducted in order to enhance 
cellular binding and internalisation of cationic nanoparticles. Semple et al. recently 
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described the preparation of a new series of cationic lipid, DLin-K-DMA.114 The lipids 
was optimised from the prior DLinDMA cationic lipid, which was used as a key lipid in 
stable nucleic acid particle (SNALP) and was shown to be effective for siRNA delivery. 
115 The DLin-K-DMA lipids contained the same linoleyl hydrocarbon chain as found in 
DLinDMA, dioxolane linker and dimethylamino head group (Figure 1-14). The pKa of 
the head group was optimised to range between 6-7 in order to have minimal charge 
density (or be unprotonated) in blood circulation but become protonated in the acidic 
environment of the endosome (pH 5.5), and this should promote fusion with the 
endosomal membranes. Incorporation of a new cationic lipid, DLin-KC2-DMA (pKa  
6.7), within SNALP formulation resulted in efficient hepatic gene silencing in vivo at low 
siRNA doses. 
 
 
 
Figure 1-14: Structure of DLin-KC2-DMA 
 
A recent report by Mevel et al. demonstrated the synthesis of the novel cationic lipid 
N’,N’-dioctadecyl-N-4,8-diaza-10-aminodecanoylglycine amide (DODAG), by 
conjugating a polyamine head group to a long chain hydrocarbon dialkylglycylamide 
moiety (Figure 1-15).116 The lipid structure was designed based on the hydrophilic head 
group of the previously developed cationic lipid CDAN117 and the hydrophobic tail of 
cationic lipid DOGS. The head group of CDAN contains three amine groups, with a 
distribution of pKa value, rendering it high capacity for nucleic acid encapsulation and 
aiding in cellular binding. DODAG-containing nanoparticles showed efficient pDNA 
delivery to various cancer cell lines and reasonable in vivo activity of anti-hepatitis B 
virus (HBV) siRNA in murine livers. 
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Figure 1-15: Structure of DODAG 
 
Apart from cationic lipids, which are a main component of liposome formulation, 
inclusion of neutral helper lipids is believed to aid in phase transition of lipid bilayers, 
promoting endosomal escape of encapsulated nucleic acids, which in turn enhances 
transfection efficiency. Neutral helper lipids generally employed for liposome 
preparation are shown in (Figure 1-16). 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPE) is the most common helper lipid used in liposome formulation. When used with 
cationic lipids, it has been shown to enhance gene expression.117-120 The increased 
transfection efficiency may contribute to the fusogenic property of the lipid, which is 
related to its geometry. DOPE has a small polar head group and larger hydrophobic 
diacyl chains. Such a structure tends to adopt an inverted hexagonal (HII) phase, which 
is believed to aid in endosomal destabilisation and facilitate the release of nucleic acids 
into cytosol.121, 122 Other common phase structures of lipids include the lamellar 
(bilayers) and micellar phases. A lamellar phase is formed if the lipid possesses 
similarly sized head group and lipidic tails (i.e. it is cylindrical in shape), such as 
(DOPC). If lipid has a head group larger than its hydrophobic tail (i.e. it is conical in 
shape), it will assemble into a micellar phase. The different phase structures of lipids 
are presented in Figure 1-17.  
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Figure 1-16: Structures of common neutral lipids employed in liposome formulation113 
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a) 
 
b) 
 
Figure 1-17: Schematic representation of lipid phase structures a) a cone-shaped lipid 
assembles into a micellar (HI) phase, a cylindrical-shaped lipid forms lamellar (L) 
phase, and a lipid with inverse conical shape self-assembles into an inverted hexagonal 
(HII) phase; b) 2D structure of L and HII phases.123  Lipids such as DOPE can adopt the 
HII phase, which is thought to aid in endosomal disruption and facilitate the escape of 
nucleic acids into the cytoplasm.  
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Cholesterol is another neutral co-lipids commonly employed in liposome formulation. 
Inclusion of cholesterol is known to increase the packing densities of phospholipids and 
reduce membrane permeability, resulting in bilayers with greater resistance to plasma 
protein binding. Cholesterol-containing liposomes have been shown to exhibit 
increased stability and prolonged circulation half-lives.124, 125 
 
Preparation of cationic liposomes can be achieved by combining cationic lipids and 
helper lipids in an appropriate ratio.126 The vesicles are typically formulated by the 
dehydration-rehydration (DRV) method and then mixed with nucleic acids to acquire the 
desired nanoparticles. The DNA encapsulation model was proposed by Templeton et 
al.127 The condensation of DNA in liposomes results in entrapment of DNA within the 
aqueous layer of multilamellar vesicles by electrostatic interaction, forming a lipid-DNA 
sandwich (Figure 1-18). The encapsulation process is driven entropically by the release 
of counter ions associated with lipids and nucleic acids as one approaches the other, 
inducing the formation of a lipid-DNA complex.128 Other nucleic acids including ODNs 
and siRNA can be entrapped within liposomal membrane through a similar 
mechanism.129 The condensation efficiency can decrease when a PEG layer is 
introduced. The efficiency of siRNA entrapment can vary according to the preparation 
method. Hydrating a lipid film with a solution of siRNA has been shown to increase 
encapsulation of siRNA in the liposome core, whereas the classic method of adding 
siRNA to the preformed liposome usually results in most of the siRNA becoming bound 
to the outer layer of the PEGylated liposomes.130  
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Figure 1-18: Proposed model showing DNA encapsulation within cationic liposomes. 
Lipid bilayers electrostatically interact with negatively charged DNA and wrap around to 
form vesicles in which DNA is completely entrapped. Modified Modified from Templeton 
et al. Nat. Biotech. 1997, 15, 647-652.    
 
Although cationic nanoparticles are necessary in order to increase cell uptake by 
electrostatic interaction with plasma membranes, their positive charge also leads to 
detrimental effects for systemic delivery. Positively charged nanoparticles induce 
opsonisation and enhance uptake by the mononuclear phagocyte system, resulting in 
their rapid clearance from blood circulation. In addition, interaction with serum proteins 
leads to aggregation of the nanoparticles. These effects prevent the accumulation of 
nanoparticles in tumour tissue. To overcome these difficulties, nanoparticles should 
have low positive charge while still being capable of condensing nucleic acids. In 
addition to this, a stealth layer is an important component that confers stability to 
liposomes. A PEG layer renders steric stabilisation to nanoparticles and hinders their 
surface charges, resulting in decreased RES recognition and hence prolonging their 
half-lives in blood circulation.  
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1.4.3 Stealth layer (C) 
 
Covering the liposomal surface with hydrophilic polymers has been shown to extend 
the blood circulation lifetime of nanoparticles by sterically hindering the binding of 
plasma protein onto the nanoparticle surface and thereby slowing down its recognition 
by RES.55, 131-134 Polymers that have been used as stealth layers are poly(vinyl 
pyrrolidone) (PVP), poly(acrylamide) (PAA), poly(vinyl alcohol) (PVA) and, in particular, 
poly(ethylene glycol) (PEG). PEG is the most commonly used protective polymer owing 
to its high water solubility and the high flexibility of its polymer chains.135-137 These 
characteristics provide a protective cloud over the surface of the liposome, repulsing 
plasma components out of the PEG layer and making it impermeable to serum opsonin 
adsorption. In addition, PEG exhibits low toxicity and does not form toxic metabolites.136 
It was found that PEG with molecular weight less than 40 kDa can be rapidly removed 
from the body through the kidneys. PEG used for liposomal preparations is usually 
conjugated to lipids to allow facile incorporation within lipid bilayers. Currently, three 
main strategies have been described for the inclusion of stealth layers, known as 
PEGylation, into liposomes: pre-modification, post-insertion, and post-conjugation. 
Firstly, pre-modification refers to the incorporation of PEG-lipid conjugates during 
liposome formation prior to the addition of nucleic acids.138, 139 Although this technique 
is considered the simplest method for the preparation of stealth liposomes, it has some 
disadvantages. Introduction of the PEG layer prior to liposomal formulation renders an 
equal possibility that the polymer chains will not only be present on the liposome 
surface but also trapped inside the lipid bilayers. This might result in insufficient 
protection of the nanoparticles from opsonisation. In particular, using this technique to 
incorporate targeting moieties reduces the number of exposed ligands on the outer 
surface of the liposomes, significantly impairing their targeting function. Secondly, post-
insertion implies the incorporation of PEG-lipids in preformed nanoparticles. The 
nanoparticles are prepared by condensation of nucleic acids into cationic liposomes, 
and then incubation with PEG-lipid micelles. The spontaneous insertion of PEG-lipid 
micelles onto the external surface of liposomes occurs as a result of relieving micellar 
strain.140, 141 Examples of commercially available PEG-lipid conjugates commonly 
employed in this method are 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (MeO-PEG2000-DSPE) and 1,2-dipalmitoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (MeO-PEG2000-
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DPPE). The post-insertion technique allows for the presence of the polymer on the 
exterior surface of liposomes. However, further purification is required, especially when 
modifying with targeting ligands. Non-incorporated ligands can blockade the receptors, 
preventing binding of the ligand-bound nanoparticles to the receptors, and therefore 
need to be removed.142 Lastly, post-conjugation involves the chemical conjugation of 
PEG molecules to preformed nanoparticles via corresponding functional groups. Similar 
to post-insertion, this method allows PEG polymers to be located on the outer layer of 
the nanoparticles. The coupling efficiency relies on the selectivity and reactivity of the 
coupling reaction. Examples of conjugating methodologies are amide coupling, 
aminoxy coupling, and maleimide coupling.143 Similar to post-insertion, this technique 
requires further purification. 
. 
To maximise the stealth effect, the molecular weight and grafting density of PEG are 
important criteria. Incorporation of a PEG layer should provide sufficient coverage for 
the nanoparticles to resist aggregation, reduce opsonisation, and prevent consequent 
uptake by RES. The PEG layer is known to exhibit two different conformations on the 
liposome surface, which are called “mushroom” and “brush” (Figure 1-19). 144-146 These 
regimes are governed by the Flory dimension (Rf), which refers to the volume occupied 
by each PEG cloud and is dependent on distance (D) between the adjacent chains. 
When D > Rf, the PEG grafting density is low, the polymer chains are far from each 
another and able to fold in on themselves to adopt a random coil-like configuration, 
called the mushroom regime. With an increased PEG grafting density, when D < Rf, 
each polymer chain encounters a packing pressure and is forced to adopt a more 
extended conformation, referred to as the brush regime. In the case of PEG2000, at 
lower than 4 mol% grafting density, PEG exhibits the mushroom conformation, whereas 
the brush configuration is formed when the grafting density is higher than 4 mol% of 
total lipid content.147  
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Figure 1-19: Schematic representation of surface-grafted PEG regimes. When D> Rf, 
terminally anchored PEG chains adopt the mushroom conformation. Conversely, when 
D< Rf, the polymer chains extend into the brush conformation. Modified from Kenworthy 
et al. Biophys. J., 1995, 68, 1921-1936. 
 
Of the two regimes, the brush conformation is believed to provide the most resistance 
to plasma protein adsorption owing to the extension of the polymer chain away from the 
grafting surface, generating greater protein repulsion out of the PEG layer.134, 148, 149 
Inclusion of PEG beyond its maximum loading is known to cause disruption of PEG-
lipids from the lipid bilayers due to increased repulsion forces between each PEG 
chain.150-152 This dissociation usually results in the formation of micellar aggregates, 
either as small disks or spherical micelles. For PEG2000-lipid, 5-7 mol% of total lipid 
concentration is the saturated density at which PEG can be incorporated into bilayers 
before being transformed into a micellar-like structure. The dissociation results in a 
liposome surface partially covered by a lesser PEG density, which markedly diminishes 
the delivery potential of the nanoparticles.     
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1.4.4 Targeting layer (D) 
 
Apart from the three main layers of liposomal constitutions – the nucleic acid core, lipid 
envelope layer, and stealth layer – the targeting layer (D) also offers a potential 
advantage for site-specific binding to target cells to selectively improve cellular 
internalisation and reduce possible toxic side effects to non-target cells. Targeting 
ligands should be designed to exhibit high specificity to the receptors that are uniquely 
expressed or overexpressed on the cell of interest, but minimally expressed on normal 
cells. In addition, ligands should also have high affinity for the corresponding receptors 
and be able to induce receptor-mediated endocytosis. Ligands/receptors employed for 
nucleic acid delivery can be antibodies, growth factors, cytokines, proteins, and 
peptides.30, 58 For cancer targeting, examples of receptor targets that have been 
extensively studied include the transferrin receptor (TfR)153, the human epidermal 
growth factor receptor 2 (HER-2)154, the folate receptor (FR)155 and the prostate-specific 
membrane antigen (PSMA) receptor.156 The targeting moiety should be stable while 
circulating in vivo so that it is able to interact with the receptor and accumulate in target 
tissues.  
.  
The modification of liposomes with the layer of protective polymer and targeting ligand 
demonstrates several advantages including increased circulation lifetime, decreased 
macrophage uptake, specific targeting to certain pathological sites, and enhanced 
cellular uptake. Long-circulating nanoparticles may be preferable for efficient 
accumulation at the target tissue (tumour); however, the presence of a stealth layer on 
liposomes inhibits cell binding and subsequent release of the internalised nanoparticles 
from the endosome into the cytoplasm. This observation suggests that the stealth layer 
may not always be favourable, especially for cellular internalisation of the 
nanoparticles. A strategy that enables the triggerable detachment of PEG is necessary 
to overcome steric hindrance in cell membrane binding and endosomal membrane 
fusion which may lead to improved therapeutic efficacy.    
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1.5 Triggerable modification of stealth liposomes via stimuli sensitivity 
 
Surface modification with a PEG layer has been shown to be essential to prolong the 
circulation half-lives of nanoparticles. This characteristic, in conjunction with limited 
nanoparticle sizes (between 100-200 nm), enables them to preferentially accumulate in 
tumour cells. However, PEG has been found to inhibit the internalisation and 
endosomal escape of the nanoparticles, resulting in significant loss of transfection 
efficiency.157, 158 The use of PEG therefore creates a dilemma: it is required for altering 
the pharmacokinetics of the nanoparticles, but it poses a problem for cellular interaction 
with tumours. A potential triggerable mechanism capable of detaching PEG once 
deposited at the target tissues (pre-internalisation) or after internalisation (post-
internalisation) would restore to it the therapeutic effect of nucleic acid delivery. 
 
Recently, work has been published concerning the development of long-circulating 
liposomes by attaching PEG in a detachable fashion in order to improve endocytosis 
and endosomolysis of the nanoparticles. One approach is the use of diffusible PEG-
lipid conjugates159, 160, which can be dissociate from liposomes over time once presence 
in blood circulation, revealing their surface positive charges that allow for interaction 
with anionic cell membranes. The rate of diffusion varies according to half-life of lipid 
anchor. Shorter lipid anchors are found to dissociate more quickly from the bilayer. 
Optimisation of the length of lipid anchor, conjugated to PEG, is required in order to 
achieve a controllable rate of dissociation that benefits both stability and transfection 
efficiency of the nanoparticles. Other approaches for triggered release of the PEG coat 
that are more extensively studied include the use of extrinsic physical stimuli, such as 
heat, light, and ultrasound161, 162 and intrinsic stimuli associated with pathological sites, 
such as pH, redox conditions, and specific enzymes. Physical stimuli or triggers, 
usually combined with an imaging technique, are useful in the design of treatments for 
primary tumours, but less for metastases. This leaves the intrinsic stimuli as the 
preferable choice for triggerable release of the stealth layer at tumour tissues. 
Triggerable liposomes are usually achieved by conjugation of a suitable sensitive linker 
between the PEG polymer and lipid anchor within liposomes. This modification results 
in a multifunctional nanoparticle that is able to exhibit long circulation in vivo and a 
stealth layer that is removable when exposed to appropriate stimuli.  
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1.5.1  pH triggered release  
 
An acidic environment is found in tumours and endosomal compartments. The pH in 
tumours may drop to 6.5, further decreasing inside the endosomes to around 5.161 This 
difference in pH from the physiological value (pH 7.4) is sufficient to be utilised as a 
triggerable mechanism for PEG detachment through a labile linker capable of 
degradation in acidic conditions. A number of pH-sensitive liposomes have been 
developed. Examples of acid labile linkers that have been reported include hydrazones, 
diorthoesters, vinyl ethers, and cis-aconitic and oxime moieties.  
 
A series of diorthoester-linked PEGylated lipid conjugates (POD) (Figure 1-20) with 
three different PEG chain lengths (750, 2000, and 5000 Da) was reported by Szoka et 
al.163  The POD-stabilised nanoparticles were shown to be relatively stable at pH 8.5, 
but rapidly destabilised at pH 5 in approximately 10 min. Improved in vitro transfection 
efficiency was mediated by POD-contained nanoparticles. Among the diorthoester 
derivatives being tested, PEG2000 nanoparticles were shown to be the most effective 
system with respect to particle size, stability, transfection efficiency, and cytotoxicity.  
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Figure 1-20: General structure of the diorthoester described by Szoka et al. 
 
Boomer and co-workers reported the successful detachment of the PEG coat from 
liposomes by acid catalysed hydrolysis of vinyl ether linker (Figure 1-21) at pH 4, while 
minimal degradation of the linker was observed at pH 7.4.164  The degradation half-life 
of the sterically stabilised liposomes containing vinyl ether linker was reported to be 25 
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min. The nanoparticles showed improved release of the encapsulated content 
compared to non-hydrolysable PEGylated conjugates.  
 
 
Figure 1-21: Structure of the vinyl ether reported by Boomer et al. 
 
A recent work by Carmona et al. demonstrated the preparation of pH-triggerable 
PEGylated-siRNA nanoparticles utilising chemoselective reactions for the post-coupling 
of a PEG polymer, PEG2000-(CHO)2, to an aminoxy functional group of lipid-anchoring 
nanoparticles (Figure 1-22).143 The conjugation resulted in the formation of oxime 
bonds which are relatively stable at pH 7 but labile at pH 5.5 and below. The pH-
sensitive PEGylated nanoparticles containing anti-HBV siRNA were able to mediate 
significant gene silencing in vivo. 
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a) 
 
b) 
 
 
Figure 1-22: a) Structure of CPA lipid containing aminoxy functional group b) 
Formation of pH-sensitive oxime bond via conjugation of PEG2000(CHO)2 and aminoxy 
group of CPA. 
 
A pH-triggerable release mechanism can be utilised for the preparation of 
multifunctional nanoparticles with temporarily “hidden” functions, such as cell-
penetrating peptides (CPPs). CPPs, such as TAT and polyArg, have been 
demonstrated to facilitate intracellular internalisation.165, 166 Temporary shielding by 
PEG shells of the cell penetrating function should confer long circulation times, in order 
to accumulate nanoparticles in target tissues as well as reduce nonspecific uptake in 
non-target cells. However, the protective PEG should be removed once it experiences 
an acidic environment at the target cell, to allow for effective internalisation. A study by 
Sawant et al. demonstrated that incorporation of hydrazone-linked PEGylated lipid 
conjugates within antibody-targeted nanoparticles containing TAT peptides resulted in 
relative stability at physiological pH with limited internalisation in cells. In acidic 
conditions (pH 5-6), loss of the PEG layer was observed due to hydrolysis of hydrazone 
linkers, exposing the hidden TAT peptides and thereby resulting in effective 
internalisation.167  
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1.5.2 Redox trigger 
 
The redox potential difference between reducing intracellular space and oxidising 
extracellular space can be utilised as a potentially useful stimulus for stealth layer 
detachment. The most well-established redox-triggered linker is that of the disulfide 
bond (S-S). The disulfide bond is relatively stable in the mildly oxidising environment of 
the bloodstream but is easily reduced to two thiols in the presence of high glutathione 
(GSH) concentrations inside cells. Glutathione is a cellular reducing agent, the function 
of which is to prevent cellular components from oxidative damage. The intracellular 
concentration of glutathione is approximately 100-fold higher than its normal 
extracellular level.168  
 
Kirpotin and colleagues reported the synthesis of disulfide-linked PEGylated lipid 
conjugate (Figure 1-23).169 The sterically stabilised DOPE liposomes containing 
disulfide linker were found to be stable in a serum environment for 36 h at 37 C. 
However, upon incubation with a thiolytic reducing agent, dithiothreitol (DTT), the 
liposomes were destabilised and the entrapped dye was released. The loss of bilayer 
stability was presumably due to the thiolytic cleavage of disulfide bonds, leading to the 
detachment of PEG moiety. 
 
 
 
Figure 1-23: The thiolytically cleavable PEGylated lipid conjugate described by Kirpotin 
et al. 
 
Further in vivo study was carried out by Ishida et al. The sterically stabilised liposomes 
containing disulfide linker, targeting moiety, and loaded doxorubicin showed improved 
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therapeutic efficacy compared to the control PEGylated nanoparticles in mice. The 
nanoparticles, however, exhibited relatively short half-lives. It was suggested that this 
was due to rapid cleavage of disulfide bonds by blood components, such as cysteine, 
and consequent PEG removal. The loss of nanoparticle stability led to enhanced 
uptake by the mononuclear phagocyte system.170   
 
Like pH stimuli, the redox strategy can be employed to temporarily mask the ligand 
function. Under normal conditions, the ligands are shielded by a stealth layer but 
become unmasked after the protective PEG is removed by certain stimuli (Scheme 
1-2). This allows for the protection of targeted nanopaticles from RES clearance and 
thus enhanced circulation times. McNeeley and co-workers reported that the insertion 
of cysteine-cleavable PEG-lipid conjugates, containing disulfide bonds, into folate-
targeted nanoparticles showed prolonged circulation times of the nanoparticles in vivo, 
compared to targeted nanoparticles without PEGylated disulfide lipid conjugates. The 
PEG coat was successfully cleaved by cysteine, and the hidden ligands were exposed 
to promote binding, resulting in improved cellular uptake of the nanoparticles.171  
 
 
 
Scheme 1-2: Schematic representation of multifunctional nanoparticles described by 
McNeeley et al. A cleavable PEG mask targets ligands while in circulation, but is able 
to be detached once arriving at the target site through cleavage at a disulfide linker.171 
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1.5.3 Enzyme trigger system in cancer tissues 
 
Elevated enzyme levels, of proteases in particular, are one of the unique characteristics 
found in tumour cells. High concentration of the enzymes plays a crucial role in tumour 
metastasis by degrading the basement membrane, leading to extravasation of the 
tumour cells to distant sites. The increased enzyme levels are also involved in the 
process of angiogenesis. The enzymes are capable of recognising and cleaving 
selectively at particular bonds or domains. This site-specific feature is considered a 
potentially attractive candidate for the removal of a stealth layer via a linker sensitive to 
enzymatic cleavage in target tissues. Some enzymes have been extensively studied to 
serve this purpose, such as phospholipase A2, elastase, and matrix metalloproteinases. 
      
1.5.3.1 Phospholipase A2 
 
Phospholipase A2 belongs to a group of membrane-active enzymes that hydrolyse the 
ester linkage of the sn-2 acyl chain of phospholipids, liberating free fatty acids and 1-
acyl-lysophospholipids (Figure 1-24). This enzyme has been reported to be upregulated 
in inflammatory sites and many tumours, such as breast, pancreatic, prostate, and lung 
cancer172, making it an interesting site-specific trigger for PEG removal from sterically 
stabilised liposomes at cancer tissues. Reported by Jorgensen and co-workers, 
phospholipase A2-mediated cleavage of various PEG-PE conjugates within liposomes 
has been shown to be feasible.173, 174 Their recent work has demonstrated the efficient 
release of encapsulated doxorubicin from liposomes containing PEG-DSPE when 
incubated with culture media of colon cancer cell lines containing secreted 
phospholipase A2, whereas the doxorubicin released from Doxil was minimal. The 
enzyme-degradable liposomes in the presence of the enzyme have shown higher 
cytotoxicity to the cancer cell lines compared to Doxil, suggesting that degradation of 
the enzyme-sensitive liposomes has occurred, resulting in the release of the toxic 
drug.132 The use of phospholipase A2 as a trigger may provide an efficient, site-specific 
activation leading to destabilisation of liposomal carriers and thus enhancing the 
delivery of therapeutic agents.   
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Figure 1-24: Representation of the cleavage site by phospholipase A2 
 
The study in this thesis is concentrated on the following two enzymes: elastase and 
matrix metalloproteinase, which are the more well-established enzyme triggerable 
systems for PEG detachment at tumour sites. The following section will focus on the 
discussion of these enzymes with respect to their relations to cancer, their 
characteristics, and their application as site-specific triggers. 
 
1.5.3.2 Elastase 
 
Human neutrophil elastase (NE), also known as human leukocyte elastase (HLE), is 
one of the most widely studied enzymes for the triggered release strategy. Neutrophil 
elastase is a serine protease found in azurophil granules of neutrophils.175, 176 Its main 
function is to degrade foreign microorganisms which have invaded the body. It also has 
the ability to degrade a range of substrates, mainly elastin and other important 
connective tissue proteins such as collagen and fibronectin. While in blood circulation, 
the neutrophil does not cause any damage; however, on activation it rapidly secretes 
enzymes into the extracellular space to destroy the basement membrane in order to 
migrate and perform its function.177 Under normal conditions, its destructive feature is 
regulated by its natural protease inhibitor, 1-antitrypsin. The imbalance of these two 
counterparts, due to either a deficiency of 1-antitrypsin or elevated neutrophil 
elastase, leads to abnormally high levels of neutrophil elastase, increasing the 
possibility of tissue damage.175 Elevated levels of this enzyme have been detected in 
various types of cancers and are believed to promote tumour development and 
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progression by degrading the extracellular matrix around tumours and facilitating their 
invasion to sites of metastasis. The normal range of neutrophil elastase has been found 
to be 56-136 g/L; however, its concentration varies under certain conditions, such as 
inflammation and some types of lung disease, and is dependent on the stage of cancer. 
Late stages of cancer (stage IIIB and IV) have higher enzyme concentrations than 
earlier stages (stage I, II and IIIA). The enzyme level is therefore a significant 
prognostic factor for cancer. It has been reported that patients with breast cancer who 
have high levels of the enzyme have a lower chance of survival than those with low 
enzyme levels.175   
 
Neutrophil elastase is a glycoprotein composed of a single peptide chain of 218 amino 
acids and four disulfide bridges, with sugar chains linked to Asn-109 and Asn-159.178 It 
is a member of the chymotrypsin subfamily of serine proteases, which includes 
chymotrypsin, trypsin, and elastase. The structure of neutrophil elastase is shown in 
Figure 1-25. 
.  
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Figure 1-25: The crystal structure of human neutrophil elastase (PDB ID 1EAS). The 
catalytic triad, His57, Asp102 and Ser195, is included.  
 
The active site of the chymotrypsin subfamily typically contains three amino acid 
residues, termed a catalytic triad, including His57, Asp102, and Ser195, obtained from 
X-ray crystallography.178, 179 In some experimental studies, the catalytic triad of 
neutrophil elastase has been reported with different residue numbers (His41, Asp88, 
and Ser173).180 Each residue co-ordinately serves a catalytic role in peptide bond 
hydrolysis. The mechanism of the peptide hydrolysis reaction is composed of two major 
steps: acylation and deacylation.179 Acylation involves the cleavage of the amide bond 
of the peptide substrate and the formation of an ester bond between the carbonyl 
carbon of the peptide and the enzyme, forming an acyl-enzyme intermediate (Scheme 
1-3). To enter and bind to the active site, the substrate is assisted by hydrogen bonds 
formed between the NH of Ser1195 and the carbonyl oxygen of the substrate, forming 
a non-covalent enzyme-substrate complex called the Michaelis complex. The OH group 
of Ser195 then performs a nucleophilic attack on the carbonyl carbon of the Michaelis 
complex to form a tetrahedral intermediate. The carboxylate group of Asp102 hydrogen 
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bonds to the imidazole ring of His57, making the N atom in the ring more nucleophilic. 
The electron pairs on the N atom of His57 that form hydrogen bonds to Ser195 accept 
protons (H+) from the OH group of Ser195. The intermediate reforms the carbonyl 
double bond and breaks the peptide bond, generating an acyl-enzyme intermediate and 
releasing an amine product. During the acylation step, the tetrahedral intermediate 
formed is stabilised by hydrogen bonding to the H atoms of the amide backbones of 
Gly193 and Ser195, known as the oxyanion hole. The oxyanion hole is believed to 
activate the cleavage of the peptide bond.   
 
Acylation step: 
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Scheme 1-3: Reaction mechanism of the acylation step of peptide hydrolysis by 
proteases. This step involves the formation of an acyl-enzyme intermediate by the 
nucleophilic attack of the OH group of Ser195.   
 
The second step, deacylation, involves the breakdown of the ester linkage of the acyl-
enzyme intermediate and the regeneration of the enzyme active site (Scheme 1-4). The 
carbonyl carbon of the acyl-enzyme intermediate is attacked by a water molecule. The 
imidazole ring of His57 accepts a proton from the water molecule to produce another 
tetrahedral intermediate, which is stabilised by the oxyanion hole. The intermediate 
  Chapter One: Introduction 
70 
 
recreates the carbonyl group, leading to the breakdown of the ester bond and the 
release of the carboxylic acid product. The oxygen anion of Ser195 withdraws a proton 
from the imidazole ring of the His57 and the hydrogen bond between His57 and Ser195 
is reformed.  
 
Deacylation step: 
 
 
 
  Chapter One: Introduction 
71 
 
 
 
Scheme 1-4: Reaction mechanism of the deacylation step of peptide hydrolysis by 
proteases. In this step, an acyl-enzyme intermediate is attacked by water to form a 
tetrahedral intermediate and liberates carboxylic acid.  
 
The nomenclature used for describing enzyme binding sites and substrate binding 
pockets was first introduced by Schechter and Berger in 1967.181 The individual amino 
acid residues of a peptide substrate are designated as Pn,…P2, P1, P1’, P2’,…,Pn’ and 
the corresponding enzyme binding sites are designated as Sn,…S2, S1, S1’, S2’,...Sn’. 
The bond between P1 and P1’ is called a scissile bond, where the enzyme cleavage 
occurs. The nomenclature demonstrated by Schechter and Berger is present in (Figure 
1-26). The specificity of the enzyme generally relies on P1 and S1 interaction. S1 is a 
pocket located adjacent to Ser195, formed by amino acid residues. Individual 
chymotrypsin-like serine proteases exhibit varying specificity and this is mainly 
governed by the identity of the S1 pocket. Chymotrypsin shows a preference for Phe, 
Tyr, and Trp at the P1 position due to its hydrophobic S1 pocket formed by the 
combination of Ser189, Gly216, and Gly226.182 However, the negatively charged S1 
site of trypsin created by Asp189, Gly216, and Gly 226 shows a strong favour for 
positively charged amino acids, such as Arg and Lys at the P1 pocket.183, 184 Unlike 
chymotrypsin and trypsin, the presence of Val-190 and Val 216 near the top of the S1 
pocket of elastase forms a relatively small hydrophobic hole, hence only small, 
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uncharged amino acids such as Ala and Val are preferable at the P1 position (Figure 
1-27).185 
N
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Figure 1-26: The Schechter and Berger Nomenclature for the description of substrate 
and protease interaction. The substrate subsites – each amino acid residue – are 
denoted as P, whereas enzyme binding sites are denoted as S. The peptide hydrolysis 
occurs at the scissile bond P1-P1’. The prime subsites of both substrates and enzymes 
are the residues of the carboxylic terminal sides. 
 
 
 
Figure 1-27: Representation of the S1 site of neutrophil elastase, showing Val190 and 
Val216 near the top of the pocket, allowing small, hydrophobic amino acids to fit in. 
Modified from Berg et al., Biochemistry, 2002. 186  
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Although the S2-Sn sites display less influence in enzyme specificity compared to the 
S1 site, their presence is important for the enzyme-substrate interaction. In particular, 
the hydrogen bonds formed between the carbonyl oxygen of Ser214 and the NH of the 
P1 residue, the NH of Phe215 and the carbonyl of P3, and the carbonyl of Val216 and 
the NH of P3, are vital for substrate hydrolysis efficiency, but to a lesser extent 
compared with the S1 pocket (Figure 1-28).178, 179 In the case of neutrophil elastase, the 
interaction between P3 and S3 was shown to improve the rate of substrate 
hydrolysis.187   
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Figure 1-28: Illustration of substrate and neutrophil elastase interaction, showing a 
catalytic triad (red), substrate recognition sites (blue and green), and interaction 
between amino acids at P1 subsite and S1 pocket.  
 
Having similarity in structure to neutrophil elastase is its pancreatic counterpart. 
Pancreatic elastase is found in the pancreas and is secreted into the intestines upon 
activation by trypsin to participate in digestion. It has been shown to be mainly related 
to pancreatic diseases.188, 189 Unlike its counterpart, neutrophil elastase is widely known 
for its pathological role in various disease, such as cystic fibrosis, rheumatoid arthritis, 
inflammatory diseases, emphysema and, in particular, tumour invasion.175, 190, 191 Since 
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the main function of neutrophil is host defense, neutrophil elastase is essential for 
migration of neutrophil out of the vasculature and through the basement membrane for 
destruction of foreign invaders. To achieve this process, many connective tissue 
proteins are degraded – in particular, elastin, which is rich in small, hydrophobic amino 
acids, i.e. the preferable substrates for the enzyme. This destructive characteristic of 
the enzyme causes tissue damage which is associated with the diseases mentioned 
above 
 
In the case of cancer, degradation of the basement membrane and connective tissue 
by the enzyme facilitates tumour invasion and metastasis. The disease is usually 
observed alongside elevated levels of the enzyme, unlike in normal tissue. The high 
concentration of neutrophil elastase associated with tumour cells has been shown to be 
a suitable candidate for a site-specific trigger for the detachment of stealth layers at the 
tumour sites.192 The removal of PEG layers can be achieved through enzyme-mediated 
hydrolysis of a peptide linker, conjugated between PEG and lipid. So far, the use of 
neutrophil elastase for triggerable release of PEG coats to improve cell internalisation 
of nanoparticles has not yet been reported. However, the relevant studies that are 
worth mentioning are the works of Pak et al.193 Known to enhance endosomal escape 
due to its ability to induce HII phase transition, DOPE does not form stable bilayers at 
physiological pH and is therefore too unstable for in vivo application. In addition, DOPE-
contained liposomes exhibit nonspecific fusion to cell membranes. Modification of the 
DOPE head group by the addition of a bulkier group renders the lipid to form a stable 
lamellar structure. DOPE was chemically conjugated to elastase substrate peptide, N-
acetyl-Ala-Ala (N-Ac-AA), to generate a peptide-lipid, N-Ac-AA-DOPE.  The peptide 
linker not only altered the stability of DOPE but also temporarily inactivated its 
fusogenicity. While conjugated, the fusogenic property of the lipid was masked, and 
was unmasked upon activation by a specific stimulus, elastase, through the cleavage of 
the peptide linker. The enzyme degradation of the linker resulted in the conversion of 
N-Ac-AA-DOPE to DOPE (Figure 1-29), creating a fusogenic property of liposomes on 
arrival at therapeutic sites. 
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Figure 1-29: Enzyme cleavage of N-Ac-AA-DOPE to unmask fusogenic lipid, DOPE.193 
 
Further study by Pak et al. demonstrated that a tetrapeptide linker, N-methoxy-succinyl-
Ala-Ala-Pro-Val (MeO-suc-AAPV), exhibited greater sensitivity and selectivity for 
elastase cleavage compared to N-acetyl-AA.194 Liposomes containing Dioleoyl 
dimethylammonium propane (DODAP)/MeO-suc-AAPV-DOPE pretreated with HLE 
showed the successful delivery of an encapsulated fluorescence probe, calcein, into 
the cytoplasm of ECV304 endothelial cells.  
 
Collectively, it can be postulated that conjugation of an enzyme substrate peptide 
between a PEG moiety and a lipid-anchoring liposome may render a strategy to detach 
PEG from the liposomal surface in response to specific enzyme at the site of interest, 
which could result in improved cell binding and promote endosomal escape of nucleic 
acids into cytosol.  
 
1.5.3.3 Matrix metalloproteinases  
 
Matrix metalloproteinases (MMPs) have attracted much attention from researchers as a 
new target for cancer therapeutics owing to its direct association with tumours, which is 
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believed to play a major role in tumour invasion and metastasis. There has been a 
recent increase in the number of studies focusing on the use of the enzyme for 
activation of PEG detachment at tumour sites. To achieve metastasis, tumour cells 
have to overcome a series of sequential steps including detachment from the tumour 
mass, disruption of the basement membrane, entry of cells into the vascular or 
lymphatic system (intravasation), cell migration to distal sites and adhesion to 
endothelial cells, escape of cells from blood circulation (extravasation), cell 
proliferation, and induction of angiogenesis (Figure 1-30).195-197 The degradation of the 
basement membrane and extracellular matrix (ECM), consisting of connective tissues 
such as elastin, collagen, fibronectin, and other glycoproteins, is considered the key 
event in tumour metastasis. Since MMPs are capable of digesting various ECM 
components, the action of these enzymes is required for tumour invasion. In addition, 
MMPs play a crucial role in angiogenesis, which is an essential process for tumour 
growth. The basement membrane is degraded and the endothelial cells are induced to 
migrate through the digested membrane into tumour interstitium to create a lumen, 
which eventually turns into a blood capillary.198  
 
 
 
 
Figure 1-30: MMPs are involved in the process of tumour metastasis by degrading the 
basement membrane and facilitating intravasation and extravasation of tumour cells to 
proliferate at the distant site. MMPs are also thought to initiate angiogenesis.195 
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Typically, MMPs are few or absent in normal cells; however, their elevated expression 
is associated with various tumours, such as breast, ovarian, and prostate tumours. An 
increased level of MMPs has been found to be related to the stage of tumour 
development. The enzyme concentration increases with increasing tumour 
progression.195-197 Regulation of MMP function can be achieved at multiple levels 
including transcription, which is in response to growth factors, cytokines, and 
hormones; activation of zymogen by a proteolytic process to release the active enzyme; 
and inhibition of the active enzyme by their natural inhibitors, which are the tissue-
localised tissue inhibitors of metalloproteinases (TIMPs).195  
 
MMPs are a family of zinc-dependent endopeptidases that are synthesised as inactive 
proenzymes (zymogens) which require further proteolytic processing to become active 
enzymes. MMPs can be divided into subgroups on the basis of their structure and 
specificity including collagenases, stromelysins and stromelysin-like, matrilysins, 
gelatinases and membrane-type MMPs (MT-MMPs).195 Over 20 human MMPs and 
other homologues from other species have been reported to date (Figure 1-31).199, 200 
Among the identified MMPs, MMP-2 (gelatinase A, 72 kD) and MMP-9 (gelatinase B, 
92 kD) are thought to be key enzymes involved in tumour metastasis and angiogenesis. 
This is due to their ability to degrade type IV collagen, which is the major constituent of 
the basement membrane, and denatured collagen (gelatin).197 The expression of MMP-
2 is more constitutive while the MMP-9 level is found to be restricted, but it can be in 
rapidly induced under certain conditions.196 The structure of MMP-2 is shown in Figure 
1-32. 
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Figure 1-31: Schematic representation of the 24 human matrix metalloproteinases 
(MMPs).200 MMPs have similar domain structures with a signal peptide to target for 
secretion, a propeptide to maintain latency, a catalytic domain that contains a Zn(II) 
binding site, a hemopexin domain, and a fibronectin region for substrate recognition. 
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Figure 1-32: Representation of the pro-MMP-2/TIMP-2 complex. The domain structure 
of the enzyme is shown: propeptide, catalytic Zn(II) (coloured red), hemopexin, and 
fibronectin regions. The light blue circles indicate the interaction between the 
proenzyme and its inhibitor.201 
 
MMPs share similar structural domains with zinc-binding active sites. Three His 
residues at the active site are required for ligating with Zn(II) ions, which is essential for 
catalytic activity. Glu residue also plays a role in catalytic function. The mechanism of 
peptide hydrolysis starts with coordination of the scissile amide bond of the peptide 
substrate to the catalytic Zn(II) ligated to three residues of His (Scheme 1-5).202, 203 The 
water molecule that is hydrogen bonded to the Glu residue (Glu404 in MMP-2) attacks 
the carbonyl carbon of the substrate and the carbonyl oxygen anion is stabilised by the 
Zn(II) ion. The water molecule donates one proton (H+) to the NH of the scissile amide 
bond. The carbonyl double bond is reformed and the scissile bond is disconnected, 
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releasing carboxylic and amine products. The conserved Ala residue (Ala192 in MMP-
2) helps stabilise the positive charge at the nitrogen of the scissile amide bond.  
 
 
 
Scheme 1-5: General reaction mechanism of peptide hydrolysis by MMPs.204 
 
Recently, MMP-2 has gained much interest in cancer research due to its critical role in 
tumour invasion, metastasis, and angiogenesis, and its constitutive expression in many 
cancers, such as fibrosarcoma, lung, bladder, and colon cancer.195 MMP-2 offers 
several attractive benefits for cancer therapeutics. Of particular interest is the 
exploitation of the enzyme as a potential site-specific trigger for PEG detachment at 
tumour sites. Unlike serine proteases, the selectivity of MMP-2 is dependent on the 
interaction between the S1’ sites and the P1’ residue, as the S1’ pocket is relatively 
deep compared with the S3-S1 subsites that form the shallow region, thus having a 
greater possibility of recruiting amino acid substrates. This feature is also accounted for 
in other MMP enzymes in the family.202 MMP-2 has shown specificity toward collagen, 
the cleavage site of which has been found to be between Gly and Leu/Ile bonds.205, 206 
The design of the MMP-2 substrate is usually based on modification around these 
amino acid residues.  
 
Exploitation of MMP-2 in triggerable release strategies to detach PEG at tumour cells 
has been reported in some studies. Lee et al. has shown that conjugation of MMP-2 
specific peptide substrates, Gly-Pro-Leu-Gly-Val (GPLGV) or Gly-Pro-Leu-Gly-Val-Arg-
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Gly (GPLGVRG), to doxorubicin (DOX) and PEG2000, namely, P5D and P7D 
respectively (Figure 1-33), resulted in cleavable PEGylated peptide-DOX conjugates.207 
The micelles containing P5D, P7D, doxorubicin-loaded P5D, or doxorubicin-loaded 
P7D exhibited longer circulation in blood plasma compared to free doxorubicin, and 
efficiently inhibited mouse tumour growth by about 50-72%.  
 
 
 
 
Figure 1-33: PEGylated peptide-DOX conjugates P5D and P7D. 
 
A MMP-2 sensitive peptide sequence, Gly-Gly-Gly-Val-Pro-Leu-Ser-Leu-Tyr-Ser-Gly-
Gly-Gly-Gly (GGGVPLSLYSGGGG), conjugated between DOPE and PEG2000 has been 
reported on by Hatakeyama et al.208 The PEGylated peptide-DOPE was proved to be 
sensitive to MMP-2 cleavage. Although liposomes consisting of PEGylated peptide-
DOPE exhibited high transfection activity in a MMP-2 positive cell line, HT1080, the in 
vivo study highlighted the need for improvements in order to increase nanoparticle 
stability and maximise their transfection efficiency. 
. 
A successful multifunctional delivery to hepatocellular carcinomas (HCC), exploiting a 
combined strategy of an MMP-2 triggerable release system and targeting moiety, has 
recently been reported by Terada and colleagues.209 HCC is known to highly express 
asialoglycoprotein receptors, which have high affinity for galactose (Gal) ligands. 
However, the problem of targeting delivery to HCC is that the galactosylated liposomes 
can also be taken up by healthy hepatocytes, which highlights the need for further 
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modification. MMP-2, found to be overexpressed in HCC tissues, was used to detach 
the PEG layer and elicit the ligand function at the target sites, improving the selectivity 
of the delivery system. A MMP-2 substrate peptide, Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln 
(GPLGIAGQ), conjugated to DOPE and PEG, was hydrolysed by MMP-2. MMP-2 
pretreated, Gal-targeted liposomes containing the cleavable PEG-peptide-lipid 
conjugate showed increased uptake in HepG2 cells compared with the non-cleavable 
counterpart and the targeted liposome, suggesting that the PEG layer was cleaved by 
MMP-2 and the liposomes were internalised via receptor-meditated endocytosis.     
 
The exploitation of upregulated enzymes associated with tumours provides effective 
advantages not only for triggerable release of the stealth layer but also for targeting of 
tumour cells. The sterically stabilised nanoparticles bearing enzyme sensitive linker are 
able to retain their stability while in blood circulation, but are destabilised after arrival in 
tumour tissues as the PEG coat is removed as a result of peptide hydrolysis by the 
overexpressed enzymes, consequently improving cell uptake (endocytosis) and 
subsequent endosomal escape of the internalised nanoparticles. In addition, since the 
enzymes are expressed at high levels in tumour tissues, unlike in normal cells, this 
feature may be useful for site-specific delivery of the encapsulated agent, reducing non-
specific interaction with non-target cells. 
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1.6 Thesis aim and objectives 
 
The aim of this project is to design, synthesise, and characterise enzyme-sensitive 
PEGylated lipid conjugates that address the limitations of stealth liposomes: poor 
endocytosis and endosomolysis. 
 
The use of a PEG layer presents a dilemma: it is necessary for prolonged nanoparticle 
stability, since it confers greater resistance to opsonisation and thus slows down RES 
recognition; however, its presence at the target site is unfavourable as it significantly 
inhibits cellular interaction and, as a result, diminishes transfection efficiency. To attain 
the beneficial stealth property while in the circulation, and maintain the efficacy of the 
therapeutic agent when it reaches the tumour tissues, a site-specific triggerable release 
mechanism for PEG detachment may improve cell trafficking of the nanoparticles. Of 
the several possible stimuli that could be employed for this purpose, an enzyme trigger 
is the preferred option in this study. The elevated enzyme levels associated with 
tumours, in particular leukocyte elastase (neutrophil elastase) and MMP-2, are found to 
facilitate tumour invasion and metastasis. This feature could be employed as a potential 
site-specific trigger for the removal of the stealth layer.   
 
In this study, a series of enzyme-sensitive PEGylated peptide-lipid conjugates were 
synthesised by conjugation of PEG polymer to a lipid via a peptide linker, either AAPV 
or GPLGV, sensitive to either human leukocyte elastase (HLE) or MMP-2 respectively. 
The ability of the PEGylated compounds to detach the PEG layer through enzymatic 
cleavage of the peptide linker was investigated using analytical techniques. The 
physicochemical properties of the formulated nanoparticles containing the PEGylated 
peptide-lipid conjugates, optimised with respect to size, surface charge, and nucleic 
acid encapsulation efficiency, were examined in order to ensure desirable 
characteristics for nucleic acid delivery. The stability and cytotoxicity of the 
nanoparticles were also assessed, and their ability to improve in vitro nucleic acid 
delivery as a result of PEG detachment in response to the enzymes was then 
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investigated, with the hope of promoting cellular internalisation and endosomal escape 
of the liposomal content inside the cells.   
 
 
 
 
  
 
 
 
 
 
 
2. Synthesis and degradation analysis of 
PEGylated peptide-lipid conjugates 
sensitive to HLE and MMP-2  
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2.1 PEGylated peptide-lipid targets  
 
PEGylated lipid conjugates bearing enzyme sensitive linkers have been incorporated 
within liposomes to enable both stability and, in particular, site-specific triggerable 
release of the stealth layer required for enhanced endocytosis. The design of the 
enzyme cleavable PEGylated lipid involves the coupling of the peptide linker between 
PEG and lipid. The peptide spacer should bear amino acid residues corresponding to 
the target sequence of the enzymes of interest, which are HLE and MMP-2. The 
peptide is conjugated to the head group of a fusogenic lipid for anchoring into lipid 
bilayers, and to a PEG chain for providing the stealth property when incorporated into a 
liposome.  
 
According to the work reported by Pak et al. mentioned in the previous chapter, MeO-
suc-AAPV-DOPE has shown great sensitivity to HLE cleavage; however, the enzyme-
mediated cleavage of the PEGylated compound has not yet been demonstrated. 
Investigation of its enzyme cleavable ability may allow the possibility of utilising this 
system for enzyme triggerable release of the PEG layer at the target site. In this 
project, HLE sensitive PEG-peptide-lipid was synthesised by the conjugation of a short 
peptide sequence, AAPV, between a helper lipid and PEG. HLE shows preferential 
cleavage after V.194 Various peptide linkers have been shown to be sensitive to MMP-2 
cleavage, as discussed previously. Of the peptide sequences that can be degraded by 
MMP-2, GPLGV is the preferred choice for the synthesis of a MMP-2 sensitive PEG-
peptide-lipid target, due to the simplicity of its preparation and also due to it being the 
minimum sequence that matches the active site of MMP-2.207 MMP-2 shows specific 
cleavage between G and V.210, 211 
 
There are a variety of helper lipids that are suitable for incorporation within liposomes, 
including phospholipids and steroid-based lipids. Cholesterol, a steroid-based lipid, was 
recruited due to its ability to stabilise liposomal membranes by increasing packing 
density of phospholipid molecules, resulting in bilayers with greater resistance to 
destabilisation by plasma proteins.124 Cholesterol has minimal toxicity due to its 
endogenous nature.212 In addition, it has shown good stability in a wide range of 
chemical reactions. PEG polymers are commercially available in various sizes and 
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functionalities. The molecular weight of the polymer and its grafting density are proven 
to be crucial for maximising the stealth effect. Many studies have shown that longer 
PEG chains are more capable of preventing plasma protein adsorption and hence 
prolonging blood residence time of the nanoparticles213, 214, but some studies have 
suggested that high grafting densities can be compensated for by low PEG molecular 
weight.146 The most commonly used PEG for liposome formulations is that with 
molecular weight of 2000, due to its ability to sufficiently prevent nanoparticles from 
aggregating and extend their circulation lifetimes, with varied grafting density to about 
10 mol% for in vivo applications.84, 131, 215 PEG with molecular weight of 2000 Da is 
therefore a particularly good choice as a stealth layer in this study. These criteria led to 
the design of PEGylated peptide-cholesterol lipid targets sensitive to HLE and MMP-2, 
shown in Figure 2-1. 
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Figure 2-1: PEGylated peptide-cholesterol lipid targets sensitive to HLE 1 and to  
MMP-2 2 
 
The retrosynthetic analysis of the target molecules 1 and 2 is presented in Scheme 2-1. 
Firstly, HLE and MMP-2 sensitive targets were obtained from the coupling of 6 to PEG 
acid 7. PEG acid is available in activated N-hydroxy succinimide (NHS) ester form, 
providing a facile approach when reacted with primary amines. Disconnection of the 
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amide bond on 6 results in the N’-cholesteryloxy-3-carbonyl-1,2-diaminoethane 5 and 
the peptide 3 or 4. The N-Fmoc-protected short peptides were prepared using solid 
phase peptide synthesis (SPPS). The lipid, N’-cholesteryloxy-3-carbonyl-1,2-
diaminoethane, was synthesised from commercial cholesteryl chloroformate and 1,2-
ethylenediamine.  
 
 
 
Scheme 2-1: The retrosynthetic analysis of target compounds 1 and 2 
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2.1.1 Synthesis of N-Fmoc-protected peptide: substrates of HLE and MMP-2 
 
The peptide substrates were synthesised on solid phase using H-Val-2-chlorotrityl resin 
8 (Scheme 2-2). The coupling agents, 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) and 1-hydroxybenzotriazole (HOBt), 
and base, N,N-diisopropylethylamine (DIPEA), were used for each coupling step 
(Scheme 2-3). The Fmoc group was removed with 20% piperidine/DMF (Scheme 2-4) 
after each amino acid coupling, and deprotection was confirmed by a positive Ninhydrin 
test. The N-Fmoc-protected peptides were finally cleaved from the resin in mildly acidic 
conditions (Scheme 2-5), yielding 9 in good yield (82%) and 10 in reasonable yield 
(49%). The identities of the peptides were confirmed by electrospray ionisation (ESI) 
mass spectrometry and 1H and 13C NMR spectroscopy, and their purities (> 95%) were 
verified by reverse-phase HPLC.    
 
Scheme 2-2: (i) Extension of peptide chain via standard Fmoc method216  a) amino 
acid coupling using N-Fmoc-amino acid, HBTU, HOBt, DIPEA, DMF, rt, 45 min per 
coupling; b) Fmoc deprotection using 20% piperidine/DMF, rt, 10 min (twice); (ii)  0.5% 
TFA/DCM, rt, 4 h, 9 82%, 10 49%  
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Scheme 2-3: Mechanism of peptide bond formation using coupling agents 
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Scheme 2-4: Mechanism of Fmoc deprotection using piperidine 
 
 
 
Scheme 2-5: Mechanism of peptide cleavage from resin using TFA 
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2.1.2  Coupling of N-Fmoc protected peptide to cholesterol lipid 
 
The protection of the amine functional group of the peptides is essential to prevent a 
side reaction (polymerisation of the peptide chains) that can occur otherwise, resulting 
in the loss of product yield. The Fmoc protection allows only a carboxylic acid terminus 
to react with the amine group of N’-cholesteryloxy-3-carbonyl-1,2-diaminoethane 5 to 
yield peptide-cholesterol lipid conjugate. N’-cholesteryloxy-3-carbonyl-1,2-
diaminoethane 5 was prepared by a 1-step coupling reaction between commercial 
cholesteryl chloroformate 12 and excess 1,2-ethylenediamine 11 (Scheme 2-6).  
 
 
Scheme 2-6: i) CHCl3, rt, 18 h, 86% 
 
The N-Fmoc-protected peptides 9 and 10 were then reacted with the free amine group 
of 5, using HBTU and 4-dimethylaminopyridine (DMAP) as carboxylic acid activators, to 
yield 13 and 14, respectively (Scheme 2-7). The reaction mixture was carried out with 
an acidic work-up using 4% citric acid solution, and afforded 13 and 14 in reasonable 
yield and purity. The presences of the conjugated products were confirmed by ESI 
mass spectrometry and 1H and 13C NMR spectroscopy.  
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Scheme 2-7: i) N’-cholesteryloxy-3-carbonyl-1,2-diaminoethane 5, HBTU, DMAP, dry 
CHCl3, rt, 18 h, 13 68%, 14 74%  
 
2.1.3 Synthesis of PEGylated peptide-cholesterol conjugates sensitive to HLE  
and MMP-2  
 
To allow for PEGylation, the Fmoc-protected peptide-cholesterol conjugates 13 and 14 
had to be first deprotected and then functionalised using the commercially available 
pre-activated PEG acid, PEG2000-NHS ester (Scheme 2-8) 
. 
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Scheme 2-8: i) 20% piperidine/dry DCM, rt, 4 h, 15 83%, 16 83%; (ii) PEG2000-NHS, 
DIPEA, dry DCM, rt, 18 h, 17 55%, 18 47%  
 
Fmoc deprotection of 13 and 14 were achieved using 20% piperidine/DCM solution, 
giving 15 and 16 in good yield. Thin layer chromatography (TLC), ESI mass 
spectrometry, and 1H NMR spectroscopy confirmed complete Fmoc removal and the 
formation of the deprotected products. The PEGylation was then carried out in basic 
conditions using DIPEA. The completion of the reaction was facilely monitored using 
HPLC due to the distinguishable retention time (RT) of bound and unbound PEG 
moiety. Compounds 17 and 18 were obtained after purification in moderate yields and 
good purities. The reason for affording the products in moderate yield might be the 
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degradation of PEG-NHS ester during storage and handling, as PEG-NHS ester is 
sensitive to moisture and susceptible to hydrolysis. Hence, only active ester forms can 
react with the amine functionality of peptide-lipid conjugates, resulting in loss of product 
yield. The problem can be overcome by proper handling to minimise the compound’s 
exposure to moisture, or alternatively by use of PEG acid with activating agents such 
as HBTU and DMAP. The formation of 17 and 18 were confirmed by reverse-phase 
HPLC, matrix assisted laser desorption ionisation (MALDI) mass spectrometry, and 1H 
and 13C NMR spectroscopy. The PEGylated peptide-cholesterol (PPC) conjugates were 
named with respect to the specificity of the peptide attached, i.e. PPHLEC and d PPMMP-
2C (Figure 2-2).  
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Figure 2-2: The synthesised PEGylated peptide-cholesterol conjugates: PPHLEC 17 and 
PPMMP-2C 18 
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a) 
 
b) 
 
Figure 2-3:  a) MALDI mass spectrometry traces and b) HPLC traces of PPHLEC 17: 
column reverse phase C-4 protein, gradient mix A = H2O/ 0.1% TFA; B = MeCN/ 0.1% 
TFA; C = MeOH, 0.0 min [100% A], 15.0-25.0 min [100% B], 25.1-45.0 min [100% C], 
45.1-55.0 min [100% A], flow: 1 mL min-1, ELSD detector (similar MALDI and HPLC 
patterns were observed for PPMMP2C 18). 
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2.1.4 Synthesis of control PEGylated cholesterol conjugate 
 
In order to examine the hypothesis that incorporation of cleavable PEG within liposome 
should improve endocytosis of nanoparticles via enzymatic cleavage of the peptide 
linker, non-cleavable PEGylated cholesterol conjugate with the absence of the peptide 
linker was synthesised as a control for in vitro study. Similarly to 17 and 18, the 
PEGylation was carried out in DIPEA, using N’-cholesteryloxy-3-carbonyl-1,2-
diaminoethane 5 and PEG2000-NHS ester, and afforded 19 in excellent yield (Scheme 
2-9). The formation of 19 was confirmed by reverse-phase HPLC, MALDI mass 
spectrometry, and 1H and 13C NMR spectroscopy. The resulting PEGylated cholesterol 
compound was named PC. 
 
 
 
Scheme 2-9: i) PEG2000-NHS, DIPEA, dry DCM, rt, 18 h, 98% 
 
2.1.5 PEGylated peptide-dialkylglycylamide (C18) conjugates sensitive to HLE  
and MMP-2 and control PEGylated C18 conjugate  
 
A new series of PEGylated peptide-lipid conjugates was synthesised using a saturated, 
long-chain hydrocarbon, dialkylglycylamide moiety (C18), in order to compare the effect 
of lipid anchor on enzyme-mediated cleavage, physicochemical properties, and cell 
uptake efficiency of nanoparticles. The PEGylated C18 conjugate series PEG2000-
AAPV-C18, PEG2000-GPLGV-C18, and the control PEG2000-C18 were synthesised and 
supplied as a gift by Dr. Carla Prata in this project. The synthetic procedures of the 
PEGylated C18 conjugate series were quite similar to those of the PEGylated 
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cholesterol conjugate series described above; however, the synthesis of the peptides 
was performed by liquid phase peptide synthesis (LPPS) to scale up the synthesis, and 
the PEGylation was carried out using PEG acid with HBTU and DMAP, as carboxylic 
activators yielded in good yields and purities (Scheme 2-10).217 PEG2000-GPLGV-C18 
21 and PEG2000-C18 22 were synthesised using similar synthetic procedures. The 
compounds 20, 21, and 22 were named as follows: PPHLEC18, PPMMP-2C18, and PC18 
(Figure 2-4). 
 
 
Scheme 2-10: Synthesis of PEG2000-AAPV-C18 20 i) HBTU, DMAP, dry DCM, rt, 90%, 
ii) 50% TFA/ dry DCM, quant., iii) HBTU, DMAP, dry DCM, iv) 20% piperidine/dry DCM, 
quant., v) NaHCO3, H2O/THF, 89%, vi) HBTU, DMAP, dry DCM vii) 50% TFA/ dry 
DCM, quant., viii) PEG2000-COOH, HBTU, DMAP, dry DCM, 20 80% 
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Figure 2-4: The PEGylated peptide-C18 conjugates, PPHLEC18 20 and PPMMP-2C18 21 
and the control PEGylated C18, PC18 22. 
 
2.2 Determination of HLE and MMP-2 activities 
 
Due to batch-to-batch variation of enzyme activity, a determination of enzyme activity is 
necessary to obtain reliable results in all experiments. The amount of enzyme required 
for cleavage studies can also be estimated from this activity.  
 
Determination of HLE activity is based on a colorimetric assay using MeO-suc-AAPV-
pNA 23 as an enzyme substrate218 (Scheme 2-11). pNA 25 is released from the 
substrate as a result of enzymatic cleavage, which can be monitored at 410 nm. The 
HLE activity was calculated based on the calibration curve of pNA, previously 
established. 
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Scheme 2-11: HLE activity assay 
 
MMP-2 activity was determined using a fluorogenic substrate, Mca-PLGL-Dpa-AR-
NH2219 26 (Scheme 2-12). The release of the product, Mca-PL-COOH 27, was 
monitored at ex = 328 nm and em = 393 nm. The MMP-2 activity was defined based 
on the calibration curve of 27, previously obtained.  
 
 
Scheme 2-12: MMP-2 activity assay 
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2.3 Enzyme cleavage study of the synthesised PEGylated peptide-lipid  
conjugates 
  
The PEGylated peptide-lipid conjugates, when incorporated within liposomes, should 
exhibit two features. Firstly, they should exhibit a stealth property, providing stability to 
liposomes while circulating in blood, a high salt/serum environment. Secondly, they 
should exhibit the ability to undergo PEG detachment by enzymes associated with 
tumours, promoting association/fusion with the cellular membrane and uptake, and 
hence enhancing the therapeutic efficacy of the encapsulated agent. To show their 
potential in improving endocytosis, the synthesised PEGylated peptide-lipid conjugates 
should undergo hydrolysis and subsequently detach the PEG layer in the presence of 
these specific enzymes. The ability of the compounds to be degraded by enzymes was 
therefore examined. 
 
MeO-suc-AAPV-pNA 23 is a substrate generally employed for HLE activity assay, as 
the release of pNA after enzyme cleavage can be monitored by UV spectroscopy. To 
initially evaluate the effect of PEGylation on substrate selectivity, a new substrate, 
PEG2000-AAPV-pNA 29, which is the PEGylated form of the original compound, was 
synthesised by Dr. Carla Prata (Figure 2-5) and the cleavage study was performed by 
Dr. Carla Prata using the original substrate 23 and the PEGylated substrate 29.217 The 
hydrolysis rates of these compounds were then compared. 
 
 
 
 
Figure 2-5: The synthesised PEG2000-AAPV-pNA 
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HLE was added to the substrates to a final concentration of 0.05 M and the reaction 
was performed at 37 C in 10 mM HEPES, 154 mM NaCl, 0.1 mM EDTA, pH 7.4. As 
expected, the hydrolysis rate of the PEGylated substrate 29 was significantly slower 
than that of the original substrate 23 (Figure 2-6). The result suggested that the 
presence of conjugated PEG probably affects the enzyme-substrate interaction by 
inhibiting the accessibility of the enzyme to the cleavage site, resulting in a decreased 
rate of substrate hydrolysis.  
 
 
 
 
 
Figure 2-6: The kinetics of free pNA release from HLE catalysed hydrolysis reaction of 
MeO-suc-AAPV-pNA 23 and PEG2000-AAPV-pNA 29, monitored by UV spectroscopy. 
0.12 mM of 23 or 0.20 mM of 29 was incubated with HLE (final concentration of 0.05 
M) at 37 C and the reaction was carried out for 60 min. 
 
The enzyme reactions of the synthesised PEGylated peptide-lipid conjugates were then 
examined. As the PEGylated compounds do not bear a UV-active group, the enzyme 
cleavage study was alternatively performed using reverse phase HPLC in conjunction 
with an evaporative light scattering detector (ELSD). ELSD is classified as a universal 
detector owing to its ability to detect most non-volatile compounds, including those that 
do not absorb UV light – for example, carbohydrates, lipids, amino acids, and polymers 
– like a refractive index detector (RID). However, ELSD offers advantages over RID: 
 Chapter Two: Synthesis and degradation analysis of PEGylated peptide-lipid conjugates  
103 
 
higher sensitivity, compatibility with gradient elution for faster separation and good 
resolution, and stable baselines that are not affected by changes in column 
temperature or solvent gradient. ELSD is therefore a more efficient method for analysis 
of multiple components.  
 
HPLC allows the cleavage reaction to be facilely monitored due to distinguishable 
retention times of parent substrates and cleavage products. Since the PEGylated 
peptide-cholesterol conjugates, PPHLEC 17 and PPMMP-2C 18, were synthesised at the 
initial stage of the project, their enzyme hydrolysis results were discussed first. The 
enzyme cleavage reaction of 17 and 18 are shown below (Scheme 2-3 and Scheme 
2-4).  
 
  
Scheme 2-13: HLE cleavage reaction of PPHLEC 17 
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Scheme 2-14: MMP-2 cleavage reaction of PPHLEC 18 
 
The PEGylated compounds 17 and 18 were incubated with various concentrations of 
HLE and MMP-2, in appropriate buffers at 37 C for various time intervals. After a 
certain incubation period, the reaction was stopped by adding TFA (to HLE reaction) or 
EDTA (to MMP-2 reaction) and aliquots were then subjected to HPLC for analysis. Only 
the peaks of the parent substrates, 17 and 18, were detected with no sign of the 
cleavage products. Several HPLC conditions were performed and the cleavage 
products, 30, 5, 31, and 32, were unable to be observed by ELSD. There are two 
possible explanations. First, the enzyme cleavage of the peptide linker might not 
happen due to the steric hindrance of the PEGylated substrates 17 and 18, which may 
prevent its interaction with the enzyme binding sites and thus inhibit peptide hydrolysis. 
Another possible explanation is that the structural arrangement of the PEGylated 
compounds in aqueous solution may limit the interaction with the enzymes. It is likely 
that the PEGylated peptide lipids form micelles, owing to the amphiphilic nature of the 
molecules, with cholesterol being hydrophobic and the PEG polymer being hydrophilic. 
Further evidence was demonstrated by the determination of the critical micelle 
concentration (CMC) of the compounds using a fluorescence probe, pyrene. The CMC 
of 17 and 18 were found to be 6 and 10 M, respectively. The substrate concentrations 
employed in the enzyme reactions ranged between 0.36-0.37 mM (120-150 L, 1 
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mg/mL) in order to obtain good sensitivity and resolution from the technique. These 
concentrations are, however, above the CMC of the compounds, thus they tend to 
organise themselves in the micellar arrangement, where the PEG polymer forms a 
hydrated sphere around the cholesterol interior (Figure 1-27). In this arrangement, the 
cleavage site is greatly shielded by the PEG polymer due to the steric hindrance of the 
polymer and, consequently, prevents the enzyme from reaching to the cleavage site.  
 
 
 
 
 
Figure 2-7: An illustration of PEGylated peptide-lipid conjugate micelle 
 
It was suggested that the introduction of the PEGylated substrates within a liposomal 
membrane would result in lower PEG density in a hydrated sphere compared to that of 
the micellar form, which may result in improved presentation of the substrate and better 
enzyme-substrate interaction. The compounds 17 and 18 were introduced in the lipid 
bilayers and their grafting densities were varied up to 10 mol% of total lipid 
concentration, which corresponded to the level of PEG typically employed for in vivo 
application. The stabilised liposomes were then incubated with HLE and MMP-2 
respectively at different enzyme concentrations and to various time intervals. Displayed 
by HPLC analysis, the peaks of the parent substrates were very small compared to the 
peaks of other lipid compositions and buffer, owing to their relatively low percentages in 
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the liposome formulations. The tiny substrate peaks detected by the HPLC technique 
make the measurement of the degradation of the linkers difficult. The absence of 
hydrolysis products might be because the reaction did not occur in the first place, or 
because the HPLC and ELSD analysis lack the sensitivity to measure the degraded 
residues.  
 
According to the Derjaguin-Landau-Verwey-Overbeek (DLVO) theory85, for colloidal 
nanoparticles to maintain their stabilities and resist aggregation, the repulsive forces 
(electrostatic and/or steric repulsion) must be greater than the van der Waals attractive 
forces. Liposomes with large positive charge will repel each other and remain stable, 
while liposomes with low positive charge or neutral charge will tend to form aggregates. 
This aggregation results in increased nanoparticle sizes, which could be measured by 
dynamic light scattering. The theory therefore could be applied to the design of the 
enzyme cleavage study and the detection of the degraded products. In buffer solution, 
neutral liposomes containing the PEGylated substrates should retain their stability due 
to steric repulsion between PEG layers on the external surface of the liposomes. 
Conversely, in the presence of the enzyme, PEG detachment through the cleavage of 
the peptide linker exposes the neutral liposomes, which are susceptible to aggregation 
owing to the repulsive forces being less dominant than the van der Waals attractive 
forces87, 157, resulting in an increase in size. The PEGylated substrates 17 and 18 
incorporated into neutral liposomes at 1-5 mol% were incubated with various enzyme 
concentrations at 37 C and their sizes were monitored at different time intervals. The 
diameters of the liposomes, however, were found to be stable while being incubated 
with the enzymes. This observation suggests that the enzyme-mediated cleavage of 
the peptide linker may not occur. According to Basanez and co-workers, the activity of 
phospholipase C was inhibited at PEG grafting densities above 1 mol%, which was 
probably because PEG hindered the enzyme from accessing its substrate.220 Terada et 
al. showed that MMP-2-mediated cleavage of peptide linker was inhibited when 
PEGylated peptide lipid was incorporated within liposomes at 0.5-1 mol%.209 However, 
there was another possibility that the peptide hydrolysis might have occurred 
incompletely, and thus the remaining PEG may provide the nanoparticles with 
adequate resistance to aggregation. Torchillin et al. demonstrated theoretically and 
experimentally that the presence of grafted PEG as low as 1 mol% could reduce protein 
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adsorption and hence confer stability to liposomes.137 In addition, Santos et al. reported 
that circulation longevity of liposomes was enhanced with 0.5 mol% of PEG grafting 
density compared with non-PEGylated liposomes.221  
 
ESI mass spectrometry was also employed, however the degradation of the PEGylated 
compound was not observed. Thereafter, another attempt to verify the enzymatic 
cleavage of the PEGylated substrates was carried out by Dr. Carla Prata using HPLC 
and ELSD analysis. PPHLEC 17 and PPHLEC18 20 were incubated with HLE for 2 h at 37 
C. The denaturation of the enzyme was achieved by freezing the reaction mixture in N2 
(liq.) and aliquots were subjected to HPLC analysis. In the case of PPHLEC18 20, a new 
tiny peak was detected around 25 and 30 min, similar to the retention time of free PEG 
acid (1 in Figure 2-8), suggesting that the compound might be degraded by the enzyme 
but to a very low extent. The retention time of the degraded residue observed was not 
exactly the same as that of free PEG acid, assuming that the degraded product might 
be corresponding to the peptide conjugated to PEG polymer. Although the peaks of 
both the degraded residue and the PEGylated compounds 20 were very tiny, this 
observation suggested the possibility of enzyme-mediated cleavage of the PEGylated 
compounds which may have occurred partially. The enzymatic degradation of the 
PEGylated compound 17, however, was not observed 
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Figure 2-8: The degradation of PPHLEC18 20 after incubation with HLE (200 L, 1.03 
M) for 2 h at 37 C, monitored by HPLC. HPLC: column reverse phase C-4 protein; 
gradient mix A = H2O/ 0.1% TFA; B = MeCN/ 0.1% TFA; C = MeOH, 0.0-10.0 min 
[100% A], 25.0 min [30% A and 70% B], 40.0-45.0 min [100% B], 46.0-55.0 min [100% 
C], 56.0-65.0 min [100% A]; flow rate 1.5 ml min-1, ELSD detector. 
 
Under the same HPLC condition, the MMP-2-mediated cleavage of PPMMP-2C 18 and 
PPMMP-2C18 21 were not detected, suggesting that the peptide cleavage may not occur. 
This might be a consequence of poor substrate-enzyme interaction, which could result 
from the presence of PEG or unsuitable peptide linker. To examine if PEG inhibits the 
peptide hydrolysis, synthesis of the peptide substrate conjugated to chomophore, such 
as pNA, may provide a mean to facilely monitor the hydrolysis reaction. Since MMP-2 
cleaves within amino-acid chain, GPLGV, resulting in di-peptide derivatives conjugated 
to pNA, which is unable to be detected by UV spectrometry. The synthesis of GPLGV-
pNA or PEG2000-GPLGV-pNA might not be advantageous to the enzyme cleavage 
study. 
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2.4 Chapter summary 
 
In conclusion, the synthesis of the PEGylated peptide-lipid conjugates sensitive to HLE 
and MMP-2 was achieved and the enzyme cleavage study of the compounds was 
examined using analytical techniques. So far, only the enzyme cleavage of PEG2000-
AAPV-pNA 29 and PPHLEC18 20 were shown by UV and HPLC respectively, while the 
degradation of the rest of the PEGylated compounds was not observed. The presence 
of PEG in the peptide conjugate may inhibit the enzyme-substrate interaction, as seen 
in the case of MeO-AAPV-pNA 23 and PEG2000-AAPV-pNA 29. The overall results 
obtained from the enzyme study may suggest two possibilities. First, the degradations 
of the PEGylated peptide-lipid conjugates were not feasible as PEG might prevent the 
accessibility of the enzyme to the substrate, resulting in inhibited peptide hydrolysis. In 
this case, modification of the peptide linker, either by coupling small amino acids that 
do not affect the catalytic activity of the enzymes to the original peptide linker or by 
conjugating repeated unit of the active peptide sequence between PEG and the lipid, 
may alter substrate availability and ultimately improve enzyme-substrate interaction. 
The micellar formation of the PEGylated peptide-lipid conjugates in aqueous solution 
could potentially block the accessibility of the enzyme to the cleavage site due to steric 
hindrance of the PEG layer. Another plausible explanation for no observation of the 
degraded linker was the detection limit of the techniques employed. According to the 
enzymatic cleavage of PPHLEC18 20, the degraded residues shown by HPLC were 
detected with very low intensities, suggesting that the degradation of the substrate may 
have occurred partially. It would be possible that the other PEGylated compounds 
might have been degraded by the enzyme but could not be detected. Future work on 
enzyme cleavage studies could involve the use of a colorimetric assay, such as TNBS 
(2,4,6-trinitrobenzenesulfonic acid) or fluorescamine to detect the cleavage of the 
PEGylated compounds. The assay is used for quantitating the amount of protein or 
peptides in solution by rapidly react with primary amine to form an adduct which can be 
detected by UV, or a fluorescent product and the assays could therefore be adopted for 
the detection of the degrade peptide linker. The technique may also allow for the use of 
the substrate concentration below its CMC in order to prevent micellar formation. The 
use of fluorescent PEG, such as Rhodamine-PEG, conjugated with peptide and lipid 
may provide an alternative means to detect the degradation of the PEGylated 
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compounds. The enzyme reaction of the fluorescently labelled PEGylated peptide-lipid 
may be carried out using a dialysis membrane with a certain molecular weight cut-off 
(MWCO), allowing only the degraded residue which is fluorescent PEG-peptide 
conjugate to pass through. This experiment will allow facile monitoring of the enzyme 
reaction by diffusion of coloured fluorescent residues out of the dialysis membrane.  
 
 
 
 
Figure 2-9: Schematic illustration of enzyme-mediated cleavage of fluorescent 
PEGylated peptide-lipid in dialysis chamber that allows only for the passage of 
fluorescent PEG-peptide residue out of the dialysis membrane.       
  
 
 
 
 
 
 
 
3. Biophysical and in vitro biological 
evaluation of PEGylated peptide-lipid 
conjugates: DNA system 
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3.1 Proof of concept study of enzyme-assisted pDNA delivery in vitro   
 
Although the ability of the PEGylated peptide-lipid conjugates to undergo enzymatic 
degradation remained unclear using the analytical techniques, it was decided to further 
investigate their ability to promote pDNA delivery in vitro. PPHLEC was incorporated into 
DODAG/DOPE liposomes in order to obtain PEGylated liposomes bearing the short 
peptide linker sensitive to HLE cleavage. The choice of DODAG/DOPE formulation to 
test the cleavage hypothesis is based on the fact that this formulation has been shown 
to be optimum and generic for in vitro cell transfections in our lab. In these initial 
biological tests, 50 mol% DODAG/DOPE lipoplexes containing either PPHLEC or control 
PC (1 and 5 mol%) was examined for their pDNA transfection efficiency in the presence 
and absence of HLE in OVCAR-3 (human ovarian carcinoma cell lines). The pDNA 
used in this study was pEGFPLuc encoding for enhanced green fluorescence protein 
(EGFP) and luciferase protein. The detail of this pDNA will be discussed later in this 
chapter. Monocytic cell lines, such as U937 and THP-1, are found to secrete HLE upon 
PMA (phorbol 12-myristate 13-acetate) stimulation. However, these suspension cell 
lines are known to be difficult to transfect due to less contact of nanoparticles with cell 
membranes, leaving adherent cell lines, such as OVCAR-3 as an alternative choice for 
the in vitro experiment. The nanoparticles were divided into two groups: HLE-treatment 
and non-treatment, in order to verify the effect of the enzyme on the transfection 
efficiency of these nanoparticles. The result demonstrated that incorporation of PPHLEC 
into DODAG/DOPE nanoparticles resulted in increased gene expression in response to 
HLE compared to non-treated PPHLEC nanoparticles (p < 0.05), and this enhancement 
was more pronounced when compared to non-cleavable PC nanoparticles (p < 0.05) 
(Figure 3-1). The improved gene expression may be a consequence of PEG 
detachment via enzymatic cleavage of the peptide linker, thus promoting endocytosis. 
This encouraging result suggested that although the cleavage of the peptide linker was 
not observed with the techniques discussed in the previous chapter, the use of an 
enzyme triggerable system to mediate nucleic acid delivery may be possible in a 
biological system in vitro. We therefore decided to further investigate the possibility of 
using nanoparticles containing the PEG-peptide-lipid conjugates to improve pDNA 
delivery in response to specific enzymes. 
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Figure 3-1: Preliminary HLE transfection data of 50 mol% DODAG/DOPE 
nanoparticles, containing non-PEG, PPHLEC (1 and 5 mol%), and PC (1 and 5 mol%), 
with HLE-treatment (black) and non-treatment (white), in OVCAR-3 cell lines. The 
transfection efficiency was expressed as % RLU/mg protein of non-PEGylated control 
with HLE-treatment. Each result represents the mean  S.D. (n = 3),  indicates p < 
0.05. (In collaboration with Dr. Mathieu Mevel) 
 
3.2 Liposome formulation 
 
For efficient nucleic acid delivery to tumours, nanoparticles should be formulated such 
that they have favourable properties including size, surface charge, nucleic acid 
encapsulation efficiency, and stability. However, these characteristics mainly allow for 
their long circulation and effective accumulation at the target sites. To maximise cell 
uptake, the stabilised nanoparticles may require a PEG–dissociation strategy to elicit 
the electrostatic ability required for endocytosis. Therefore, the PEGylated peptide-lipid 
conjugates sensitive to HLE and MMP-2 introduced into liposomes were assessed for 
their ability to improve endocytosis through an enzyme-cleavable linker. The 
immunogenicity and cytotoxicity of liposomal carriers in vitro might limit their viable 
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application in vivo. Thus, the effect on cell viability of the added nanoparticles was also 
assessed in this study. 
 
Cationic liposomes generally consist of a cationic lipid and a neutral co-lipid, each of 
which serves different functions essential for the delivery process. The cationic lipid 
incorporated into the formulation confers a positive charge to the liposomes, which is 
required to bind nucleic acids and promote cellular binding and internalisation via 
electrostatic interactions with anionic cell surfaces. The cationic lipid employed in this 
study was N’,N’-dioctadecyl-N-4,8-diaza-10-aminodecanoylglycine amide, known as 
DODAG. It is a novel cationic lipid synthesised by our group, composed of a polyamine 
head group and dialkylglycylamide lipidic tails. It has demonstrated efficient in vitro 
pDNA delivery to many cell lines and also in vivo siRNA delivery to the liver.116 Unlike 
the conventional cationic lipid DOTAP, the polar head group of DODAG consists of 
three amine groups that can be protonated, allowing for more cationic charges 
available for condensing nucleic acids. Although a cationic lipid is critical for improved 
cellular entry, its high molar percentage has been associated with increased toxicity.222, 
223 Another important lipid constituent is a neutral co-lipid. It is believed to facilitate 
cellular internalisation and the endosomal escape of nucleic acids into the cytoplasm. 
DOPE is the most commonly used neutral co-lipid, due to its fusogenicity which is 
associated with a tendency to adopt an inverted hexagonal (HII) phase.121, 122 Despite 
being shown to enhance in vitro transfection efficiency, DOPE poses a problem for in 
vivo use as its fusogenic nature decreases nanoparticle stability as a result of 
increased aggregation in serum environments.224, 225 Other helper lipids, such as 1,2-
dioleoyl-sn-glycero-3-phosphocholine (DOPC) and cholesterol, are therefore more 
attractive candidates for the liposome formulation in this study. Owing to its cylindrical 
shape, DOPC is thought to allow the formation of the stable and small nanoparticles 
essential for long circulation.226 Cholesterol is known to increase liposome stability due 
to its ability to decrease membrane permeability and prevent plasma protein 
adsorption.124, 125 Replacement of DOPE with cholesterol has been shown to increase 
the level of gene expression in vivo.127, 224, 225 Because of these reasons, DOPC and 
cholesterol were chosen as co-lipids in this study. The structures of lipids employed in 
liposome formulation are presented in Figure 3-2. 
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Figure 3-2: The structures of lipids used in liposome formulation, a cationic lipid 
DODAG 33, and neutral co-lipids, DOPC 34 and cholesterol 35. 
 
In this study, we compared the effect of a high concentration of the cationic lipid (50 
mol% DODAG), termed a DODAG-high formulation, and a low concentration of the 
cationic lipid (20 mol% DODAG), termed a DODAG-low formulation, with respect to 
physicochemical characteristics, in vitro transfection efficiency, and stability. Since this 
study aims to improve endocytosis of the steric stabilised nanoparticles through 
enzyme-mediated cleavage of the peptide linker conjugated to PEG, the effect of PEG 
grafting densities of the PEGylated peptide-lipid conjugates (1 and 5 mol%) were also 
examined and compared to the PEGylated lipid control and non-PEGylated 
nanoparticles.  
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Figure 3-3: A schematic diagram illustrating detachment of the PEG layer in response 
to proteolytic enzymes overexpressed in tumour cells via the cleavage of the peptide 
linker (green diamond) leading to increased uptake (left and centre), whereas non-
cleavable PEGylated nanoparticles, with no peptide linker, are unfavourably taken up 
by cells (right).    
   
3.3 DODAG-high formulation with PEGylated peptide-cholesterol conjugates 
 
In this formulation, the cationic lipid DODAG was introduced into lipid bilayers at 50 
mol% of the total lipid concentration, as this concentration was shown to enhance gene 
expression in vitro with minimal cytotoxicity.116 Inclusion of cholesterol at 30 mol% has 
found to increase liposome stability and extend their blood circulation half-lives.124 This 
amount of cholesterol is thus considered optimal for the formulation of long-circulating 
nanoparticles. Since the steric hindrance of PEG depends on its grafting density and 
could significantly affect both the enzyme-substrate interaction and the cellular uptake, 
different molar percentages of the PEGylated compounds (PPHLEC 17 and PPMMP-2C 18, 
and the PEGylated control PC 19), 1 and 5 mol%, were examined. These left the 
remaining molar percentage for the DOPC component. After detachment of the polymer 
through enzyme-mediated cleavage of the linker, the nanoparticles should show similar 
cell internalisation to their non-PEGylated counterparts. The non-PEGylated liposomes 
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were thus prepared as a control for in vitro study. The lipid compositions in a high-
charge formulation are presented in Table 3-1.  
 
  Lipid Molar % of total lipid 
  DODAG 
  DOPC 
  Cholesterol 
  PPHLEC 17, PPMMP-2C 18 or PC 19 
50 
20 (or 19 or 15) 
30 
0 (or 1 or 5) 
 
Table 3-1: Lipid compositions in DODAG-high formulation 
 
The PEGylated conjugates were introduced into liposomes using pre-modification 
technique. Although incorporation of PEG by this method might result in its partial 
entrapment in the liposomal interior, the technique is considered simple and adequate 
for a proof of concept study of enzyme triggerable release of the stealth layer to 
promote cell uptake in vitro.  The liposomes were prepared using a standard technique 
of lipid film hydration. The combined lipid solutions were evaporated to obtain a thin 
lipid film, which was then hydrated in buffer and sonicated to yield unilamellar vesicles. 
The pDNA nanoparticles could typically be produced by mixing an appropriate volume 
of pDNA (pEGFPLuc, 6.4 kb) with the preformed liposomes under heavy vortex.  
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Figure 3-4: Illustration of the assembled PEGylated peptide-lipid nanoparticles. 
 
3.3.1 Physicochemical characterisations of DODAG-high nanoparticles 
 
Since the efficiency of nucleic acid delivery depends on the physicochemical properties 
of the delivery system, including nucleic acid encapsulation efficiency, size, and surface 
charge, optimisation of these properties is necessary to maximise the pharmacological 
activity of the nanoparticles. The physicochemical characteristics of the formulated 
nanoparticles were examined as a function of the lipid: pDNA weight ratio. 
 
3.3.1.1 pDNA encapsulation efficiencies 
 
To maximise the therapeutic effect of delivered pDNA, it is crucial to determine the 
optimal lipid to pDNA ratio required to fully protect pDNA from nuclease degradation 
and retain its integrity. Since pDNA condensation is facilitated by electrostatic 
interaction between positively charged liposomes and negatively charged nucleic acids, 
pDNA encapsulation is mainly dependent on the charge ratios of lipid: DNA, which 
corresponds to their weight ratios. The higher the amount of the lipid, the more the 
positive charges presence for interaction with pDNA. At optimal lipid: pDNA ratio, high 
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efficiency of pDNA entrapment will be achieved, indicating that most of pDNA is 
protected from external environment. The encapsulation of pDNA in liposomes was 
determined using propidium iodide (PI) assay. PI is a nucleic acid intercalating agent 
that exhibits enhanced fluorescence (20- to 30-fold) upon binding to DNA bases. Since 
the dye is membrane impermeant, the amount of non-entrapped pDNA, including 
surface-bound pDNA, can be quantified. This amount can then be converted to the 
amount of encapsulated pDNA, i.e. the encapsulation efficiency. pDNA nanoparticles 
containing PPHLEC, PPMMP-2C and PC, and non-PEGylated nanoparticles were prepared 
at various lipid: pDNA w/w. The encapsulation efficiency of pDNA is presented as a 
percentage of the amount of pDNA initially used in the preparation (Figure 3-5). 
 
 
Figure 3-5: pDNA encapsulation efficiency of DODAG-high nanoparticles with non-
PEG, 1 and 5 mol% PPHLEC, 1 and 5 mol% PPMMP-2C, and 1 and 5 mol% PC at various 
lipid: pDNA w/w (1 ug pDNA), using propidium iodide assay.  
 
The result demonstrated that the increased encapsulation efficiency was associated 
with increased lipid: pDNA w/w, owing to the higher cationic charge available for 
interaction with pDNA. 1 mol% PPHLEC, 1 mol% PPMMP-2C, and 1 mol% PC 
nanoparticles showed almost complete pDNA entrapment at weight ratio of 4, showing 
that the inclusion of 1 mol% PEG and the presence of the peptide linker did not affect 
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the nucleic acid encapsulation efficiencies. At 5 mol% PPMMP-2C and 5 mol% PC 
nanoparticles, the pDNA entrapment was nearly to completion at weight ratio of 12, 
suggesting that increased PEG density decreases surface charge presence to bind to 
pDNA. Thus, higher concentrations of cationic lipid are needed for complete pDNA 
encapsulation. Unlike their 5 mol%-PEGylated nanoparticle counterparts, 5 mol% 
PPHLEC nanoparticles exhibited more than 80% encapsulation efficiency at weight ratio 
of 4. The only differences between these PEGylated liposomes are the types of peptide 
linkers (AAPV and GPLGV) and the presence and absence of the linkers. All amino 
acid residues have neutral hydrophobic side chains, suggesting that there is no 
contribution to the nanoparticle zeta potential from the presence of the peptide linker. 
However, the result suggested that there might be an interference of the peptide linker 
with the pDNA encapsulation that requires further investigation. For all formulations, 
pDNA encapsulation went to completion at weight ratio of 12, and no significant change 
in entrapment efficiency was observed at weight ratios higher than 12. 
 
The pDNA encapsulation efficiency was further visualised and confirmed by agarose 
gel electrophoresis. During electrophoresis, non-encapsulated pDNA bearing negative 
charge due to their phosphate backbones migrate towards the positively charged 
electrode, which is shown by the migration band. A lack of migration band indicates 
complete encapsulation, which means that pDNA is retained in the liposomes (Figure 
3-6). 
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Figure 3-6: 0.8% agarose gel electrophoresis demonstrated pDNA encapsulation of 
DODAG-high nanoparticles with a) non-PEG, b) 1 mol% PPHLEC, c) 1 mol% PPMMP-2C, 
d) 1 mol% PC, e) 5 mol% PPHLEC, f) 5 mol% PPMMP-2C and g) 5 mol% PC at different 
lipid: pDNA w/w (gel a): lane 1= DNA ladder, lane 2 = pDNA, lane 3= empty liposomes, 
lane 4-7 = lipid: pDNA w/w of  1:1, 4:1, 8:1 and 12:1; gel b-g): lane 1= empty liposomes, 
lane 2-5 = lipid: pDNA w/w of  1:1, 4:1, 8:1 and 12:1). The electrophoresis was 
performed at 65 mV for 180 min and the gels were visualized under UV light using 
Alliance 4.7 UVITEC Cambridge.  
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The result from gel electrophoresis was similar to the finding of the PI assay. In the 
case of non-PEGylated, 1 mol% PPHLEC, 1 mol% PPMMP-2C, and 1 mol% PC 
nanoparticles, encapsulation of pDNA was completed at a weight ratio of 4, whereas 
increased molar percentage of PEG required higher cationic lipid concentrations. 5 
mol% PPHLEC showed almost complete encapsulation at weight ratio of 4, which was in 
line with the finding of the PI assay, while pDNA entrapment by 5 mol% PPMMP-2C and 
PC went to completion at weight ratio of 8, slightly lower than that obtained from the PI 
assay. Overall results demonstrated that pDNA was fully encapsulated in all liposome 
formulations at weight ratio of 12.   
 
Preparation of pDNA nanoparticles by direct mixing of the preformed PEGylated 
liposomes and pDNA solution resulted in efficient entrapment of nucleic acids.  
According to the results obtained from the PI assay and agarose gel electrophoresis, 
12:1 lipid: pDNA w/w was found to be optimal to achieve complete pDNA 
encapsulation. This ratio was therefore employed for all experiments involving DODAG-
high formulations.      
 
3.3.1.2 Size measurements 
 
According to the EPR effect, only nanoparticles with small diameters, 100-200 nm, are 
capable of passage through the tumour-vasculature fenestrations, and are thus able to 
accumulate in tumour tissues. Nanoparticles with diameter above 300 nm (with smaller 
surface curvature) are susceptible to opsonisation and uptake by Kupffer cells and 
spleen macrophages.146, 227 The size of the nanoparticles is therefore one of the most 
important characteristics required for effective delivery to tumours. pDNA nanoparticles 
were prepared as described at 12:1 lipid: pDNA w/w. Size measurements were then 
performed using a photon correlation spectrometer (PCS) by characterisation of 
scattered light as a result of the Brownian motion of spherical nanoparticles and size 
distribution obtained was intensity size distribution. The diameters of liposomes ranged 
from 90-130 nm (Figure 3-7). The sizes of 1 mol% PPHLEC, 1 mol% PPMMP-2C, and 1 
mol% PC nanoparticles appeared similar to that of their non-PEGylated counterparts. 5 
mol% PPHLEC, 5 mol% PPMMP-2C and 5 mol% PC exhibited similar size ranges and 
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were approximately 20-25 nm larger than their non-PEGylated counterparts. These 
observations might be related to conformation of PEG on nanoparticle surfaces, which 
is related to its grafting density. PEG is said to adopt a mushroom conformation at low 
surface PEG densities (< 4 mol%), while at higher PEG densities (> 4 mol%), the 
polymer arranges in a brush configuration.147, 152 For PEG2000, the polymer length, 
defined by the Flory dimension (RF), is reported to be approximately 5.6 nm.228  The 
extension of PEG, incorporated at 5 mol%, into a brush regime thus increased the 
overall diameter compared with 1 mol% PEG, which collapses into a mushroom 
regime. After pDNA encapsulation, the nanoparticle diameters were determined to be 
within 120-180 nm and, in all cases, were larger than those of empty liposomes. This 
observation was supported by the work of Wasan et al., which found that pDNA-
liposome complexes had greater diameters, ranging from 200-2000 nm, than that of 
their initial liposomes (100 nm).229 This was probably due to the sandwiching of pDNA 
between lipid bilayers (predicted thickness of 10.5 nm), resulting in the formation of 
multilamellar vesicles, as proposed by Templeton et al..127 The mechanism has been 
known for the formation of non-PEGylated cationic liposome-pDNA complexes, called 
lipoplexes. The formation of multilamellar vesicles was also shown to be possible in the 
case of PEGylated pDNA nanoparticles, demonstrated by the study of Martin-Herranz 
et al. using x-ray diffraction technique.230 Variation in diameter of both liposomes and 
pDNA nanopaticles was observed from preparation to preparation; however, the size of 
liposomes and pDNA nanoparticles was found to fall in the same range as indicated 
above, which are 90-120 nm in the case of liposomes and 120-180 nm in the case of 
pDNA nanoparticles with polydispersity index of 0.2-0.7 for liposomes and 0.5-1.2 for 
pDNA nanoparticles.    
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Figure 3-7: Average diameters of DODAG-high liposomes containing non-PEG, 1 
mol% PPHLEC, 1 mol% PPMMP-2C, 1 mol% PC, 5 mol% PPHLEC, 5 mol% PPMMP-2C and 5 
mol% PC, and their pDNA nanoparticles (12:1 lipid: pDNA w/w), determined by PCS. 
Each result represents the means  S.D. of three measurements. 
 
3.3.1.3 Zeta potential measurements 
 
The surface charge exhibited by nanoparticles can affect both their stability and 
longevity in blood circulation. The determination of the surface charge is therefore 
crucial to establish a stable delivery system and is usually referred to as a 
measurement of zeta potential. When dispersed in solution, nanoparticles generally 
acquire surface charges that influence the distribution of the surrounding ions. This 
results in an electrical double layer surrounding the nanoparticles, termed the Stern 
layer and diffuse layer. Stern layer refers to an inner layer where counter ions are 
closely and tightly bound to the nanoparticle surface, while diffuse layer is an outer 
region where the ions of the opposite charges are associated with the Stern layer 
(Figure 3-8). Within the diffuse layer, there is a notational boundarywhere the 
nanoparticles and the ions form a stable entity, called slipping plane. When the 
nanoparticles diffuse under Brownian motion, the ions within this layer move as part of 
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the nanoparticles with the same velocity. The potential at this boundary is the zeta 
potential. The charged nanoparticles travel toward the electrode in an applied electric 
field with velocity corresponding to the magnitude of their apparent surface charges. 
When the nanoparticles are illuminated with laser beam, the moving nanoparticles 
cause the fluctuation of light intensity detected, which is proportional to the velocity of 
the nanoparticles. The electrophoretic mobility of the nanoparticles is then converted to 
the zeta potential. Based on the DLVO theory that the stability of colloidal nanoparticles 
is dependent on repulsive forces and van der Waals attractive forces, the magnitude of 
zeta potential could be an indicator of the stability of the colloidal system. The 
nanoparticles with large zeta potential, either positive or negative, will repel each other 
and resist aggregation, where as the nanoparticles with low zeta potential are prone to 
aggregation since their repulsive forces are less dominant than their van der Waals 
attractive forces. Although high zeta potential is assumed to be advantageous for in 
vitro gene transfer, as it enhances interaction between nanoparticles and the cell 
surface, nanoparticles with low zeta potential are more preferable for in vivo 
applications since they are less susceptible to opsonisation, which can result in rapid 
uptake by RES, and the nanoparticles therefore exhibit increased blood circulation 
lifetimes.  
 
 
            Chapter Three: Biophysical and in vitro biological evaluation of PEGylated peptide-lipid conjugates: DNA system  
126 
 
 
 
Figure 3-8: Schematic representation of zeta potential of colloidal nanoparitcles. In 
suspension, nanoparticles are associated with electrical double layers. The outer layer 
has a notational boundary where particles and ions form a stable entity and the zeta 
potential is defined as the potential at this boundary. Adapted from 
http://www.malvern.com. 
 
A PEG layer enhances liposome stability by providing steric repulsion and minimises its 
surface charge by forming a protective shell, resulting in nanoparticles with greater 
resistance to aggregation and reduced recognition by macrophages. Here, the effect of 
PEG and its density on apparent surface charges, compared to non-PEGylated 
nanoparticles, was examined. pDNA nanopaticles were prepared at 12:1 lipid: pDNA 
w/w. The pH of the solution was adjusted to 7 and the zeta potential measurement was 
then performed using a zetasizer.  
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Figure 3-9: Zeta potentials of DODAG-high liposomes containing non-PEG, 1 mol% 
PPHLEC, 1 mol% PPMMP-2C, 1 mol% PC, 5 mol% PPHLEC, 5 mol% PPMMP-2C and 5 mol% 
PC, and their pDNA nanoparticles (12:1 lipid: pDNA w/w), determined by zetasizer. 
Each result represents the means  S.D. of three measurements. 
 
The result in Figure 3-9 showed that the zeta potential decreased as the degree of 
PEGylation increased, and non-PEGylated liposomes exhibited the highest zeta 
potential. The reduction in zeta potential is presumably because PEG shifts the slipping 
plane to a greater distance from the liposome surface, resulting in a reduction in zeta 
potential.231, 232 Further decrease in the zeta potential of liposomes was observed for 
pDNA nanoparticles. This reduction in surface charge after pDNA encapsulation was 
presumably a result of charge neutralisation between nucleic acids and cationic 
liposomes, indicating the formation of DNA-liposome complexes.  
 
3.3.2 In vitro pDNA delivery of DODAG-high nanoparticles 
 
The DODAG-high nanoparticles were optimised to achieve desirable physiochemical 
properties required for efficient nucleic acid delivery, as demonstrated previously. The 
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next step would be to assess the potential of PPHLEC and PPMMP-2C nanoparticles in 
promoting cellular uptake (endocytosis) and in improving the endosomal release of 
liposomal contents in the presence of specific enzymes, compared to non-cleavable PC 
nanoparticles. The ability of the nanoparticles to mediate pDNA delivery can be 
examined by means of transfection using a reporter pDNA encoding for a protein. The 
level of the protein expressed in the cells post-transfection represents the transfection 
efficiency of the nanoparticles. Here, the pDNA used was pEGFPLuc (Figure 3-10), 
which encodes for enhanced green fluorescence protein (EGFP) and luciferase protein 
(Luc), isolated from the firefly Photinus pyralis.233 The plasmid contains human 
cytomegalovirus (CMV) as a promoter sequence, which is necessary for the expression 
of the encoded genes, and this promoter is commonly used for the expression of genes 
in many cell lines.234  The pDNA also carries gene encoding for kanamycin/neomycin 
antibiotic resistance. 
 
 
 
Figure 3-10: The pEGFPLuc plasmid 
(http://www.clontech.com/images/pt/dis_vectors/PT3347-5.pdf) 
 
The efficiency in transfection of the nanoparticles was determined by measuring the 
level of luciferase protein expressed, using the luciferase assay system (Promega). The 
luciferase protein produced complexes with the added luciferin substrate, in the 
            Chapter Three: Biophysical and in vitro biological evaluation of PEGylated peptide-lipid conjugates: DNA system  
129 
 
presence of cosubstrates Mg2+ and ATP, to form luciferase-luciferyl-AMP complex. This 
complex is subsequently oxidised by molecular O2, resulting in the production of 
oxyluciferin, CO2, AMP, and light (detectable at 560 nm) (Scheme 3-1). The amount of 
light emitted is proportional to the amount of luciferase protein expressed in cells, i.e. 
the transfection efficiency, which is reported in terms of relative light units (RLU). Since 
the number of cells can vary in each experiment, the comparable transfection efficiency 
can be achieved by normalising the total protein content per experiment using a 
bicinchoninic acid (BCA) protein assay235 (Thermo Scientific). The result is expressed 
as RLU/mg protein. 
 
 
 
Scheme 3-1: The reaction catalysed by the firefly luciferase.233  
 
To assess the transfection activity of the nanoparticles containing PEGylated peptide-
lipid conjugates in response to the specific enzymes, the cell lines used should be able 
to secret the enzymes of interest. HLE is found to be secreted from monocytic cell 
lines, such as U937 and THP-1 upon PMA stimulation. However, transfection of these 
suspension cell lines is known to be difficult due to less contact of nanoparticles with 
cell membranes, and therefore adherent cell lines were used in this study. Elevated 
levels of HLE are found to be associated with tumour progression and development in 
many solid cancers, including breast cancer. MCF-7 (a human breast adenocarcinoma 
cell line), which is an adherent cell line, was chosen here for this reason and also 
because the cells are robust and require minimum handling, making it adequate for a 
proof of concept study of enzyme-assisted gene delivery. Since HLE is mainly secreted 
from neutrophils associated with cancer cells, the nanoparticles were pretreated with 
HLE before being used for transfection. For the MMP-2 experiment, HT1080 (a human 
fibrosarcoma cell line) was chosen because MMP-2 is highly expressed from this cell 
line.208  
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In the HLE experiment, PPHLEC nanoparticles were assessed for their ability to mediate 
gene transfer in response to the enzyme, and their transfection efficiency was 
compared to that of non-PEGylated counterpart, non-cleavable PC control and naked 
pDNA. The effect of PEG density on transfection activity was also examined. To ensure 
that the gene expression was a result of enzyme-assisted delivery, the nanoparticles 
were divided into two groups: HLE-treatment and non-treatment. The nanoparticles 
were incubated with MCF-7 for 6 h. After this incubation period, the cells were washed 
and incubated with fresh complete medium for a further 24 h. The cell lysates were 
then analysed for luciferase expression.  
 
 
 
Figure 3-11: The HLE transfection data of DODAG-high nanoparticles containing non-
PEG, PPHLEC (1 and 5 mol%) and PC (1 and 5 mol%), with HLE-treatment (black) and 
non-treatment (white), in  MCF-7 cell lines. The transfection efficiency is expressed as 
% RLU/mg protein of non-PEGylated control with HLE-treatment. Each result 
represents the mean  S.D. (n = 3),  indicates p < 0.05.   
 
The result of the transfection study showed that PPHLEC nanoparticles after 
pretreatment with HLE (both 1 and 5 mol%) exhibited higher transfection efficiency 
compared with non-treated PPHLEC nanoparticles and non-cleavable PEGylated 
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cholesterol (PC) nanoparticles with HLE treatment and non-treatment (p < 0.05) (Figure 
3-11). The finding suggested that PPHLEC nanoparticles might be cleaved by HLE and 
the resulting nanoparticles, with PEG removal, were favourably taken up by MCF-7 
cells. However, there might be other biophysical changes to the nanoparticles that lead 
to this observation. The transfection efficiency of the nanoparticles after PEG 
detachment should be restored to the same level as that of their non-PEGylated 
counterpart. However, it was found that PPHLEC nanoparticles exhibited a significantly 
increased level of gene expression compared to that of non-PEGylated nanoparticles. 
This is possibly due to the instability of non-PEGylated nanoparticles in the transfection 
medium (normal cell growth medium containing 10% FBS). It was demonstrated by 
Zelphati et al. that binding of negatively charged FBS components, such as bovine 
serum albumin (BSA), lipoproteins, fibrinogen, and heparin, to cationic nanoparticles 
dramatically decreased the level of gene transfer. Two possible mechanisms were 
suggested: (1) destabilisation of nanoparticle structures upon interaction with serum 
components, thus inducing dissociation of pDNA from the complexes; (2) charge 
neutralisation leading to colloidal destabilisation and aggregation.236 The reduction in 
surface charge, as a result of adsorption of serum proteins, weakened the electrostatic 
interaction required for cell association and pDNA delivery was thereby reduced. 
However, nanoparticles with negative charge were shown to be capable of binding to 
cell membranes with a lesser degree of transfection efficiency, suggesting the 
interference of the nanoparticle components with the endosomal release of pDNA, 
since both the endosomal membrane and the complexes bear negative charge.236, 237 
Inclusion of PEG, as in the case of PPHLEC nanoparticles, should delay the adsorption 
of serum components and therefore reduce aggregation. The enhanced gene 
expression by PPHLEC nanoparticles, compared to that by non-PEGylated 
nanoparticles, also suggests that the nanoparticles may undergo partial peptide 
hydrolysis, leading to partial PEG detachment from the surface of the nanoparticles. 
The remaining PEG layer may allow the nanoparticles to maintain their stability in the 
transfection medium, and the partial surface exposure may render them to re-obtain 
their positive charge (or part of it) sufficient to facilitate interaction with negatively 
charged cell membranes that leads to cell uptake. 
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Transfection with naked pDNA did not show improvement in gene expression, possibly 
due to its degradation by nucleases in FBS. This highlighted the importance of carriers 
to retain nucleic acid integrity as well as their therapeutic function. The transfection 
efficiency of the HLE-pretreated PPHLEC nanoparticles decreased with increasing molar 
percentage of PEG. This observation was in line with several other studies using 
PEGylation systems, which is believed to result from reduced cell internalisation and 
also decreased level of endosomal escape.238 This result also suggests the lesser 
extent of PEG detachment in 5 mol% PPHLEC compared with that of 1 mol%, shown by 
the decrease in gene expression level. The PEG effect was also seen for the other 
PEGylated nanoparticles. Non-treated PPHLEC nanoparticles and non-cleavable PC 
nanoparticles, with HLE treatment and non-treatment, showed increased level of gene 
expression but to a lesser extent than HLE-treated PPHLEC nanoparticles, suggesting 
that PEGylated nanoparticles were capable of internalisation into the cell but may 
inhibit the endosomal escape of nucleic acids. The study of Song et al. showed that 
PEG-lipid had minimal effect on cell binding and subsequent endocytosis of cationic 
nanoparticles, but instead substantially inhibited the endosomal disruption of the lipid 
complexes, possibly by preventing fusion with endosomal membranes.158 Keller et al. 
also demonstrated that although PEG-lipid could be taken up by cells, its presence 
severely inhibited transgene expression.239 In the non-treatment group, 5 mol% PPHLEC 
nanoparticles showed a similar level of gene expression to that of their 5 mol% PC 
counterparts, presumably because of the steric hindrance effect. However, non-treated 
1 mol% PPHLEC exhibited increased transfection efficiency compared to that of 1 mol% 
PC (p < 0.05) which might be due to nonspecific hydrolysis of the peptide linker. 
Although the serum does not affect the cleavage of the peptide linker as seen by 
experiment using HLE chromogenic substrate, MeO-Suc-AAPV-pNA in cell culture 
medium, it is possible that the peptide linker may be cleaved by other nonspecific 
peptidases at different positions in the peptide chain. The effect of non-specific 
hydrolysis, however, was minimal when 5 mol% PEG was incorporated, possibly due to 
steric hindrance of PEG. Non-cleavable PC nanoparticles with HLE treatment and non-
treatment showed comparable transfection efficiencies, and a similar finding was 
observed for non-PEGylated nanoparticles, indicating that the enzyme had minimal 
effect on cellular internalisation of the control PEGylated nanoparticles. The 
transfection efficiency of HLE-treated 1 mol%-PPHLEC nanoparticles was found to be as 
efficient as that of the commercial transfection agent Lipofectamine 2000 (data not 
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shown), demonstrating the efficiency of the developed nanoparticle system and its 
possibility for in vivo use.  
 
In the MMP-2 experiment, the ability of PPMMP-2C nanoparticles to mediate pDNA 
delivery was assessed on the MMP-2 positive cell line, HT1080, and their transfection 
efficiency was compared to that of naked pDNA, non-PEGylated counterpart, and 
PEGylated lipid control (PC). Transfection study of PPMMP-2C and the control 
nanoparticles was carried out on HT1080 for 24 h. Then, the cells were washed and 
incubated with fresh complete medium for a further 24 h before cell lysates were 
analysed for luciferase expression.  
 
 
Figure 3-12: The MMP-2 transfection data of DODAG-high nanoparticles containing 
non-PEG, PPMMP-2C (1 and 5 mol%) and PC (1 and 5 mol%), in HT1080 cell lines. The 
transfection efficiency is expressed as % RLU/mg protein of non-PEGylated control. 
Each result represents the mean  S.D. (n = 3),  indicates p < 0.05.   
 
The transfection data obtained showed that transfection efficiency of PPMMP-2C 
nanoparticles (1 and 5 mol%) was significantly higher than that of non-cleavable PC 
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nanoparticles (Figure 3-12). This result suggested that enzyme-mediated cleavage of 
the peptide linker on the surface of the nanoparticles might occur, leading to the 
detachment of the PEG layer and the subsequent restoration (i.e. increase) of positive 
charge required for enhanced cellular internalisation. The resulting nanoparticles, after 
PEG removal, should exhibit comparable levels of gene expression to that of their non-
PEGylated counterpart. However, as with the HLE transfection study, non-PEGylated 
nanoparticles exhibited relatively lower transfection efficiency, which was presumably 
due to their instability (aggregation and destabilisation) in the transfection medium 
(normal cell growth medium). No improvement in gene expression was observed when 
using naked pDNA, suggesting its inability to enter the cells and its degradation by 
nucleases in the cell culture medium and thereby loss of gene expression function. The 
transfection efficiency of PPMMP-2C nanoparticles was shown to decrease as molar 
percentage of PEG increased. This result indicated that PEG might be cleaved to a 
lesser extent from 5 mol% PPMMP-2C compared with that of 1 mol%, and the remaining 
stealth layer might inhibit the cellular uptake and/or the release of nucleic acids from 
endosomes. In contrast to PPMMP-2C nanoparticles, non-cleavable PC nanoparticles 
exhibited similar gene expression levels irrespective of PEG concentrations, indicating 
that in this condition (normal cell growth medium) this 1% level of stealth might be 
sufficient to prevent transfection. PC nanoparticles also showed decreased levels of 
transfection compared with their non-PEGylated counterpart, presumably due to the 
effect of steric hindrance. Although the transfection efficiency of PPMMP-2C nanoparticles 
was found to be considerably lower than that of Lipofectamine 2000 (data not shown), 
they exhibited a significant increase in gene expression levels compared with their non-
cleavable controls, indicating the feasible use of enzyme-assisted delivery in improving 
cellular uptake and subsequent pDNA escape from endosomes. 
 
According to the transfection data obtained from the HLE and MMP-2 experiments, the 
transfection efficiency was markedly enhanced when PPHLEC and PPMMP-2C 
nanoparticles were used in the presence of the enzymes, compared to that of the 
control PC nanoparticles with no peptide linkers. Overall data suggested that partial 
peptide hydrolysis by the specific enzymes may have occurred, leading to partial 
detachment of the PEG layer. The resulting nanoparticles then reveal more of their 
positive charges, facilitating interaction with anionic cell membranes and leading to 
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more favourable uptake by cells, whilst the remaining PEG helps to maintain the 
nanoparticle stability in the transfection medium. However, it is possible that other 
biophysical changes to the nanoparticles may have occurred, leading to an increase in 
transfection efficiency, for example the enzymes may require a certain PEG 
conformation found only on the surface of these nanoparticles in order to interact with 
the substrate or the association of the enzyme at the cleavage site may increase 
sedimentation of the complexes onto the cell surface and thereby enhance cell 
association. In the future, more information on the mechanism of enzyme-assisted 
delivery and cellular uptake of these nanoparticles should be accumulated.    
 
For in vivo applications, the overall therapeutic efficiency of nanoparticles could be 
hampered by their instability in blood circulation. Interaction of charged nanoparticles 
with plasma proteins may cause aggregation, dissociation, and increased recognition 
by the circulating macrophages, consequently diminishing the therapeutic efficacy of 
the nanoparticles. In addition, aggregation could activate the complement system, 
leading to the rapid clearance from blood circulation and increased toxicity of the 
administered nanoparticles. It is therefore crucial that nanoparticles should exhibit good 
colloidal stability, a characteristic required for extended circulation lifetimes and 
enhanced accumulation at target tissues. Inclusion of a stealth layer has been shown to 
increase the colloidal stability of nanoparticles. To investigate the effectiveness of PEG 
in preventing aggregation, 1 and 5 mol% of PPHLEC and PPMMP-2C nanoparticles, which 
were previously used in transfection experiments, were examined for their stability in 
transfection medium (10% FBS) compared to that of the non-PEGylated system. The 
nanoparticles were incubated in transfection medium at 37 C and their increase in size 
(aggregation) was monitored as a function of time over a period of 4 hours.  
 
            Chapter Three: Biophysical and in vitro biological evaluation of PEGylated peptide-lipid conjugates: DNA system  
136 
 
 
Figure 3-13: The stability of DODAG-high nanopaticles containing non-PEG, PPHLEC (1 
and 5 mol%), and PPMMP-2C (1 and 5 mol%) in transfection medium (10% FBS), 
assessed by monitoring the change in nanoparticle diameter as a function of time 
(every 30 min over 4 h).  
 
The non-PEGylated nanoparticles were found to be unstable, and rapidly aggregated 
with diameter increasing to almost 300 nmcompared with their original size (Figure 
3-13). Increasing stability was observed when PEG was incorporated, shown by a 
smaller increase in diameter. 1 mol%-PPHLEC nanoparticles showed a level of 
aggregation comparable to that of the non-PEGylated counterpart after 120 min of 
incubation, and the aggregation decreased when the molar percentage of PEG was 
increased to 5 mol%. Similar to the PPHLEC counterpart, PPMMP-2C nanoparticles 
exhibited greater resistance to aggregation with increasing PEG concentration. From 
this result, it can be postulated that the inclusion of PEG provided steric repulsive 
barriers between two approaching nanoparticles and thus reduced interparticle van der 
Waals attraction. The polydispersity index of the nanoparticles was found to be 1.4-2.0 
over the incubation period.  
 
Although the PEGylated nanoparticles showed increased stability compared with the 
non-PEGylated system, a significant change in size over the course of the experiment, 
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indicating aggregation, was observed. In higher  protein concentrations, such as in 
blood, high-charged nanoparticles would be rapidly aggregated leading to increased 
RES recognition and accumulation in the liver and lungs.240, 241 Although the PEGylated 
nanoparticles enhanced transfection efficiency in the presence of the enzymes, their 
instability in the transfection medium (containing 10% FBS) limited their use in vivo. 
Thus, the nanoparticles with lower surface charge (zeta potential) are more favourable 
due to their lower susceptibility to opsonisation and uptake by macrophages and 
thereby increased blood residence time.242, 243 The effects of DODAG-low nanoparticles 
on transfection activity and stability are discussed in the following section. 
 
3.4 DODAG-low formulation with PEGylated peptide-cholesterol conjugates 
 
Nanoparticles with high zeta potential are associated with efficient gene expression due 
to increased cell membrane association. Although a decrease in effective charge would 
significantly diminish their transfection activity, low-charge nanopaticles exhibit 
extended circulation half-lives.222, 244  From a therapeutic point of view, an efficient 
nucleic delivery system should be a compromise between good stability in blood 
circulation and high transfection ability. Here, the effects of charge on the transfection 
efficiency of PPHLEC and PPMMP-2C nanoparticles as well as on their stability were 
investigated. The minimisation of the surface charge could be generally achieved by 
decreasing the amount of the cationic lipid incorporated in the liposome formulation, as 
long as there is good association with nucleic acids. This also reduces the cytotoxicity 
associated with using high concentrations of the cationic lipids. In the DODAG-low 
formulation, the cationic lipid, DODAG, was reduced to 20 mol% since this percentage 
was previously found by our group to be a favourable minimum to obtain pDNA 
nanoparticles on the order of 100 nm in diameter with good encapsulation efficiency. 
The molar percentage of cholesterol was 30 mol%, the same as that of the DODAG-
high formulation since this amount was shown to be optimal for extended half-lives of 
nanoparticles. The PEGylated compounds PPHLEC, PPMMP-2C, and PC were 
incorporated at 1 and 5 mol%, which left the remaining percentage to DOPC lipid. The 
lipid compositions in the DODAG-low formulation are shown in Table 3-2. 
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  Lipid mol % of total lipid 
  DODAG 
  DOPC 
  Chol 
  PPHLEC 17, PPMMP-2C 18 or PC 19 
20 
50 (or 49 or 45) 
30 
0 (or 1 or 5) 
 
Table 3-2: Lipid compositions in DODAG-low formulation 
 
3.4.1 Physicochemical characterisations of DODAG-low nanoparticles 
 
The cationic lipid in the DODAG-low formulation was decreased by 2.5 times compared 
to that in the DODAG-high formulation. This should have led to a reduction in the 
overall surface charge, which may affect the ability of the nanoparticles in nucleic acid 
association. Similar physiochemical characterisations, including pDNA encapsulation 
efficiency, size, and surface charge, were examined for the DODAG-low nanoparticles 
and compared with the DODAG-high system. 
 
3.4.1.1 pDNA encapsulation efficiencies 
 
Similar to the DODAG-high formulation, pDNA nanoparticles containing PPHLEC, PPMMP-
2C, and PC, and non-PEGylated nanoparticles were prepared at various lipid: pDNA 
w/w. The encapsulation efficiency was determined by PI assay and the result was 
expressed as a percentage of the amount of pDNA initially used in the preparation 
(Figure 3-14). Like the DODAG-high formulation, encapsulation efficiency increased as 
lipid: pDNA w/w increased, presumably due to the greater amounts of cationic lipid 
available for binding to pDNA. Most of the DODAG-low nanopaticles showed almost 
complete pDNA entrapment at weight ratio of 12 and no significant change in 
encapsulation efficiency was observed at higher weight ratios. However, as previously 
demonstrated, pDNA entrapment was almost to completion at weight ratio of 4 for most 
DODAG-high nanoparticles. In addition, the DODAG-high non-PEGylated counterpart 
            Chapter Three: Biophysical and in vitro biological evaluation of PEGylated peptide-lipid conjugates: DNA system  
139 
 
showed more than 80% encapsulation efficiency at weight ratio of 2 compared with 
weight ratio of 8 for the DODAG-low system. These results suggest that the ability of 
the nanoparticles to condense nucleic acids is dependent on the amount of the cationic 
lipid, since the DODAG-low formulation consisted of 2.5 times less cationic lipid than 
the DODAG-high formulation. 1 mol% PPHLEC and 1 mol% PPMMP-2C nanoparticles 
exhibited higher encapsulation efficiencies compared to that of their 5 mol% PEGylated 
counterparts, suggesting less cationic charge presence for interaction with pDNA due 
to higher PEG concentrations. Compared to their 1 mol% PPHLEC and 1 mol% PPMMP-2C 
counterparts, 1 mol% PC nanoparticles required higher weight ratio (weight ratio of 12) 
for almost complete pDNA entrapment. This result suggested that the presence of the 
peptide linkers may facilitate the entrance of pDNA into liposomes or prevent it from 
leaving the core of the liposomes.  
 
 
Figure 3-14: pDNA encapsulation efficiency of DODAG-low nanoparticles with non-
PEG, 1 and 5 mol% PPHLEC, 1 and 5 mol% PPMMP-2C, and 1 and 5 mol% PC at various 
lipid: pDNA w/w (1 ug pDNA), using propidium iodide assay.  
 
Agarose gel electrophoresis was then performed to visualise and confirm the data 
obtained from PI assay. The result from gel electrophoresis was similar to the finding of 
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the PI assay (Figure 3-15). pDNA encapsulation by 1 mol% PPHLEC went to completion 
at slightly lower weight ratio compared to that from PI assay. 1 mol% PPMMP-2C and 1 
mol% PC nanoparticles exhibited complete pDNA encapsulation at weight ratios of 8 
and 12 respectively, while pDNA entrapment by their 5 mol% PEGylated counterparts, 
including PPHLEC, went to completion at weight ratio of 12. This result was in agreement 
with the finding of PI assay. For all low-charge nanoparticles, pDNA was fully 
encapsulated at weight ratio of 12. 
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         (a                    (b       (c  
      
 (d            (e           (f                               (g 
             
Figure 3-15: 0.8% agarose gel electrophoresis demonstrated pDNA encapsulation of 
DODAG-low nanoparticles with a) non-PEG, b) 1 mol% PPHLEC, c) 1 mol% PPMMP-2C, 
d) 1 mol% PC, e) 5 mol% PPHLEC, f) 5 mol% PPMMP-2C and g) 5 mol% PC at different 
lipid: pDNA w/w. (gel a) lane 1= DNA ladder, lane 2 = pDNA, lane 3= empty liposomes, 
lane 4-7 = lipid: pDNA weight ratio of  1:1, 4:1, 8:1 and 12:1; gel b-g) lane 1= empty 
liposomes, lane 2-5 = lipid: pDNA weight ratio of  1:1, 4:1, 8:1 and 12:1). The 
electrophoresis was performed at 65 mV for 180 min and the gels were visualized 
under UV light using Alliance 4.7 UVITEC Cambridge. 
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Overall pDNA encapsulation data obtained from both PI assay and agarose gel 
electrophoresis showed that complete encapsulation of pDNA was achieved at 12:1 
lipid: pDNA w/w. The ratio was the same as the finding from the DODAG-high system, 
although slight differences in entrapment efficiency were observed in each formulation. 
The weight ratio of 12 was thus used for all experiments related to the DODAG-low 
formulation. 
 
3.4.1.2 Size measurements 
 
The diameter of the liposomes and pDNA nanoparticles (12:1 lipid: pDNA w/w) were 
measured using PCS. The diameters of the DODAG-low liposomes were found to be 
between 80-100 nm (Figure 3-16), slightly smaller than that of the DODAG-high 
liposomes (90-130 nm). At higher molar percentages of PEG, the PEGylated 
nanoparticles exhibited smaller sizes compared with their non-PEGylated counterparts. 
This was presumably due to the lateral steric repulsion between PEG chains, causing 
nanoparticles to increase their surface curvatures in order to relieve the strain, thus 
reducing their sizes. 245 After complexing with pDNA, the diameters of the nanoparticles 
were greater than that of the initial liposomes, indicating nucleic acid encapsulation. 
The polydispersity index of both liposomes and pDNA nanoparticles in each 
preparation was found between 0.2-0.8. 
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Figure 3-16: Average diameters of DODAG-low liposomes containing non-PEG, 1 
mol% PPHLEC, 1 mol% PPMMP-2C, 1 mol% PC, 5 mol% PPHLEC, 5 mol% PPMMP-2C and 5 
mol% PC, and their pDNA nanoparticles (12:1 lipid: pDNA w/w), determined by PCS. 
Each result represents means  S.D. of three measurements. 
 
3.4.1.3 Zeta potential measurements 
 
The zeta potential measurement of the DODAG-low liposomes showed a decrease in 
zeta potential as PEG concentration increased, with the effect being more pronounced 
at 5 mol% PEG (Figure 3-17), indicating greater shielding of the surface charge. All 
DODAG-low liposomes exhibited smaller zeta potentials compared to the DODAG-high 
formulation due to the reduced amount of the cationic lipid in the formulation. After 
nucleic acid encapsulation (12:1 lipid: pDNA w/w), the nanoparticles showed a further 
decrease in zeta potential owing to charge neutralisation, indicating the complexation 
between liposomes and pDNA. The zeta potential was found to be less than 10 mV for 
1 mol%-PEGylated and non-PEGylated nanoparticles, and almost neutral for 5 mol%-
PEGylated systems.  
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Figure 3-17: Zeta potentials of DODAG-low liposomes containing non-PEG, 1 mol% 
PPHLEC, 1 mol% PPMMP-2C, 1 mol% PC, 5 mol% PPHLEC, 5 mol% PPMMP-2C and 5 mol% 
PC, and their pDNA nanoparticles (12:1 lipid: pDNA w/w), determined by zetasizer. 
Each result represents means  S.D. of three measurements.  
 
3.4.2 MTS cell proliferation assay with DODAG-low nanoparticles containing 
PEGylated peptide-cholesterol conjugates 
 
The effect of the nanoparticles on in vitro cell viability can be assessed by the 
determination of the cell population’s response to the nanoparticles using MTS assay. 
MTS is a colorimetric method for assessing the number of viable cells (balance 
between cell proliferation and cell death), which decreases if apoptosis or necrosis 
occurs. Similar to MTT, the assay involves the reduction of a tetrazolium compound by 
the dehydrogenase enzyme found in metabolically active cells (Figure 3-18). However, 
MTS requires fewer steps than MTT. The formazan product from MTT reduction is a 
crystalline precipitate that requires solubilisation before recording the absorbance, while 
the formazan product from MTS assay is soluble in tissue culture medium and its 
absorbance can be read immediately. The conversion of the yellow tetrazolium MTS 
(3,(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
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tetrazolium, inner salt) to the soluble purple product, formazan, by dehydrogenase 
enzyme can be measured spectrophotometrically at 490 nm. The absorbance of 
formazan is proportional to the number of living cells, allowing for measuring and 
quantifying the viability of cells in the presence of the nanoparticles.   
 
a) 
 
b) 
 
 
 
Figure 3-18: The reduction of tetrazolium compounds a) MTT and b) MTS to formazan 
product as a result of the metabolic activity of dehydrogenase enzyme. 
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The nanoparticles containing PPHLEC and PPMMP-2C (1 and 5 mol%) at three lipid: pDNA 
w/w (8:1, 12:1, and 16:1; 1 ug pDNA/well) were assessed for their effects on cell 
viability. The nanoparticles were incubated with MCF-7 and HT1080, respectively, for 
three incubation periods (4, 8, and 24h). Cells with no nanoparticles added were 
employed as positive controls and the measured cell viability is expressed as a 
percentage.  
 
       a)                                                                        b) 
 
 
       c)                                                                         d) 
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        e)                                                                         f)                                                           
 
Figure 3-19: MTS cell viability results of DODAG-low nanoparticles containing 1 and 5 
mol% PPHLEC incubated with MCF-7 for 4, 8 and 24 h (a-c) and 1 and 5 mol% PPMMP-2C 
nanoparticles incubated with HT1080 for 4, 8, and 24 h (d-f). The cell viability data are 
expressed as a percentage of the positive control cells without nanoparticles added to 
them. 
 
The result of the MTS assay (Figure 3-19 a-c) showed that the cell viability was 
maintained above 80% for PPHLEC nanoparticles regardless the molar percentages of 
PEG, weight ratios, and incubation times. A similar finding was observed for PPMMP-2C 
nanoparticles, of which the cell viability was found to be greater than 70% (Figure 3-19 
d-f). The results suggested that the added nanoparticles had a minimal effect on cell 
viability and that the cells continued normal growth despite the presence of the 
nanoparticles. A second assay that was used to confirm the results of the MTS assay 
was the lactate dehydrogenase (LDH) cytotoxicity assay, which was further carried out 
to quantify the level of cell death due to the PEGylated nanoparticles.  
 
3.4.3 Lactate dehydrogenase (LDH) cytotoxicity assay with DODAG-low  
nanoparticles containing PEGylated peptide-cholesterol conjugates 
 
To assess the toxic effect of the nanoparticles, LDH cytotoxicity assay was carried out 
using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega). LDH assay is a 
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colorimetric assay that quantitatively measures a stable cytosolic enzyme, lactate 
dehydrogenase (LDH), released upon cell lysis during cell death. The LDH enzyme 
assay results in the conversion of a tetrazolium salt, 2-p-(iodophenyl)-3-(p-nitrophenyl)-
5-phenyltetrazolium chloride (INT), with the aid of diaphorase (an enzyme catalysed 
dehydrogenation of NADH to NAD+), to a red formazan product, the absorbance of 
which can be measured at 490 nm (Figure 3-20). The amount of colour formed 
(formazan) is proportional to the number of lysed cells (dead cells). This allows for 
measuring the level of cell death due to the cytotoxicity of the added nanopaticles.  
 
 
 
Figure 3-20: General chemical reactions of the LDH cytotoxicity assay.  
 
Similar to the MTS assay, PPHLEC and PPMMP-2C nanoparticles (1 and 5 mol%) were 
assessed for their cytotoxicity at three lipid: pDNA w/w (8:1, 12:1, and 16:1; 1 ug 
pDNA/well). The nanoparticles were incubated with MCF-7 and HT1080, respectively, 
for 4, 8, and 24 h. The cells with no nanoparticles added were used as a positive 
control and the cell death from cytotoxicity was measured and expressed as a 
percentage (Figure 3-21).  
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          a)                                                                         b) 
 
          c)                                                                          d) 
 
          e)                                                                          f) 
 
Figure 3-21: LDH assay results showing % cytotoxicity as a result of the added 
DODAG-low nanoparticles containing: a-c) 1 and 5 mol% PPHLEC nanoparticles 
incubated with MCF-7 for 4, 8, and 24 h and d-f) 1 and 5 mol% PPMMP-2C nanoparticles 
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incubated with HT1080 for 4, 8, and 24 h. The result is expressed as a percentage 
normalised against control cells without added nanoparticles.  
 
PPHLEC nanoparticles showed no significant differences in toxicity irrespective of PEG 
concentrations, lipid: pDNA weight ratios, and incubation times over the incubation 
period of 4 and 8 hours. However, LDH release from the cells increased to 10-12% 
after 24 h incubation for all formulations and weight ratios. For 1 mol% PPMMP-2C 
nanoparticles, LDH release was less than 8% during all three periods of incubation. 
When PEG concentration was raised to 5 mol%, enhanced LDH release with increased 
lipid: pDNA weight ratio and incubation times was observed. At the conclusion of 24 h, 
the weight ratio of 16 showed approximately 20% cell death whereas around 15% and 
10% were observed at weight ratios of 12 and 8, respectively. This result suggests that 
enhanced toxicity was associated with the concentration of PPMMP-2C incorporated into 
the liposome formulation, the weight ratio of lipid: pDNA, and also the duration of time 
over which the nanoparticles were exposed to the cells. This observed effect on cell 
viability may indicate an impurity from the synthesis, or that the amphiphile has an 
effect on cell viability. Although increased LDH release was observed in some 
formulations, the release levels were minimal, <15% in most cases, suggesting that the 
added nanoparticles do not greatly affect cell proliferation. 
 
From MTS cell viability and LDH toxicity data, it was concluded that PPHLEC and PPMMP-
2C nanoparticles (1 and 5 mol%) for all weight ratios are not associated with significant 
toxicity. Along with high pDNA encapsulation efficiency, the weight ratio of 12 exhibited 
an acceptably low level of toxicity and is therefore optimal for cell uptake study.  
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3.4.4 In vitro pDNA transfection of DODAG-low nanoparticles containing  
PEGylated peptide-cholesterol conjugates 
 
The DODAG-low nanoparticles containing PPHLEC and PPMMP-2C were then investigated 
for their ability to mediate pDNA delivery, and the effect of charge on transfection 
efficiency was also examined and compared with that of the DODAG-high formulation. 
 
3.4.4.1 Transfection study of PPHLEC nanoparticles 
 
Transfection study of PPHLEC nanoparticles was carried out under the same conditions 
and in the same cell line as that of the high-charge formulation. The transfection data 
showed enhanced transfection efficiency when using 1 and 5 mol% of PPHLEC 
nanoparticles after pretreatment with HLE, compared with non-treated PPHLEC 
nanoparticles and non-cleavable PC nanoparticles with HLE treatment and non-
treatment (p < 0.05) (Figure 3-22a). These findings are similar to those of the DODAG-
high nanoparticles. Once more, the transfection efficiency of non-PEGylated 
nanoparticles was markedly lower than that of the PEGylated nanoparticles, indicating 
that non-PEGylated nanoparticles with lower zeta potential were still susceptible to 
aggregation, leading to less electrostatic interaction with cell membranes. The inhibiting 
effect of PEG on endosomal disruption as the molar percentage of PEG increased was 
also observed for both PPHLEC and PC nanoparticles with both HLE-treatment and non-
treatment. Similar transfection efficiency was observed for non-cleavable PC 
nanoparticles with HLE-treatment and non-treatment as well as in the case of the non-
PEGylated system, suggesting minimum effect of the enzyme on cellular uptake of the 
nanoparticles. In the non-treatment group, similar levels of transfection was observed 
for 5 mol% PPHLEC and PC nanoparticles irrespective of the presence or absence of the 
peptide linker, presumably due to steric effects. The effect of the peptide linker, 
however, was more pronounced when using 1 mol% PEG, showing increased 
transfection efficiency by PPHLEC nanoparticles compared with PC nanoparticles (p < 
0.05). This observation was similar to the finding of the DODAG-high, non-treated 1 
mol%-PPHLEC nanoparticles, which might be due to non-specific peptide hydrolysis by 
non-specific peptidases in serum.  
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In comparison with the DODAG-high formulation, what was firstly observed was a 
considerably lower level of transfection by the DODAG-low nanoparticles, 
demonstrating a decrease in cell membrane association and uptake due to a lower 
amount of cationic lipid in the liposome formulation.246 Considering the HLE treatment 
group, 1 mol% PPHLEC high-charge nanoparticles exhibited increased transfection 
efficiency of 2.6-fold, similar to that of the low-charge nanoparticles (3.7-fold) (Figure 
3-22b). This result indicated that PPHLEC nanoparticles may undergo partial peptide 
hydrolysis, leading to partial exposure of cationic surface charges that facilitate cellular 
binding. Similar findings were observed for 5 mol% PPHLEC high-charge and low-charge 
nanoparticles (Figure 3-22c).  
 
a) 
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b) 
 
c) 
 
Figure 3-22: a) The HLE transfection data of DODAG-low nanoparticles containing 
non-PEG, PPHLEC (1 and 5 mol%) and PC (1 and 5 mol%), with HLE-treatment (black) 
and non-treatment (white). The transfection was performed in MCF-7 cell lines. The 
transfection efficiency is expressed as % RLU/mg protein of non-PEGylated control 
with HLE-treatment. Each result represents the mean  S.D. (n = 3),  indicates p < 
0.05. Comparison of transfection efficiencies of DODAG-high and DODAG-low 
nanoparticles after pretreatment with HLE: b) 1 mol% PPHLEC and PC, and c) 5 mol% 
PPHLEC and PC. 
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3.4.4.2 Transfection study of PPMMP-2C nanoparticles 
 
Similar to the DODAG-high formulation, the transfection efficiency of low-charge PPMMP-
2C nanoparticles was assessed on the MMP-2 positive cell line, HT1080. Moreover, the 
effect of PPMMP-2C nanoparticles on MMP-2 negative cell lines was also examined to 
compare the specificity of the nanoparticles. Cell lines including HT1080, MCF-7, 
HEK293T, DU145, and HeLa were characterised for their levels of MMP-2 expression 
in culture medium using MMP-2 human ELISA assay kit (Invitrogen). HT1080 was 
shown to secrete high levels of MMP-2 (Figure 3-23), in line with other reported studies 
involving MMP-2 study.247, 248 The other cell lines showed relatively poor expression of 
MMP-2. Of these cell lines, MCF-7 was chosen as the MMP-2 negative cell line for use 
in this study since it was already being used in the HLE experiment.  
 
 
Figure 3-23: The expression of MMP-2 levels in cell culture medium, evaluated by 
ELISA MMP-2 assay.  HT1080 was shown to have higher levels of MMP-2 expression 
compared with other tested cell lines. 
 
The transfection of PPMMP-2C nanoparticles was first carried out on HT1080 and the 
level of gene expression was compared to that of the DODAG-high nanoparticles. The 
transfection level was significantly enhanced by PPMMP-2C nanoparticles (1 and 5 mol%) 
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compared to non-cleavable PC (p < 0.05) (Figure 3-24a), suggesting that PPMMP-2C 
nanoparticles were activated in response to MMP-2 expression. The in vitro MMP-2 
level was less than the amount of the enzyme used in the enzyme cleavage study 
(chapter 2); however, the molar ratio of the substrate to the enzyme in both 
experiments was found to be similar. The effect of PEG on preventing the endosomal 
escape of pDNA was seen for PEGylated nanoparticles and the effect increased as the 
degree of PEGylation increased.     
 
As expected, considerably lower transfection efficiency by DODAG-low nanoparticles 
was observed compared to that of the DODAG-high formulation (Figure 3-24b and c). 
Since binding of cationic nanoparticles to the cell membrane was purely via 
electrostatic interaction, the decrease in gene expression demonstrates the reduction in 
cellular binding and internalisation as a result of lowering the amount of the cationic 
lipid. The level of gene expression was 9.0-fold enhanced by 1 mol% PPMMP-2C 
DODAG-high nanoparticles; however, a dramatic increase in cell transfection was 
observed when using 1 mol% PPMMP-2C DODAG-low nanoparticles. Further 
enhancement in the gene expression level was observed for 5 mol% PPMMP-2C low-
charge nanoparticles. This observation clearly demonstrates that the decrease in 
cationic charge limits the non-specific uptake of the nanoparticles to the cell membrane 
and thereby dominates the effect of enzyme-mediated gene transfer.  
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a) 
 
b) 
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Figure 3-24: a) The MMP-2 transfection data of DODAG-low nanoparticles containing 
non-PEG, PPMMP-2C (1 and 5 mol%), and PC (1 and 5 mol%) in HT1080 cell lines. The 
transfection efficiency is expressed as % RLU/mg protein of non-PEGylated control. 
Each result represents the mean  S.D. (n = 3),  indicates p < 0.05. Comparison of 
transfection efficiencies of DODAG-high and DODAG-low nanoparticles: b) 1 mol% 
PPMMP-2C and PC and c) 5 mol% PPMMP-2C and PC.  
 
The ability of PPMMP-2C nanoparticles to mediate transfection in MCF-7, a cell line that 
poorly expresses MMP-2, was then examined. The transfection was performed under 
the same conditions as those of HT1080. In the MMP-2 negative cell line, enhanced 
efficiency in transfection by PPMMP-2C nanoparticles was also observed (p < 0.05) 
(Figure 3-25), but to a lesser extent than that obtained from HT1080, the MMP-2 
positive cells. In HT1080 cells, the transfection activity of 1 mol% PPMMP-2C 
nanoparticles was 15-fold higher than that of 1 mol% PC (Figure 3-24b), whereas the 
enhancement was less prominent, 1.8-fold, in MCF-7 cells. Similar to their 1 mol% 
counterparts, a substantial increase in gene expression, 92.5-fold, by 5 mol% PPMMP-2C 
nanoparticles was observed in HT1080 cells (Figure 3-24c), while the efficiency was 
enhanced 2.5-fold in MCF-7 cells. This result suggests that PPMMP-2C nanoparticles 
were activated by the secreted MMP-2, and this activation was more pronounced in 
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MMP-2 positive cell lines, demonstrating that the transfection efficiency was related to 
the cellular expression level of MMP-2. The data were in agreement with the study of 
Hatakeyama et al. which showed a remarkably higher transfection activity by 
nanoparticles containing MMP-2 substrate peptide in the cell lines that highly express 
MMP-2, with a significantly lower enhancement observed in MMP-2 negative cells.208    
 
 
Figure 3-25: The MMP-2 transfection data of DODAG-low nanoparticles containing 
non-PEG, PPMMP-2C (1 and 5 mol%) and PC (1 and 5 mol%) in MCF-7 cell lines. The 
transfection efficiency is expressed as % RLU/mg protein of non-PEGylated control. 
Each result represents the mean  S.D. (n = 3),  indicates p < 0.05. 
 
The stability of the DODAG-low nanoparticles containing 1 and 5 mol% PPHLEC and 
PPMMP-2C in the transfection media (10 % FBS) was then assessed by measuring the 
particle sizes over time. Non-PEGylated nanoparticles showed a marked increase in 
size during the course of the experiment, whereas no significant increase in diameter 
due to aggregation was observed for all PEGylated nanoparticles (Figure 3-26). This 
result suggests that PEG is crucial for conferring stability to the nanopaticles and 
preventing their aggregation. 1 mol% PEG was shown to be sufficient to enhance 
nanoparticle stability in 10% serum, shown by a small increase in size. The aggregation 
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was more pronounced in the case of non-PEGylated nanoparticles. This may contribute 
to their decreased transfection activity in MCF-7 and HT1080 cells compared to the 
other PEGylated nanoparticles. Unlike the DODAG-high formulation, the DODAG-low 
nanoparticles exhibited greater resistance to aggregation, presumably due to a 
decrease in the effective surface charge of the nanoparticles as a result of reduced 
molar percentage of the cationic lipid in the formulation, confirmed by the reduction in 
zeta potential compared to the DODAG-high system. The lowered surface charge 
resulted in less interaction with counter ions and serum components, thus reducing 
aggregation. The polydispersity index of the nanoparticles was found between 1.5-1.9 
for non-PEGylated nanoparticles and 0.9-1.4 for the PEGylated nanoparticles.  
 
Figure 3-26: The stability of DODAG-low nanopaticles containing non-PEG, PPHLEC (1 
and 5 mol%), and PPMMP-2C (1 and 5 mol%) in transfection media (10% FBS), assessed 
by monitoring the change in nanoparticle diameter as a function of time (every 30 min 
over 4 h).  
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3.4.5 Fluorescence microscopy of rhodamine labelled DODAG-low liposomes  
containing PEGylated peptide-cholesterol conjugates 
 
Fluorescence microscopy was employed to visualise the internalisation of the 
PEGylated nanoparticles inside the cells. To analyse the degree of intracellular uptake, 
the PEGylated liposomes were labelled with 1 mol% of rhodamine-DOPE. The 
incorporation of a small amount of the fluorescently labelled lipid should prevent it 
causing significant changes to the overall properties of the liposomes. The labelled 
PPHLEC and PC liposomes were incubated with MCF-7 for 6 h (the same uptake period 
as in the transfection study) and non-internalised liposomes were removed at the end 
of the incubation period. After the cells were fixed, their nuclei were further stained 
using 4-6-diamidino-2-phenylindole (DAPI), resulting in blue fluorescence upon binding 
to nuclear double stranded DNA.249 The fluorescence images of 1 mol% PPHLEC and 1 
mol% PC liposomes with HLE treatment and non-treatment are shown below (Figure 
3-27). The fluorescence microscopy revealed that the PEGylated liposomes were 
successfully uptaken by cells and dispersed throughout the cytoplasm. However, the 
degree of internalisation varied significantly. 1 mol% PPHLEC liposomes pretreated with 
HLE showed higher rhodamine intensities inside the cells, compared to that of non-
treated 1 mol% PPHLEC and the PEGylated control PC liposomes with HLE treatment 
and non-treatment. This result was in agreement with the transfection data that HLE-
pretreated PPHLEC nanoparticles were preferably taken up by cells, resulting in 
enhanced gene expression. This could be attributed to enzyme-mediated detachment 
of the stealth layer, leading to increased cell association. Cellular internalisation was 
observed for the other PEGylated liposomes, but to lesser extent.             
                 i) Bright field                        ii) DAPI                             iii) Rhodamine 
 
a) 1% PPHLEC with HLE treatment 
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                i) Bright field                         ii) DAPI                            iii) Rhodamine 
    
b) 1% PPHLEC with non-treatment 
 
c) 1% PC with HLE treatment 
 
d) 1% PC with non-treatment 
Figure 3-27: Fluorescence microscopy images (40x magnifications) of MCF-7 cells 
after incubation with rhodamine labelled DODAG-low liposomes: a) 1% PPHLEC with 
HLE treatment, b) 1% PPHLEC with non-treatment, c) 1% PC with HLE treatment, and d) 
1% PC with non-treatment, showing i) bright field ii) DAPI stained nuclei and iii) 
rhodamine labelled liposomes images. 
 
Fluorescence microscopy of PPMMP-2C liposomes was also carried out by incubating the 
rhodamine labelled liposomes with HT1080 for 24 h, similar to the uptake period in the 
transfection experiment. The fluorescence images of 1 and 5 mol% of PPMMP-2C and the 
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PEGylated control PC liposomes are presented in Figure 3-28. Similar to PPHLEC, 
PPMMP-2C and PC liposomes were successfully delivered into the cytoplasm of the cells. 
Both 1 and 5 mol% PPMMP-2C liposomes showed significantly higher fluorescence 
intensities than that of their PEGylated controls, and 1 mol% PPMMP-2C liposomes 
exhibited increased rhodamine intensity compared to their 5 mol% counterparts. This 
result suggests that the presence of the peptide linker may contribute to enhanced cell 
uptake through PEG removal by the enzyme action, hence facilitating cellular 
internalisation. This finding was in agreement with the transfection data of the PPMMP-2C 
system.  
                 i) Bright field                         ii) DAPI                             iii) Rhodamine 
 
a) 1 mol% PPMMP-2C 
 
b) 1 mol% PC 
 
c) 5 mol% PPMMP-2C 
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                 i) Bright field                         ii) DAPI                             iii) Rhodamine 
 
d) 5 mol% PC 
Figure 3-28: Fluorescence microscopy images (40x magnifications) of HT1080 cells 
after incubation with rhodamine labelled DODAG-low liposomes: a) 1 mol% PPMMP-2C, 
b) 1 mol% PC, c) 5 mol% PPMMP-2C, and d) 5 mol% PC, showing i) bright field ii) bright 
field ii) DAPI stained nuclei and iii) rhodamine labelled liposome images. 
 
To further examine the localisation of the fluorescently labelled liposomes inside the 
cells, confocal microscopy was employed to provide serial imaging throughout the cells, 
producing ‘z’ stack images that can be used to confirm the internalisation of the labelled 
liposomes. The confocal image revealed that the liposomes were internalised and 
located around the nucleus as well as throughout the cytoplasm (Figure 3-29). The 
appearance of localised hyperintense fluorescence dots may indicate the enclosure of 
the rhodamine-DOPE probe by endosomes.  
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Figure 3-29: Confocal microscopy image (40x magnification) of rhodamine labelled 
HT1080 cells after incubation with 1% PPMMP-2C liposomes, a ‘z’ stack showing a cross 
section through the labelled HT1080 cells.  
 
3.4.6 Stability of DODAG-low nanoparticles containing PEGylated peptide- 
cholesterol conjugates in 80% serum 
 
Although the previous stability data in the transfection medium showed that 1 mol% 
PEG was adequate to obtain good nanoparticle stability in 10% serum, this 
concentration may not be adequate at higher concentrations of serum, such as in blood 
circulation. The effect of high serum concentration (80% FBS) on the stability of the 
nanoparticles (1-5 mol%) was therefore examined. FBS contains small protein 
aggregates, which makes size measurement using PCS unsuitable for monitoring 
aggregation at high serum contents, so the turbidity assay was employed instead. The 
change in turbidity of the nanoparticles in solution can be observed by measuring their 
absorbance at  = 600 nm. 1 and 2 mol% PPHLEC nanoparticles showed rapid 
increases in absorbance over the experiment period, indicating the formation of large 
aggregates which increased the turbidity of the solution (Figure 3-30a). Small changes 
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in absorbance were observed as PEG concentration was increased to 3 mol%, and 
similar levels of absorbance were shown by 4 and 5 mol% PEG, indicating that the 
nanoparticles were capable of maintaining their initial size during the course of the 
experiment. 3-5 mol% PEG exhibited comparable levels of protection against 
aggregation. Similar findings were observed in the case of PPMMP-2C nanoparticles. It 
was found that 1 and 2 mol% PPMMP-2C showed immediate increases in absorbance, in 
contrast to 3-5 mol% PEG (Figure 3-30b). The smallest change in absorbance was 
demonstrated by 5 mol% PEG, suggesting the most resistance to aggregation. This 
stability study highlighted the importance of the PEG layer in reducing inter-particle 
attraction by providing a repulsive barrier between nanoparticles.   
 
a) 
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b) 
 
Figure 3-30: The stability of DODAG-low nanoparticles in 80% FBS assessed by 
measuring the absorbance at 600 nm, a) 1-5 mol% PPHLEC and b) 1-5 mol% PPMMP-2C. 
The UV absorbance was monitored every 30 min over 4 h using a UV spectrometer.  
 
pDNA delivery by PPHLEC and PPMMP-2C nanoparticles was shown to be activated by 
the enzymes, shown by a considerable increase in transfection efficiency compared 
with non-cleavable PC nanoparticles. It was reported that PEG-cholesterol in serum 
environments can be transferred between lipid bilayers and biological lipids, 
presumably due to ineffective anchoring associations with the liposomal phospholipids 
provided by the hydrophobic moiety of cholesterol.250, 251 The transfer of PEG-
cholesterol from liposome bilayers before enzymatic activation may interfere with cell 
transfection by increasing the transfection efficiency of the PEGylated nanoparticles. To 
investigate this effect, a new series of PEGylated lipid conjugates was synthesised by 
conjugating a saturated long-chain hydrocarbon, a dialkylglycylamide moiety, to PEG, 
since a saturated long-chain lipid exhibits stronger anchoring due to its ability to 
increase the rigidity of the liposomal membrane, and it was shown to be associated 
with liposomes for an extended period after in vivo injection.252 Incorporation of these 
PEGylated lipid conjugates should prevent lipid transfer and may result in a decrease in 
transfection efficiency. 
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3.5 DODAG-low formulation with PEGylated peptide-C18 conjugates 
 
The synthesised PEGylated peptide-C18 conjugates, PPHLEC18 20 and PPMMP-2C18 21, 
and the PEGylated lipid control PC18 22 were incorporated into the same DODAG-low 
formulation as that of the PPHLEC and PPMMP-2C nanoparticles, and at the same PEG 
densities, 1 and 5 mol%. The physiochemical properties of PPHLEC18 and PPMMP-2C18 
nanoparticles with respect to nucleic acid encapsulation efficiency, size, and surface 
charge were examined before their transfection abilities were assessed. 
 
3.5.1 Physicochemical characterisation of DODAG-low nanoparticles  
containing PEGylated peptide-C18 conjugates  
 
3.5.1.1 pDNA encapsulation efficiencies 
 
PPHLEC18, PPMMP-2C18, and PC18 nanoparticles were prepared at different lipid: pDNA 
w/w and their encapsulation efficiency were examined using PI assay. Similar to their 
cholesterol counterparts, encapsulation efficiency increased as lipid: pDNA w/w 
increased (Figure 3-31). A marked increase in pDNA encapsulation efficiency was 
shown at weight ratio of 8 for 1 and 5 mol% PEGylated nanoparticles, and no 
significant change was observed at weight ratios higher than 12.  
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Figure 3-31: pDNA encapsulation efficiency of DODAG-low nanoparticles with 1 mol% 
PPHLEC18, 1 mol% PPMMP-2C18, 1 mol% PC18, 5 mol% PPHLEC18, 5 mol% PPMMP-2C18, 
and 5 mol% PC18 at various lipid: pDNA w/w (1 ug pDNA), using propidium iodide 
assay.  
 
The pDNA entrapment was further visualised and confirmed by agarose gel 
electrophoresis. The gel electrophoresis result was in agreement with the finding of the 
PI assay. pDNA encapsulation of most PEGylated nanoparticles was to completion at 
weight ratio of 8. At weight ratio of 12, all nanoparticles exhibited complete pDNA 
encapsulation (Figure 3-32). 
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               (a            (b          (c 
                                           
              (d              (e                      (f 
                                            
Figure 3-32: 0.8% agarose gel electrophoresis demonstrated pDNA encapsulation of 
DODAG-low nanoparticles with a) 1 mol% PPHLEC18, b) 1 mol% PPMMP-2C18, c) 1 
mol% PC18, d) 5 mol% PPHLEC18, e) 5 mol% PPMMP-2C18, and f) 5 mol% PC18 at 
different lipid: pDNA w/w (gel a) lane 1= DNA ladder, lane 2 = pDNA, lane 3= empty 
liposomes, lane 4-7 = lipid: pDNA w/w of 1:1, 4:1, 8:1, and 12:1; gel b-g) lane 1= empty 
liposomes, lane 2-5 = lipid: pDNA w/w of 1:1, 4:1, 8:1, and 12:1). The electrophoresis 
was performed at 65 mV for 180 min and the gels were visualized under UV light using 
Alliance 4.7 UVITEC Cambridge. 
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The findings of both PI assay and gel electrophoresis were in agreement with the data 
obtained from the cholesterol-anchored PEGylated nanoparticles that the optimal pDNA 
encapsulation efficiency was found at a weight ratio of 12. This result suggests that 
different types of lipid anchor – cholesterol-based and long-chain lipids – have minimal 
affect on the pDNA entrapment ability of DODAG-low liposomes, indicating that the 
cationic lipid is the main component that controls the pDNA association. 
 
3.5.1.2 Size and zeta potential measurements 
 
The sizes of the liposomes and pDNA nanoparticles (12:1 lipid: pDNA w/w) were 
examined using PCS. The diameters of the liposomes were found to be approximately 
80-100 nm (Figure 3-33), similar to that of their cholesterol-anchored PEGylated 
counterparts. An increase in size was observed after pDNA encapsulation, with the 
diameters ranging from 160-210 nm, indicating the complexation between liposomes 
and pDNA. The polydispersity index of both liposomes and pDNA nanoparticles in each 
preparation was found to be 0.2-0.8. 
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Figure 3-33: Average diameters of DODAG-low liposomes containing 1 mol% 
PPHLEC18, 1 mol% PPMMP-2C18, 1 mol% PC18, 5 mol% PPHLEC18, 5 mol% PPMMP-2C18, 
and 5 mol% PC18, and their pDNA nanoparticles (12:1 lipid: pDNA w/w), determined by 
PCS. Each result represents the means  S.D. of three measurements. 
 
The zeta potential data showed decreased zeta potential as PEG was increased to 5 
mol% (Figure 3-34), similar to the finding of the cholesterol-anchored PEGylated 
nanoparticles. Further reduction in the surface charge was observed for pDNA 
nanoparticles (12:1 lipid: pDNA w/w) due to charge neutralisation, suggesting the 
formation of liposome: pDNA complexes. The zeta potential of 5 mol% PEGylated 
nanoparticles was found to be lower than that of their 1 mol% PEGylated counterparts, 
presumably due to greater shielding of the surface charge associated with higher PEG 
concentration.  
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Figure 3-34: Zeta potentials of DODAG-low liposomes containing 1 mol% PPHLEC18, 1 
mol% PPMMP-2C18, 1 mol% PC18, 5 mol% PPHLEC18, 5 mol% PPMMP-2C18 and 5 mol% 
PC18, and their pDNA nanoparticles (12:1 lipid: pDNA w/w), determined by zetasizer. 
Each result represents the means  S.D. of three measurements. 
 
3.5.2 MTS cell proliferation assay and LDH cytotoxicity assay with DODAG-low  
nanoparticles containing PEGylated peptide-C18 conjugates 
 
Like their PEGylated peptide-cholesterol counterparts, PPHLEC18 and PPMMP-2C18 (1 
and 5 mol%) were assessed for their effect on cell viability (MTS assay) and toxicity 
(LDH assay). The nanoparticles were prepared at three lipid: pDNA w/w (8:1, 12:1, and 
16:1; 1 g pDNA/well) and incubated with MCF-7 and HT1080, respectively, for the 
periods of 4, 8 and 24 h.    
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        a)                                                                           b) 
 
        c)                                                                           d) 
 
        e)                                                                           f) 
 
Figure 3-35: MTS cell viability result of DODAG-low nanoparticles containing 1 and 5 
mol% PPHLEC18 nanoparticles incubated with MCF-7 for 4, 8 and 24 h (a-c) and 1 and 
5 mol% PPMMP-2C18 nanoparticles incubated with HT1080 for 4, 8, and 24 h (d-f). The 
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cell viability data is expressed as a percentage of the positive control cells without the 
nanoparticles added to them. 
 
Like PPHLEC nanoparticles, PPHLEC18 nanoparticles showed little difference in cell 
viability irrespective of the molar percentages of PEG, weight ratios, and incubation 
times (Figure 3-35 a-c). Similar to PPMMP-2C18 nanoparticles, greater than 70% of cell 
viability was observed for PPMMP-2C18 nanoparticles (Figure 3-35 d-f). These results 
indicated that with similar liposomal lipid compositions, both C18 and cholesterol-based 
lipids showed minimal effect on the viability of the cells.  
 
The results obtained from LDH assay showed no significant difference in toxicity for 
PPHLEC18 nanoparticles regardless of PEG concentrations, weight ratios, and 
incubation times after 4 and 8 h of incubation; however, an increase in the amount of 
LDH released of approximately 15% was observed after 24 h (Figure 3-36:  a-c). The 
LDH released due to 1 mol% PPMMP-2C18 was found to be less than 10% for all 
incubation periods (Figure 3-36: Figure 3-36 d-f). By contrast, for 5 mol% PPMMP-2C18, 
the level of LDH released increased as the weight ratio and incubation period 
increased. After 24 h of incubation, over 20% cell death was observed at the weight 
ratio of 16 while less than 15% was observed for the weight ratio of 12. This cytotoxicity 
profile is similar to that obtained from 5 mol% PPMMP-2C. The observed effect on cell 
viability may be due to an impurity from the synthesis and nanoparticle preparation, or 
the potential effect of the amphiphile itself. The overall result obtained from LDH assay 
showed that PPHLEC18 and PPMMP-2C18 nanoparticles exhibited similar toxicity profiles 
to those of PPHLEC and PPMMP-2C nanoparticles, indicating that the type of anchoring 
lipid did not affect cell proliferation.  
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         a)                                                                        b) 
 
         c)                                                                        d) 
 
         e)                                                                        f) 
 
Figure 3-36: LDH assay results showing % cytotoxicity as a result of the added 
DODAG-low nanoparticles containing: a-c) 1 and 5 mol% PPHLEC18 nanoparticles 
incubated with MCF-7 for 4, 8, and 24 h,  d-f) 1 and 5 mol% PPMMP-2C18 nanoparticles 
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incubated with HT1080 for 4, 8, and 24 h. The result is expressed as a percentage 
normalised against control cells without added nanoparticles.  
 
From the findings of MTS and LDH assay, the lipid: pDNA weight ratio of 12 was found 
to be optimal for transfection study due to its high pDNA entrapment efficiency and 
minimal toxicity. This result corresponds to that of their cholesterol-anchored 
counterparts. 
 
The physiochemical characteristics and toxicity profiles of the PEGylated peptide-C18 
system were found to be similar to those of the cholesterol-anchored PEGylated 
nanoparticles. The result suggested that the incorporation of cholesterol or C18 
anchoring lipids, conjugated to PEG up to 5 mol% in the liposome formulation, did not 
significantly change the overall liposomal properties.  
 
3.5.3 In vitro pDNA transfection of DODAG-low nanoparticles containing  
PEGylated peptide-C18 conjugates 
 
3.5.3.1 Transfection study of PPHLEC18 nanoparticles 
 
Transfection study of PPHLEC18 nanoparticles was carried out using the same 
procedure as that of their PPHLEC counterparts. . A marked increase in the transfection 
efficiency of MCF-7 cells was observed for HLE-treated PPHLEC18 nanoparticles 
compared with that of non-treated PPHLEC18 nanoparticles and non-cleavable PC18 
nanoparticles with HLE treatment and non-treatment (p < 0.05) (Figure 3-37). The gene 
expression level decreased as PEG concentration increased, presumably due to the 
effect of steric hindrance.  Non-cleavable PC nanoparticles with HLE treatment and 
non-treatment exhibited comparable efficiencies in transfection and a similar result was 
also observed for non-PEGylated nanoparticles, suggesting that HLE had a minimal 
effect on cellular uptake of the nanoparticles. Compared with transfection data obtained 
from their cholesterol counterparts (Figure 3-22a), C18-anchored PEGylated 
nanoparticles showed a similar trend of transfection but with a significantly lower 
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transfection efficiency. This result suggests that PPHLEC18 nanoparticles may undergo 
partial peptide hydrolysis as in the case of cholesterol-anchored nanoparticles. 
Incorporation of C18 lipid anchors may well reduce the potential effect of PEG-lipid 
transfer that might occur in the case of PEG-cholesterol, resulting in more PEG 
remaining attached to the nanoparticle surface with less cationic surface exposure, and 
thereby a reduction in transfection efficiency.    
 
 
Figure 3-37: The HLE transfection data of DODAG-low nanoparticles containing non-
PEG, PPHLEC18 (1 and 5 mol%) and PC18 (1 and 5 mol%), with HLE-treatment (black) 
and non-treatment (white). The transfection was performed in MCF-7 cell lines. The 
transfection efficiency is expressed as % RLU/mg protein of non-PEGylated control 
with HLE-treatment. Each result represents the mean  S.D. (n = 3),  indicates p < 
0.05.  
 
3.5.3.2 Transfection study of PPMMP-2C18 nanoparticles 
 
In the MMP-2 positive cell line, HT1080, transfection efficiency was markedly increased 
by PPMMP-2C18 nanoparticles compared to their non-cleavable PC18 counterparts and 
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the non-PEGylated system (p < 0.05) (Figure 3-38). The steric effect of PEG on cellular 
uptake and endosomal destabilisation was observed when the molar percentage of 
PEG was increased. Compared with the transfection results obtained from their 
cholesterol counterparts (Figure 3-22a), a similar trend of transfection was observed for 
C18-anchored nanoparticles but with a significant increase in transfection level. This 
result was opposite to that of the HLE system, in which the level of gene expression 
was significantly lower when using C18-anchored nanoparticles. The results from both 
the HLE and MMP-2 systems suggested that the transfer of PEG-cholesterol out of the 
liposomal membrane may not occur, otherwise a lower level of transfection by C18-
anchored nanoparticles should have been observed in both systems. The difference in 
transfection efficiency observed is likely to be due to different cell types. 
 
 
Figure 3-38: The MMP-2 transfection data of DODAG0low nanoparticles containing 
non-PEG, PPMMP-2C18 (1 and 5 mol%), and PC18 (1 and 5 mol%) in HT1080 cell lines. 
The transfection efficiency is expressed as % RLU/mg protein of non-PEGylated 
control. Each result represents the mean  S.D. (n = 3),  indicates p < 0.05.  
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Transfection in the poorly MMP-2 expressing cell line, MCF-7, showed an enhanced 
level of gene expression by PPMMP-2C18 nanoparticles (p < 0.05) (Figure 3-39), but to a 
lesser extent than that obtained in HT1080, highly MMP-2 expressing cells. This result 
suggests a correlation between transfection efficiency and the cellular expression level 
of MMP-2. A similar finding was also observed for cholesterol-anchored nanoparticles.  
 
 
Figure 3-39: The MMP-2 transfection data of DODAG-low nanoparticles containing 
non-PEG, PPMMP-2C18 (1 and 5 mol%), and PC18 (1 and 5 mol%) in MCF-7 cell lines. 
The transfection efficiency is expressed as % RLU/mg protein of non-PEGylated 
control.Each result represents the mean  S.D. (n = 3),  indicates p < 0.05.  
 
1 and 5 mol% PPHLEC18 and PPMMP-2C18 were assessed for their stability in the 
transfection media (10 % FBS). The size measurement showed that all PEGylated 
nanoparticles exhibited good stability over the incubation period, with very little change 
in diameter (Figure 3-40). Similar to their cholesterol counterparts, 1 mol% PPHLEC18 
and PPMMP-2C18 were sufficient to prevent aggregation of the nanoparticles. The 
polydispersity index of the nanoparticles was found between 0.9-1.3 over the course of 
the experiments. 
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Figure 3-40: The stability of DODAG-low nanopaticles containing non-PEG, PPHLEC18 
(1 and 5 mol%), and PPMMP-2C18 (1 and 5 mol%) in transfection media (10% FBS), 
assessed by monitoring the change in nanoparticle diameter as a function of time 
(every 30 min over 4 h). 
 
3.5.4 Fluorescence Microscopy of rhodamine labelled DODAG-low  
nanoparticles containing PEGylated peptide-C18 conjugates 
 
Similar to their cholesterol counterparts, cellular uptake studies of PPHLEC18, PPMMP-
2C18, and PC18 liposomes were carried out by incorporating 1 mol% rhodamine-DOPE 
into the liposome formulation. The labelled PPHLEC18 and PC18 with HLE treatment 
and non-treatment were incubated with MCF-7 cells for a period of 6 h. Figure 3-41 
showed that the PEGylated liposomes were successfully taken up by the cells, and 
HLE-pretreated 1 mol% PPHLEC18 liposomes exhibited a significantly higher level of 
internalisation compared to non-treated 1 mol% PPHLEC18 and the PEGylated control 
PC18 liposomes with HLE treatment and non-treatment. This observation was similar to 
that of the PPHLEC system, presumably due to the dissociation of PEG from the 
liposome surface, leading to enhanced electrostatic interaction with the cell membrane. 
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The cell uptake study correlated well with the transfection data of PPHLEC18 
nanoparticles. 
 
                 i) Bright field                        ii) DAPI                             iii) Rhodamine 
 
a) 1% PPHLEC18 with HLE treatment 
 
b) 1% PPHLEC18 with non-treatment 
 
c) 1% PC18 with HLE treatment 
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                 i) Bright field                        ii) DAPI                             iii) Rhodamine 
 
d) 1% PC18 with non-treatment 
 
Figure 3-41: Fluorescence microscopy images (40x magnifications) of MCF-7 cells 
after incubation with rhodamine labelled DODAG-low liposomes a) 1% PPHLEC18 with 
HLE treatment, b) 1% PPHLEC18 with non-treatment, c) 1% PC18 with HLE treatment, 
and d) 1% PC18 with non-treatment, showing i) bright field ii) DAPI stained nuclei and 
iii) rhodamine labelled liposome images.  
 
The cellular internalisation of rhodamine labelled PPMMP-2C18 and PC18 liposomes is 
presented in Figure 3-42. Similar to the cellular uptake of PPMMP-2C liposomes, 1 and 5 
mol% of PPMMP-2C18 showed a marked increase in fluorescence intensities compared 
to that of their PEGylated controls. 1 mol% PPMMP-2C18 nanoparticles showed greater 
rhodamine intensity compared with their 5 mol% counterparts. This result is in 
agreement with the transfection efficiency of PPMMP-2C18 nanoparticles.  
 
                 i) Bright field                        ii) DAPI                             iii) Rhodamine 
 
a) 1 mol% PPMMP-2C 
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                 i) Bright field                        ii) DAPI                             iii) Rhodamine 
 
b) 1 mol% PC 
 
c) 5 mol% PPMMP-2C 
 
d) 5 mol% PC 
 
Figure 3-42: Fluorescence microscopy images (40x magnifications) of HT1080 cells 
after incubation with rhodamine labelled DODAG-low liposomes: a) 1 mol% PPMMP-2C, 
b) 1 mol% PC, c) 5 mol% PPMMP-2C, and d) 5 mol% PC, showing i) bright field ii) bright 
field ii) DAPI stained nuclei and iii) rhodamine labelled liposome images. 
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3.5.5 Stability of DODAG-low nanoparticles containing PEGylated peptide-C18  
conjugates in 80% serum 
 
The stability of PPHLEC18 and PPMMP-2C18 nanoparticles (1-5 mol%) in high serum 
content (80%) were further assessed using a turbidity assay by monitoring the change 
in the turbidity of the solution containing the nanoparticles at  = 600 nm. A rapid 
increase in the absorbance of 1 mol% PPHLEC18 was observed after the first 30 min of 
the experiment (Figure 3-43), indicating an increase in the turbidity of the solution due 
to nanoparticle aggregation. At 2 and 3 mol% PEG, the nanoparticles showed slower 
rates of aggregation as seen by gradual increases in absorbance. 4 and 5 mol% PEG 
exhibited constant levels of absorbance over the course of the experiment, indicating 
no aggregation. In the case of PPMMP-2C18 nanoparticles, 1 and 2 mol% PEG exhibited 
significant increases in absorbance. The aggregation was significantly reduced as PEG 
concentration increased, in particular at 4 and 5 mol% PEG. These observations were 
in agreement with the findings of PPHLEC and PPMMP-2C nanoparticles: that 4-5 mol% 
PEG appeared to be optimal to ensure sufficient nanoparticle stability in high serum 
concentration.    
 
a) 
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b) 
 
Figure 3-43: The stability of DODAG-low nanoparticles in 80 % FBS assessed by 
measuring the absorbance at 600 nm, a) 1-5 mol% PPHLEC18 and b) 1-5 mol% PPMMP-
2C18. The UV absorbance was monitored every 30 min over 4 h using UV 
spectrometer. 
 
3.6 Chapter summary 
 
In this chapter, the effect of the PEGylated peptide-lipid conjugates in liposome 
formulations was assessed with respect to physicochemical properties, toxicity, and 
stability. In addition, their ability to mediate pDNA delivery in the presence and absence 
of the specific enzyme was discussed.  
 
The effect of cationic charge on cell association was investigated using two types of 
formulations, DODAG-high (50% DODAG) and DODAG-low (20% DODAG). Both 
DODAG-high and DODAG-low formulations exhibited high pDNA encapsulation 
efficiency at 12:1 lipid: pDNA w/w and the pDNA nanoparticles formed at this ratio were 
found to be approximately 130-200 nm in diameter. The zeta potential measurement 
revealed that the surface charge of the liposomes could be altered by manipulating the 
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amount of the cationic lipid in the formulation as well as the degree of PEGylation. 
Incorporation of the same molar ratio of PPHLEC, PPMMP-2C, PC, PPHLEC18, PPMMP-2C18, 
and PC18 within liposomes did not result in any significant change in the 
physicochemical characteristics of the nanoparticles, suggesting that the peptide linkers 
and type of lipid conjugate had minimal effects on nanoparticle properties.       
 
PPHLEC and PPMMP-2C DODAG-high nanoparticles were shown to enhance transfection 
efficiency in the presence of HLE and MMP-2, respectively, compared with non-
cleavable PC nanoparticles, demonstrating that the nanoparticles may be activated in 
response to the presence of the enzymes. The level of gene expression decreased 
when transfecting with the DODAG-low nanoparticles due to the reduction in 
electrostatic interaction with cell membranes. Despite having lower transfection 
efficiency, the DODAG-low nanoparticles exhibited greater resistance to aggregation in 
the serum-contained medium compared with the DODAG-high system. The increased 
stability was also observed when PEG was incorporated. This indicated that the surface 
charge of the nanoparticles played a crucial role in both the transfection ability and the 
stability of the nanoparticles. Aggregation of cationic nanoparticles caused by 
adsorption of negatively charged serum proteins, leading to increased size and 
subsequent removal by RES, is an unfavourable event since this can limit the 
therapeutic efficacy of nanoparticles. To prolong blood circulation half-lives and enable 
maximum accumulation at tumour tissues via the EPR effect, nanoparticles with lower 
zeta potential are more preferable, although such a characteristic is often associated 
with decreased cellular binding. The introduction of PEG that can be detached by 
tumour-associated enzymes could be a strategy to improve nanoparticle stability while 
in circulation by masking their surface charge and restore electrostatic interaction with 
the cell membrane once PEG is detached by the enzymes, facilitating cellular uptake 
as well as endosomal escape.     
 
HLE-treated PPHLEC and PPHLEC18 nanoparticles showed remarkably enhanced gene 
expression levels on the tested cell lines compared with non-treated PPHLEC and 
PPHLEC18 nanoparticles and non-cleavable PC and PC18 nanoparticles with HLE 
treatment and non-treatment. A significant increase in transfection efficiency in MMP-2 
positive cell lines was observed for PPMMP-2C and PPMMP-2C18, and the enhancement in 
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gene expression was lower in MMP-2 negative cells. Non-cleavable PC and PC18 
nanoparticles showed increased levels of gene expression but to a lesser extent than 
the nanoparticles bearing peptide linkers, demonstrating the ability of PEGylated 
nanoparticles to be internalised into the cells but with reduced levels of endosomal 
escape. A similar trend of transfection was observed in both the HLE and MMP-2 
systems; however, the transfection level was found to vary for each cell line and was 
not correlated with the types of lipid conjugates. Collectively, the transfection data 
suggested the possibility of partial peptide hydrolysis by specific enzymes leading to 
partial PEG detachment. The resulting nanoparticles may then have re-obtained part of 
their positive charges, facilitating interaction with anionic cell membranes and leading to 
enhanced cellular uptake and endosomal escape. Although the mechanism of the 
enzyme-mediated pDNA delivery is not yet understood and requires further 
investigation, the enhancement of gene expression by the nanoparticles containing 
PEGylated peptide-lipid in the presence of enzymes highlighted the possibility of the 
use of enzyme-mediated nucleic acid delivery to promote endocytosis and subsequent 
release of pDNA from endosomes into cytosol. These nanoparticles were found to be 
non-toxic to the tested cell lines as assessed by MTS cell viability and LDH toxicity 
assays. The nanoparticles also exhibited good stability in higher serum concentrations 
(80%), in particular when 4-5 mol% PEG was incorporated.  
 
 
  
 
 
 
 
 
 
4. Biophysical and in vitro biological 
evaluation of PEGylated peptide-lipid 
conjugates: siRNA system 
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It was shown in the previous chapter that the transfection efficiency of the nanoparticles 
being studied could be assessed using pDNA encoding for luciferase as a reporter 
gene. However, for medical applications, the use of therapeutic nucleic acids 
encapsulated in nanoparticles would be required. siRNA has been increasingly 
recognised over the last ten years as a potential therapeutic tool for many diseases 
including cancer253, 254 due to its ability to induce specific gene silencing. siRNA is a 
short sequence of double stranded RNA, usually 21-23 nucleotides long, of which 19-
21 nucleotides form base pair duplexes and 2 nucleotides on each of the 3’ ends 
overhang (Figure 4-1a).255 siRNA mediates gene silencing through sequence-specific 
cleavage of the corresponding mRNA (Figure 4-1b). After being taken up by cells, 
siRNA is incorporated into a multi-enzyme complex, consisting of Argonaute 2 (AGO2) 
and the RNAi-induced silencing complex (RISC). AGO2 unwinds the siRNA and 
cleaves the sense strand (or passenger strand). The activated AGO2-RISC complex 
containing only the antisense strand (or guide strand) then binds to the complementary 
mRNA. The target mRNA is cleaved at a single site in the centre of the duplexes, 10 
nucleotides from the 5’ end of the siRNA, resulting in rapid degradation and thereby 
inhibiting the expression of the corresponding protein.  
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a) 
 
b) 
 
Figure 4-1: a) Structure of siRNA. Two strands of the siRNA, around 21 nucleotides, 
form approximately 19 nucleotide duplexes with 2 nucleotides overhanging on each 3’ 
end. The cleavage position is indicated by the black arrow and the seed region 
indicates the position where interaction with the target mRNA begins.256 b) 
Representation of the siRNA mechanism. On cellular internalisation, siRNA is loaded 
onto RISC and its sense strand is cleaved by AGO2. The activated RISC-antisense 
strand complex binds to and degrades the complementary target mRNA, leading to 
target gene silencing.257  
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As with DNA, siRNA is prone to nuclease digestion in blood circulation, leading to the 
loss of its therapeutic function. In addition, its negative charge due to its anionic 
phosphate backbone prevents efficient association with cell membranes. siRNA 
therefore needs to be encapsulated in a carrier in order to protect it from enzymatic 
degradation and also facilitate cellular internalisation.257, 258 For specific delivery to 
occur, the carriers should have properties that aid their long circulation and 
accumulation in tumour tissues. After administration, the delivery of siRNA faces similar 
hurdles to those of DNA delivery, except for the nuclear barrier. The mechanism of 
siRNA-mediated gene silencing occurs primarily in the cytoplasm, unlike DNA which 
requires further transportation across the nuclear membrane for transcription. The use 
of siRNA therefore avoids one of the major obstacles encountered by DNA delivery. 
Since the final destination of siRNA and DNA delivery are the cytoplasm and nucleus, 
respectively, of the target cells, being endocytosed is not sufficient. The most 
challenging part of effective gene silencing or gene expression is endosomal escape, 
which usually requires the use of helper lipids which can induce phase transition of lipid 
bilayers in order to promote the release of encapsulated nucleic acids from endosomes. 
PEGylation of nanoparticles is usually found to inhibit the interaction between cationic 
nanoparticles and anionic endosomal membranes due to the steric hindrance of PEG, 
which prevents liposomal content from being released into cytosol. The presence of a 
PEG layer appears to be problematic at the intracellular level in both DNA and siRNA 
systems. A PEG dissociation strategy, such as the enzyme-triggerable detachment of 
the PEG layer, which can be employed to promote the cellular uptake and endosomal 
escape of DNA nanoparticles may also be applied to siRNA delivery. Following the 
investigation of the low-charge PEGylated peptide-lipid nanoparticles for mediating 
pDNA delivery in response to specific enzymes, we continue to evaluate the use of this 
triggerable system for siRNA-mediated knockdown of specific proteins.  
 
4.1 DODAG-low siRNA nanoparticles 
 
Here, the same DODAG-low formulation (20% DODAG) as for pDNA delivery was 
employed for siRNA (Table 4-1). The encapsulation of siRNA was carried out using the 
same procedure as for pDNA encapsulation.  
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  Lipid Molar % of total lipid 
  DODAG 
  DOPC 
  Cholesterol 
  PPHLEC, PPMMP-2C, PC,  
  PPHLEC18, PPMMP-2C18 or PC18 
20 
50 (or 49 or 45) 
30 
0 (or 1 or 5) 
 
   Table 4-1: Lipid components in low-charge formulation for siRNA delivery 
 
4.1.1 Physicochemical characterisation of DODAG-low siRNA nanoparticles 
 
4.1.1.1 siRNA encapsulation efficiencies 
 
As with pDNA, siRNA has anionic phosphate backbones and can therefore interact 
electrostatically with positively charged liposomes to form liposome-siRNA complexes. 
However, siRNA is much smaller than pDNA with 19-21 base pair (bp) duplexes, 
whereas the minimal size of pDNA for condensation is approximately 4000 bp.259 
siRNA therefore has far fewer negative charges – a maximum of 42 negative charges 
per molecule – while pDNA has approximately 8000 negative charges. The smaller 
number of siRNA charges allows the charge ratio of nanoparticles and siRNA to be 
easily manipulated. The charge ratios or N/P ratios refer to the relative numbers of 
cationic charges from the lipids in the formulation (N) (1.7 per molecule of DODAG) and 
anionic charges from phosphate groups of siRNA molecules (2 per bp). siRNA 
nanoparticles were prepared at different charge ratios by fixing the amount of siRNA 
and increasing the amount of the preformed empty liposomes. Their encapsulation 
efficiency was then assessed using PI assay.   
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a) 
 
b) 
 
Figure 4-2: siRNA  encapsulation efficiency of DODAG-low nanoparticles with a) non-
PEG, 1 and 5 mol% PPHLEC, 1 and 5 mol% PPMMP-2C, and 1 and 5 mol% PC b) with 1 
and 5 mol% PPHLEC18, 1 and 5 mol% PPMMP-2C18, and 1 and 5 mol% PC18 at different 
lipid: pDNA charge ratios, using propidium iodide assay. The encapsulation efficiency 
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of siRNA is presented as a percentage of the amount of siRNA initially used in the 
preparation.  
 
The data from the PI assay (Figure 4-2a and b) demonstrated an increase in 
entrapment efficiency as the charge ratio increased, due to a greater amount of cationic 
lipid being present for interaction with the siRNA. For all formulations, a lower degree of 
siRNA encapsulation was found at higher PEG concentrations, suggesting that PEG 
may shield the surface charge available for binding to siRNA. A significant increase in 
entrapment efficiency was observed at charge ratios of 2 and 4. At charge ratio of 4, 
the nanoparticles exhibited more than 80% siRNA encapsulation, and no significant 
change in entrapment efficiency was found at the charge ratio higher than 4.  
 
Agarose gel electrophoresis revealed similar findings to those of the PI assay, showing 
almost complete siRNA encapsulation at a charge ratio of 4 for most of the formulations 
(Figure 4-3). However, 1 and 5 mol% PPHLEC nanoparticles showed some migration of 
siRNA at the charge ratio of 4, compared to the 99% siRNA encapsulation observed in 
the PI assay, suggesting that some siRNA may transverse at the external layer of 
liposomes, and upon the application of an electric field these surface-bound siRNAs 
may disassociate from the liposomes. This observation was supported by the study of 
Buyens et al., which demonstrated that classical mixing of siRNA with preformed 
PEGylated liposomes could result in the binding of some siRNA to the outer surface of 
the liposomes.130 It is interesting that this occurs with PPHLEC siRNA nanoparticles, 
indicating that the siRNA translocation to the surface might be affected by the peptide 
sequence. 
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       a)                         b)                     c)    
                       
       d)                                              e)                                          f) 
                            
       g)                                              h)                                          i) 
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        j)                                              k)                                          l) 
                         
 
       m)                                                                                  
              
 
Figure 4-3: 1% agarose gel electrophoresis demonstrated siRNA encapsulation of 
DODAG-low nanoparticles with a) non-PEG, b) 1 mol% PPHLEC, c) 1 mol% PPMMP-2C, 
d) 1 mol% PC, e) 5 mol% PPHLEC, f) 5 mol% PPMMP-2C, g) 5 mol% PC, h) 1 mol% 
PPHLEC18, i) 1 mol% PPMMP-2C18, j) 1 mol% PC18, k) 5 mol% PPHLEC18, l) 5 mol% 
PPMMP-2C18, m) 5 mol% PC18 at different lipid: siRNA charge ratios (gel a): lane 1 = 
siRNA, lane 2 = empty liposomes, lipid: siRNA charge ratios: lane 3 = 0.5:1, lane 4 
=2:1, lane 5 = 4:1 and lane 6 = 8:1; gel b-m): lane 1 = empty liposomes, lipid: siRNA 
charge ratios: lane 2-5 = same as lane 3-6 of gel a)). The electrophoresis was 
performed at 65 mV for 30 min and the gels were visualized under UV light using 
Alliance 4.7 UVITEC Cambridge. 
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According to the result obtained from the PI assay and agarose gel electrophoresis, all 
liposome formulations showed almost complete siRNA encapsulation at a charge ratio 
of 4. As a result, lipid: siRNA was kept at this ratio for all experiments related to 
DODAG-low siRNA nanoparticles. 
 
4.1.1.2 Size and zeta potential measurements 
 
PCS measurement (Figure 4-4a) showed increases in nanoparticle sizes after siRNA 
loading, indicating the encapsulation of siRNA. The diameters of siRNA nanoparticles 
were found to be within 93-120 nm, which is advantageous for in vivo systemic delivery 
since nanoparticles with diameter less than 200 nm are capable of bypassing the 
fenestrations in tumour vasculature and thereby accumulating in tumour tissue. The 
polydisperity index of siRNA nanoparticles was found to be 0.2-0.7.      
 
The zeta potential of siRNA nanoparticles was found to decrease after siRNA 
entrapment (Figure 4-4b), suggesting charge neutralisation as a result of the 
complexation between liposomes and siRNA. At higher PEG concentrations, the 
nanoparticles exhibited lower surface charges as a result of the shielding effect of PEG. 
The zeta potential was almost neutral when 5 mol% PEG was incorporated. This low 
zeta potential is a favourable characteristic for a nucleic acid delivery system for in vivo 
application owing to the ability of nanoparticles to avoid RES uptake, therefore 
increasing their blood circulation half-lives.  
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a) 
 
b) 
 
Figure 4-4: a) Average diameters and b) zeta potentials of DODAG-low siRNA 
nanoparticles (4:1 lipid: siRNA charge ratio) containing non-PEG, 1 mol% PPHLEC, 1 
mol% PPMMP-2C, 1 mol% PC, 5 mol% PPHLEC, 5 mol% PPMMP-2C and 5 mol% PC, 1 
mol% PPHLEC18, 1 mol% PPMMP-2C18, 1 mol% PC18, 5 mol% PPHLEC18, 5 mol% 
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PPMMP-2C18 and 5 mol% PC18, compared to their empty liposomes. Each result 
represents means  S.D. of three measurements. 
 
4.1.2 Exogenous luciferase gene knockdown using PEGylated peptide-lipid  
conjugates 
 
Although siRNA nanoparticles were shown to have the optimal physiochemical 
properties required for efficient nucleic acid delivery in vivo, the most important feature 
is their ability to deliver the siRNA and render specific gene knockdown. The biological 
activity of the siRNA nanoparticles was evaluated in vitro using a luciferase reporter 
gene. MCF-7 and HT1080 cells were pretransfected with pDNA encoding for luciferase 
(pEGFPLuc) using a commercially available transfection agent jetPEI to induce 
transient luciferase expression. Here, Lipofectamine 2000 was not used since it was 
found to be potentially toxic to HT1080, causing a high level of cell death during a 
period of incubation. The nanoparticles were prepared to encapsulate either a specific 
anti-luciferase or a control nonspecific siRNA at the charge ratio of 4. Once the cells 
were expressing the luciferease gene, the siRNA nanoparticles were administered. 
Prior to using PEGylated peptide-lipid nanoparticles for functional siRNA delivery, the 
optimal siRNA concentrations required for maximum gene knockdown were examined 
using non-PEGylated nanoparticles. The non-PEGylated nanoparticles encapsulating 
siRNA were incubated with luciferase-pretransfected MCF-7 and HT1080 cells for 6 
and 24 h, respectively. The cells were incubated for further 36 h before analysis for 
luciferase protein content.     
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a) 
 
b)  
 
Figure 4-5: Knockdown of transient luciferase expression using anti-luciferase siRNA 
encapsulated in non-PEGylated nanoparticles (at charge ratio of 4) in a) MCF-7 and b) 
HT1080 cells with different siRNA concentrations. The result is presented as % 
differential knockdown between anti-luciferase siRNA and nonspecific siRNA delivery 
calculated using the following formula: [1-(luciferase activityanti-luciferase siRNA/ luciferase 
activitynonspecific siRNA)] x 100.  
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Figure 4-5 shows a concentration dependent pattern of gene knockdown efficiency. 
The optimal dose of siRNA for maximising luciferase knockdown was found to be 15 
nmol/well (30 M) in both MCF-7 and HT1080 cells. Increasing siRNA concentrations 
above this level showed no significant enhancement in gene knockdown efficiency. 
This amount of siRNA, 30 M , was considered a high dose since siRNA 
concentrations typically employed to achieve maximum gene silencing in vitro have 
been found to be within a range of nM, depending on formulations, target genes, cell 
types, and transfection conditions.120, 212, 260, 261 The requirement for an increased 
quantity of siRNA may be due to two possibilities: the efficiency of the nanoparticles to 
mediate siRNA delivery; and a high level of transient luciferase expression (107-108 
RLU/mg protein) so that low siRNA doses (nM) were not capable of rendering 
significant gene knockdown. To investigate these possibilities, a commercially available 
siRNA transfection agent, Dhamafect, was used for siRNA delivery and its 
knockdown efficiency was compared to that of the non-PEGylated nanoparticles. Two 
siRNA doses, 15 pmol (30 nM) and 15 nmol (30 M), were chosen as low and high 
siRNA concentrations. Interestingly, both Dharmafect and the non-PEGylated 
nanopaticles showed comparable levels of luciferase knockdown at the same siRNA 
doses in both MCF-7 and HT1080 cells (Figure 4-6). This result suggests that the ability 
of non-PEGylated nanopaticles to mediate siRNA delivery were as efficient as 
Dharmafect, and therefore we assumed that it was likely that a high level of transient 
luciferase expression required high siRNA doses to effectively induce gene silencing. 
Increasing the siRNA concentration is often observed to have undesirable effects 
including nonspecific gene knockdown and toxic side effects.262-264  These effects are 
dose-dependent and can be avoided by using lower siRNA concentrations. However, 
other studies demonstrated that nonspecific effects had a similar dose response to that 
required for the silencing of the target gene.265   
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a) 
 
b) 
 
Figure 4-6: Comparison of siRNA-mediated luciferase knockdown using a 
commercially available siRNA transfection reagent, Dharmafect, and DODAG-low 
non-PEGylated nanoparticles in a) MCF-7 and b) HT1080 cells using two siRNA 
concentrations: 15 pmol/well and 15 nmol/well, 48-well plate. The result is presented as 
% knockdown of luciferase protein by anti-luciferase siRNA normalised by luciferase 
activity obtained from control nonspecific siRNA. 
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As siRNA concentrations increased, nonspecific siRNA was found to mediate luciferase 
gene knockdown to some extent, leading to downregulation of the luciferase protein 
(data not shown). The data further suggested that the expression of other cellular 
proteins might be inhibited by the nonspecific effect, and therefore high siRNA 
concentrations should be avoided. The siRNA concentration in nM when delivered 
using non-PEGylated nanoparticles, however, resulted in low knockdown efficiency 
(<15 %). We postulated that when using PEGylated peptide-lipid nanoparticles and 
their PEGylated controls for gene knockdown studies, it would be more difficult to 
clearly see the effect of enzyme-mediated delivery of siRNA. No significant detachment 
of cells from the transfection wells due to toxicity was observed at a siRNA 
concentration of 15 nmol/well and therefore the toxic effect induced by increased siRNA 
doses was not investigated. In the future, it would be useful to further assess the effect 
of siRNA quantity on cellular viability and toxicity using MTS, LDH, or apoptosis assay 
to ensure the suitability of the siRNA dose for mediating gene knockdown with minimal 
toxicity. Because of the reasons mentioned above, we decided to use 15 nmol of 
siRNA/well to examine the effect of enzyme-assisted PEG detachment on promoting 
endocytosis of the nanoparticles and ultimately enhancing the level of luciferase 
knockdown as a result of improved endosomal escape of encapsulated siRNA.   
 
4.1.2.1 Transient luciferase gene knockdown using PPHLEC and PPHLEC18  
nanoparticles 
 
In the HLE experiment, nanoparticles encapsulating either anti-luciferase or nonspecific 
siRNA were divided into two groups, HLE treatment and non-treatment, as were those 
prepared for pDNA delivery. MCF-7 cells were pretransfected with pDNA encoding for 
luciferase prior to the administration of siRNA nanoparticles. After 6 h of transfection 
and a further 36 h of incubation, it was found that PPHLEC nanoparticles after HLE 
treatment were able to silence the expression of luciferase protein, although with 
relatively modest efficiency, compared to that of non-treated PPHLEC nanoparticles and 
PC nanoparticles with HLE treatment and non-treatment (p < 0.05) (Figure 4-7a). This 
result suggests that PPHLEC nanoparticles may be activated by the enzyme, ultimately 
promoting the endosomal escape of siRNA into the cytosol where it functions. The 
silencing effect of the PPHLEC nanoparticles was found to be similar to that of the non-
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PEGylated nanoparticles (p > 0.05). Both 1 and 5 mol% PC nanoparticles were shown 
to inhibit protein expression at lower levels compared to PPHLEC nanoparticles, 
demonstrating that PEGylated nanoparticles did not inhibit cellular uptake but greatly 
interfered with the release of nucleic acids from endosomal compartments. This 
observation was in agreement with the findings of the pDNA system. The level of 
protein knockdown in the case of non-PEGylated nanoparticles and 1 and 5 mol% PC 
nanoparticles were found to be similar in both HLE treatment and non-treatment 
groups, suggesting that the cellular uptake of these nanoparticles was not affected by 
the presence of the enzyme.  
 
An enhancement in knockdown efficiency by HLE-pretreated PPHLEC18 nanoparticles 
was also observed, compared to that of PPHLEC18 with non-treatment and HLE-treated 
and non-treated PC18 nanopaticles (Figure 4-7b). The trend of luciferase silencing 
mediated by C18-anchored PEGylated nanoparticles in response to enzyme treatment 
and non-treatment was found to be similar to that of the cholesterol-anchored system 
with slight differences in knockdown efficiency.  
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a) 
 
b) 
 
Figure 4-7: Knockdown of transient luciferase expression by anti-luciferase siRNA 
encapsulated in DODAG-low nanoparticles containing a) non-PEG, PPHLEC (1 and 5 
mol%) and PC (1 and 5 mol%) b) non-PEG, PPHLEC18 (1 and 5 mol%) and PC18 (1 
and 5 mol%), with HLE-treatment (black) and non-treatment (white). The transfection 
was performed on MCF-7 cell lines and the data are presented as % differential 
            Chapter Four: Biophysical and in vitro biological evaluation of PEGylated peptide-lipid conjugates: siRNA system  
206 
 
knockdown between anti-luciferase siRNA and nonspecific siRNA delivery. Each result 
represents the mean  S.D. (n = 3),  indicates p < 0.05. 
 
4.1.2.2 Transient luciferase gene knockdown using PPMMP-2C and PPMMP-2C18  
nanoparticles 
 
In the MMP-2 experiment, HT1080 cells were pretransfected with pDNA encoding for 
luciferase prior to siRNA delivery. After 24 h of transfection and a further 36 h of 
incubation, it was shown that PPMMP-2C nanoparticles were able to inhibit protein 
expression at significantly higher levels compared to that of non-cleavable PC 
nanoparticles (p < 0.05) (Figure 4-8a), suggesting the activation of PPMMP-2C 
nanoparticles in response to the secreted MMP-2 in the culture medium. The 
knockdown efficiency of both 1 and 5 mol% PPMMP-2C nanoparticles was found to be 
higher than 50%. Non-cleavable PC nanoparticles were able to mediate siRNA 
delivery, as shown by increases in knockdown efficiency, indicating their capability of 
cellular uptake.  
 
An enhancement in the level of luciferase knockdown was also observed when using 
PPMMP-2C18 nanoparticles, compared with non-cleavable PC18 nanoparticles (p < 0.05) 
(Figure 4-8b). The inhibiting effect of PEG was clearly seen with increasing degrees of 
PEGylation. C18-anchored PEGylated nanoparticles showed a similar trend of protein 
knockdown to that of the cholesterol-anchored system, but to a lesser extent of 
efficiency.  
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a) 
 
b) 
 
Figure 4-8: Knockdown of transient luciferase expression by anti-luciferase siRNA 
encapsulated in DODAG-low nanoparticles containing a) non-PEG, PPMMP-2C (1 and 5 
mol%) and PC (1 and 5 mol%) b) non-PEG, PPMMP-2C18 (1 and 5 mol%) and PC18 (1 
and 5 mol%). The transfection was performed on MMP-2 positive HT1080 cell lines and 
the data was presented as % % differential knockdown between anti-luciferase siRNA 
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and nonspecific siRNA delivery. Each result represents the mean  S.D. (n = 3),  
indicates p < 0.05. 
 
According to transfection data obtained, the PEGylated peptide lipid nanoparticles were 
shown to mediate significant luciferase knockdown in response to the specific 
enzymes, compared with their control PEGylated counterparts. Although this system 
was somewhat remote from the knockdown of an endogenous gene since pDNA 
transfection is required prior to the delivery of siRNA, this fact should not interfere with 
the formulation parameters that were examined.  
 
4.1.3 Knockdown of luciferase gene in stably transfected cells using  
PEGylated peptide-lipid conjugates 
 
Previously, it was demonstrated that the PEGylated peptide-lipid nanoparticles were 
capable of silencing transient expression of luciferase gene in the presence of the 
enzymes. To confirm the significant of this data in a system that is more physiologically 
relevant, we continued our investigation with stably transfected luciferase cell lines, 
seeking to the knockdown of luciferase gene. Cell lines stably-expressing luciferase 
were obtained by mean of transfection using pDNA containing luciferase reporter gene, 
G418 antibiotic resistant gene and S/MAR sequence, which was kindly provided by Dr. 
Orestis Agyros and Dr. Richard Harbottle. Inclusion of S/MAR sequence into plasmid 
construct was shown to confer higher and more sustained transgene expression in both 
in vitro and in vivo.266 The transfected cells were kept under antibiotic selection to 
obtain stably luciferase expressed cell lines, which were then used for siRNA 
knockdown experiment. The level of luciferase expression was found to be 108 
RLU/mg protein. 
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4.1.3.1 Knockdown of luciferase gene in stably transfected luciferase cell lines  
using PPHLEC and PPHLEC18 nanoparticles  
 
In HLE experiment, the nanoparticles encapsulating either anti-luciferase or nonspecific 
siRNA were prepared at charge ratio of 4 and were administered to MCF-7 cell lines 
stably-expressing luciferase (MCF-7-luc). The transfection data showed that HLE-
treated PPHLEC nanoparticles were able to significantly inhibit luciferase expression 
although with modest efficiency, compared with that of non-treated PPHLEC 
nanoparticles and non-cleavable PC nanoparticles with HLE treatment and non-
treatment (p < 0.05) (Figure 4-9a). Similar finding was also observed when using C18-
anchored PEGylated nanopaticles, showing increased luciferase knockdown by HLE-
treated PPHLEC18 nanoparticles in comparison with their control PC nanoparticles (p < 
0.05) (Figure 4-9b). These observations were in line with the data obtained from 
transient luciferase expression experiment although with some variations, confirming 
the ability of the PEGylated peptide-lipid nanoparticles to promote siRNA delivery in 
response to the specific enzyme.       
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a) 
 
b) 
 
Figure 4-9: Knockdown of luciferase expression in stably transfected luciferase cell 
lines by anti-luciferase siRNA encapsulated in DODAG-low nanoparticles containing a) 
non-PEG, PPHLEC (1 and 5 mol%) and PC (1 and 5 mol%) b) non-PEG, PPHLEC18 (1 
and 5 mol%) and PC18 (1 and 5 mol%), with HLE-treatment (black) and non-treatment 
(white). The transfection was performed in MCF-7-luc cell lines and the data are 
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presented as % differential knockdown between anti-luciferase siRNA and nonspecific 
siRNA delivery. Each result represents the mean  S.D. (n = 3),  indicates p < 0.05. 
 
4.1.3.2 Knockdown of luciferase gene in stably transfected luciferase cell lines  
using PPMMP-2C and PPMMP-2C18 nanoparticles  
 
To ensure that HT1080 cell lines stably expressing luciferase (HT1080-luc) were able 
to secrete the enzyme, the transfected cells were characterised for their levels of MMP-
2 expression in cell culture medium using MMP-2 human ELISA assay. The cells were 
found to secrete high levels of MMP-2 (approximately 9 ng/mL), similar to that of 
normal HT1080 cells as shown in the previous chapter, and therefore were suitable to 
assess the ability of PPMMP-2C and PPMMP-2C18 nanoparticles to mediate siRNA delivery 
in response to the enzyme.  
 
In vitro transfecttion data showed that PPMMP-2C nanoparticles were able to silence the 
expression of luciferase protein in response to MMP-2 compared to non-cleavable PC 
nanoparticles (p < 0.05), although the knockdown efficiency was found to be modest 
(Figure 4-10a). The inhibition of luciferase expression was significantly enhanced by 
PPMMP-2C18 nanoparticles in comparison with their control PC counterparts (p < 0.05) 
(Figure 4-10b). The result was in agreement with that of the transient luciferase 
expression experiment, with some variation in knockdown efficiency. The data obtained 
confirmed that PPMMP-2C and PPMMP-2C18 nanoparticles were capable of improving 
siRNA delivery in response to the MMP-2 enzyme.       
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a) 
 
b) 
 
Figure 4-10: Knockdown of luciferase expression in stably transfected luciferase cell 
lines by anti-luciferase siRNA encapsulated in DODAG-low nanoparticles containing a) 
non-PEG, PPMMP-2C (1 and 5 mol%), and PC (1 and 5 mol%), b) non-PEG, PPMMP-2C18 
(1 and 5 mol%), and PC18 (1 and 5 mol%). The transfection was performed in HT1080-
luc cell lines and the data are presented as % differential knockdown between anti-
luciferase siRNA and nonspecific siRNA delivery. Each result represents the mean  
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S.D. of three different experiments. Each result represents the mean  S.D. (n = 3),  
indicates p < 0.05. 
 
The use of anti-luciferase siRNA served as a proof of concept to assess the ability of 
nanoparticles for functional siRNA delivery in vitro. The transfection data of all 
PEGylated peptide-lipid nanoparticles emphasises the importance of incorporating 
cleavable PEGylated lipid conjugates within nanoparticles to improve siRNA delivery. 
The luciferase knockdown efficiency was found to be variable depending on cell types 
and lipid anchoring system, but no direct relation among these parameters could be 
made. This variation may be partially attributed to the high levels of luciferase 
expression in both transient and stably transfected cell lines, making accurate analysis 
difficult in cases of low gene knockdown efficiency. In the case of transient gene 
transfection, lower gene expression may be achieved by optimising the amount of 
pDNA used for transfection and also the duration that the transfection reagent is 
exposed to cells. For stably transfected cell lines, using a cell batch with lower 
luciferase expression or seed cells at a lower density may decrease the level of gene 
expression. The reduced gene expression level may enable the use of lower siRNA 
concentrations and thus the nonspecific effects and toxicity associated with higher 
siRNA doses may be reduced.        
 
4.2 Chapter summary 
 
In this chapter, the viability of PEGylated peptide-lipid nanoparticles to enhance nucleic 
acid delivery was further investigated in a siRNA system. The nanoparticles showed a 
high siRNA encapsulation efficiency at a charge ratio of 4, and siRNA nanoparticles 
prepared at this charge ratio were small with diameters approximately less than 120 
nm. The zeta potential of the nanoparticles decreased as the degree of PEGylation 
increased, and the surface charge was found to be almost neutral when 5 mol% PEG 
was incorporated within the nanoparticles. . These features of the siRNA nanoparticles 
were advantageous for in vivo applications with respect to small size, low charge, and 
the ability to efficiently encapsulate nucleic acids. The optimisation of siRNA doses was 
investigated by performing protein knockdown experiments: non-PEGylated 
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nanoparticles produced efficient knockdown of the target gene and 15 nmol of siRNA/ 
well (48 well-plate) was found to be optimal to maximise gene silencing. Although 
increasing siRNA concentrations was observed to result in some extent of nonspecific 
effects, this amount of siRNA was used since concentrations in the pmol range resulted 
in low gene knockdown efficiency, which may hinder the investigation of the effect of 
enzyme-mediated siRNA delivery. The low level of gene knockdown observed at low 
siRNA concentrations may be due to high levels of transient gene expression (107-108 
RLU/mg protein), making efficient gene silencing difficult when using low amounts of 
siRNA. This problem may be solved by optimising the amount of pDNA used for 
transfection as well as the incubation time. Toxic effects (off-target effects) associated 
with the use of high siRNA concentrations should be further assessed in order to obtain 
a siRNA concentration that confers both high knockdown efficiency and minimum 
toxicity. In vitro transfection demonstrated that PEGylated peptide-lipid nanoparticles 
were able to significantly inhibit transient luciferase expression in response to the 
enzymes when compared to their PEGylated lipid controls. A similar finding was 
observed when further investigating their knockdown ability in stably transfected 
luciferase cell lines. Although the knockdown efficiency was modest and some variation 
was observed depending on cell lines and lipid anchors, no relationship was observed 
between these groups, and the incorporation of the PEGylated peptide-lipid conjugates 
sensitive to the specific enzymes was shown to promote siRNA delivery compared to 
non-cleavable PEGylated systems.  
 
 
  
 
 
 
 
 
 
 
5. Conclusion and future directions 
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Nucleic acid therapeutics are administered mainly intravenously and prefereably in the 
form of nanoparticles. When in systemic circulation, unmodified cationic liposomes are 
prone to plasma protein adsorption leading to the aggregation and rapid clearance by 
the mononuclear phagocyte system. PEGylation of the liposome surface by the 
incorporation of a synthetic PEG functionalised lipid is known to confer liposomal 
stability by providing steric repulsion, resulting in reduced interaction with plasma 
components. The use of PEG may be essential for the colloidal stability of all types of 
nanoparticles while in circulation; however, its presence is undesirable once at a target 
site (i.e. tumour cells) as it significantly inhibits the cellular uptake of nanoparticles as 
well as the release of the encapsulated agent. The development of stealth systems that 
could be removed in response to specific stimuli at target cells may be one strategy to 
overcome this problem.    
 
PEGylated lipid conjugates sensitive to the enzymes secreted in solid tumours were 
developed. The synthesis was achieved by the conjugation of a PEG polymer to a lipid, 
either a cholesterol-based or C18 lipid, via an enzyme substrate peptide, resulting in a 
series of cholesterol- and C18-anchored PEGylated peptide-lipid conjugates bearing an 
HLE or MMP-2 substrate sequence: PPHLEC 17, PPMMP-2C 18, PPHLEC18 20, and 
PPMMP-2C18 21. The ability of these compounds to be degraded by the enzymes was 
not observed using a series of analytical methods except in the case of PPHLEC18 20, 
the degradation of which was detected by HPLC, but to a very low extent, as shown in 
chapter 2. There are two possible explanations for this. First, the substrates may not 
have been degraded by the enzymes at all, presumably due to micelle formation by the 
conjugates, in which the PEG polymer forms a hydrated sphere around the cholesterol 
or lipid interior. In this arrangement, PEG greatly hinders cleavage due to its steric 
effect, thereby preventing the access of the enzymes to the peptide substrates. 
Second, it might be that the techniques used lack the sensitivity to measure small 
amounts of degraded products. 
 
Given preliminary in vitro data showing that the incorporation of PPHLEC within 
liposomes was able to enhance gene expression in the presence of the specific 
enzyme compared to non-cleavable PC nanoparticles, it was decided to further 
investigate the ability of nanoparticles containing PEGylated peptide-lipid conjugates to 
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improve nucleic acid delivery in response to enzyme activation. First, the effect of 
nanoparticle surface charge was examined by introducing different molar percentages 
of the cationic lipid in the liposome formulation. . The ability of the nanoparticles to 
condense pDNA was examined to ensure high pDNA encapsulation efficiency, and 
their sizes and surface charges were also measured. DODAG-high (50% DODAG) 
nanoparticles containing either PPHLEC or PPMMP-2C were able to increase transfection 
efficiency in response to the enzymes compared with non-cleavable PC nanoparticles 
and non-PEGylated control. Although the mechanism of enzyme-assisted pDNA 
delivery is not yet understood, the result suggested the possibility of partial peptide 
hydrolysis leading to partial PEG detachment. This enabled the nanoparticles to reveal 
more of their positive charges, facilitating interaction with negatively charged cell 
membranes and thus leading to cell uptake. The DODAG-high system, however, was 
found to rapidly aggregate in 10% serum and was thus unsuitable for in vivo use. 
Formulation of nanoparticles with lower charges was achieved by reducing the amount 
of the cationic lipid in the formulation. Improved gene expression by PPHLEC and PPMMP-
2C nanoparticles was also observed in the DODAG-low (20% DODAG) system, 
although with lower transfection efficiency. However, their stability in serum was found 
to increase, in particular when 4-5 mol% PEG was incorporated. Fluorescence and 
confocal microscopy revealed that the nanoparticles were internalised and dispersed 
throughout the cytoplasm. Furthermore, the toxicity of these low-charge nanoparticles 
was found to be minimal. The effect of a lipid-anchoring system on transfection activity 
was then investigated using C18-lipid anchored nanoparticles. Both PPHLEC18 and 
PPMMP-2C18 nanoparticles were shown to mediate pDNA delivery at significant levels in 
the presence of the enzymes, compared with their control nanoparticles. The 
correlation between types of lipid anchors and the mechanism of enzyme-assisted 
pDNA delivery was not observed in either the HLE or MMP-2 system. 
 
The PEGylated nanoparticles were further investigated for their ability to deliver siRNA. 
The physicochemical characterisation of siRNA nanoparticles was assessed. The 
PEGylated nanoparticles containing PPHLEC, PPMMP-2C, PPHLEC18, or PPMMP-2C18 were 
able to render protein knockdown in both transient luciferase expressing and stably 
transfected luciferase cells in response to the enzymes in comparison with their control 
PC nanoparticles. Although gene knockdown was observed, the dose of siRNA used 
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was high and this could be associated with nonspecific effects. The experiment 
therefore requires further optimisation as discussed in chapter 4. However, assuming 
that nonspecific effects are similar when using the same siRNA dose, the transfection 
data obtained showed a proof of concept for the study of enzyme-assisted siRNA 
delivery.   
 
Future work on PEGylated peptide-lipid conjugates should involve enzyme cleavage 
studies utilising fluorescent PEG conjugated to peptide and lipid as discussed in 
chapter 2 or colorimetric assay such as TNBS and fluorescamine, which allows for the 
detection of primary amine functional groups of the product as a result of enzymatic 
degradation. These methods may allow for the use of substrate concentrations below 
CMC to prevent micellar formation. For TNBS and fluorescamine assay, to remove the 
enzyme and other buffer component, the sample mixture could be centrifuged at 50000 
xg for 10 min, washed with saline, and then the lipid pellet resuspended in chloroform 
before the assay analysis.209 The liposome formulation being tested here was limited to 
one formulation using DODAG, DOPC, and cholesterol. Future work might include the 
further optimisation of liposome formulations capable of more efficient cellular uptake in 
the presence of serum. In the case of MMP-2 in vitro experiments, to ensure that the 
preferential uptake of PPMMP-2C and PPMMP-2C18 nanoparticles are due to the enzyme 
action, MMP-2 inhibitors such as Galardin (GM6001) may be preincubated with the cell 
culture before the addition of the nanoparticles and the transfection efficiency could be 
compared with that of the cells with no added inhibitor. In addition, to verify that the 
enzyme-assisted delivery is due to the specific sequence of the peptide linker, 
nonspecific peptide sequences could be conjugated to PEG and the lipid and their 
enzymatic cleavage as well as transfection efficiency could be compared to that of 
specific peptide sequences. 
 
Further development of enzyme-assisted delivery systems could involve increasing the 
sensitivity of the peptide linker required for efficient PEG detachment which would 
ultimately increase transfection efficiency. The length of the linker may be extended to 
improve the interaction with enzymes, probably by introducing small amino acids that 
do not affect the catalytic activity of enzymes, such as glycine, to the original peptide 
linker, or by conjugating repeated sequences of the active unit between PEG and the 
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lipid. Furthermore, peptide sequences including GPLGIAGQ209 and GPLGVRGC267 
have been recently reported to be effectively degraded by MMP-2. The use of these 
octapeptides may allow for more efficient removal of PEG via enzymatic cleavage of 
the peptide linker. Since cellular internalisation of this delivery system relies purely on 
electrostatic interactions between nanoparticles and cell membranes which can lead to 
nonspecific uptake, further development could involve the incorporation of a targeting 
moiety. Exposure of a targeting ligand for receptor binding once the PEG layer is 
removed could result in reduced nonspecific uptake and more efficient cell association 
and internalisation of the nanoparticles. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
6. Experimental 
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6.1 General information 
 
6.1.1 Materials 
 
Chemical reagents: H-Val-2-chlorotrityl resin, 9-Fluorenylmethoxycarbonyl (Fmoc) 
protected amino acids, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) and 1-Hydroxybenzotriazole (HOBt) were purchased 
from Novabiochem (UK). Methoxypolyethylene glycol succinamate N-
hydroxysuccinimide (PEG-NHS ester) (MW 2000) was obtained from Rapp Polymere 
(Germany). 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), cholesterol lipid, 
elastase from human leukocytes (HLE), N-methoxysuccinyl-Ala-Ala-Pro-Val p-
nitroanilide (a chromogenic substrate for HLE), agarose gel, LB broth, kanamycin, N,N-
diisopropylethylamine (DIPEA), trifluoroacetic acid (TFA), N,N-dimethylformamide 
(DMF), all buffer reagents, and all other chemicals and solvents were purchased from 
Sigma-Aldrich (UK). 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine 
rhodamine B sulfonyl) (DOPE-Rho) was obtained from Avanti Polar Lipids Inc. 
(Alabaster, AL, USA). MMP-2, active, human, recombinant, CHO cells, MCA-Pro-Leu-
Gly-Leu-Dpa-Ala-Arg-NH2 (a fluorogenuc substrate for MMP-2), and MCA-Pro-Leu-OH 
(a fluorogenic substrate control for MMP-2) were purchased from Calbiochem (UK). 
Propidium iodide and SYBR green II RNA gel stain were obtained from Molecular 
Probes (UK). SYBR safe DNA gel stain and 10X Tris-borate-EDTA (TBE) 
electrophoresis buffer were purchased from Invitrogen. DNA ladder, 6X orange DNA 
loading dye, 50X Tris-acetate-EDTA (TAE) electrophoresis buffer were obtained from 
Fermentas (UK). E.Z.N.A.  endo-free plasmid kit was purchased from Omega Bio-Tek 
(VWR international LTD, UK). 
 
Biological reagents: Human fibrosarcoma cell line (HT1080) and Human breast 
adenocarcinoma cell line (MCF-7) were obtained from the European Collection of the 
Cell Cultures (ECACC) (Salisbury, UK). Dulbecco’s Modified Eagle Medium (DMEM), 
Opti-MEM I reduced serum media, fetal bovine serum (FBS), penicillin and 
streptomycin, phosphate-buffered saline (PBS), and trypsin-EDTA were purchased 
from Gibco (Invitrogen, UK). Lipofectamine 2000 reagent and MMP-2 human ELISA 
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kit were obtained from Invitrogen (Paisley, UK). Transformed E.Coli containing 
pEGFPLuc, pUbC-Luc-S/MAR DNA, antibiotic G418 and jetPEI were kindly supplied by 
Dr Richard Harbottle and Dr Orestis Agyros. CytoTox 96 Non-Radioactive Cytotoxicity 
Assay, CellTiter 96 AQueous One Solution Cell Proliferation Assay, Luciferase assay 
system and cell culture lysis buffer 5X reagent were purchased from Promega 
(Southampton, UK). BCA protein assay kit was obtained from Pierce (Thermo 
Scientific). DharmaFECT was purchased from Dharmacon (Thermo Scientific). Anti-
luciferase siRNA (GL3) (target sequence 5’-AACTTACGCTGAGTACTTCGA-3’) was 
obtained from Qiagen. Silencer negative control siRNA was purchased from Applied 
Biosystems/ Ambion.  
 
6.1.2 General Procedures 
 
Solid phase peptide synthesis was performed on a manual peptide synthesis shaker. 
All reactions were carried out under a nitrogen atmosphere. CH2Cl2 was distilled over 
phosphorus pentoxide (P2O5). Flash column chromatography was performed using 
Merck silica gel 60 (230-240 mesh). Thin layer chromatography (TLC) was performed 
on Merck silica gel 60 F254 aluminum backed plates and visualized with UV light (254 
and 366 nm) and/or stained with acidic ammonium molybdate (IV) or potassium 
permanganate (IIV). 1H and 13C NMR were recorded on a 400 MHz Bruker Avance 400, 
using residual chloroform (CDCl3, H = 7.27 ppm, c = 77.0 ppm) as integral standard. 
Data is reported as follows: chemical shift, (integration; br = broad, s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet; coupling constants (J) in hertz (Hz); 
assignment).  
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The numbering system for the assignment of cholesterol is shown below. 
 
H1
2
3
4
5
6
7
8
9
10
11
12
13
14 15
16
17
18
19
20
21 22
23
24
25
26
27
 
 
Mass spectra were performed using Bruker Esquire 3000 ESI or Micromass MALDI 
micro MX instrument. Analytical HPLC was conducted on Hitachi-LaChrom L-7150 
pump system equipped with a Polymer Laboratories PL-ELS 1000 evaporative light 
scattering detector. The HPLC gradient assigned as follow: A = H2O/ 0.1% TFA; B = 
MeCN/ 0.1% TFA; C = MeOH. UV spectroscopy was conducted on a Pharmacia 
Biotech Ultrospec 4000 spectrometer. Fluorescence measurements were performed on 
a Varioskan flash microplate reader (Thermo Scienctific). Concentration of plasmid 
DNA was measured on Nanodrop ND-1000 UV-Vis spectrophotometer (Thermo 
Scientific). Particle sizing were performed using a Coulter Delta N4 plus photon 
correlation spectrophotometer (PCS). Zeta potentials were recorded on a Nanoseries 
Nano-ZS zetasizer (Malvern instruments). Microscopy experiments were conducted on 
a Nickon Eclipse E600 microscope and confocal microscopy was performed with an 
upright Leica instrument.  
 
6.2  Chemical Synthesis 
 
General Procedure for the synthesis of the N-Fmoc protected-peptide: H-Val-2-
Chlorotrityl resin (500 mg, 0.35 mmol) was added to a solid phase vessel and swelled 
in DMF (10 mL) and the vessel was agitated on a peptide synthesis shaker for 2h. DMF 
was removed and replaced with a solution of N-protected Fmoc-amino acid (1.05 
mmol), HBTU (386.89 mg, 1.02 mmol), HOBt (141.88 mg, 1.05 mmol), and DIPEA (180 
l, 1.05 mmol) in 10 ml DMF. The mixture was agitated for 45 min. The resin was 
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washed twice with DMF and Fmoc group was deprotected with 10 mL of 20% (v/v) 
piperidine in DMF for 10 min. Cycles of amino acid coupling and Fmoc deprotection 
were carried out under the same condition. When last coupling was achieved, the resin 
was washed successively with DMF, DCM, MeOH, and Et2O and allowed to dry under 
vacuum for 2 h. The peptide was then cleaved off the resin using 10 mL of 0.5% TFA in 
DCM for 4 h. The solution was filtered and the solvent was removed in vacuo. The 
residue was recrystallised in cold Et2O and the precipitate was freeze-dried overnight to 
afford the N-Fmoc protected-peptide as a white solid.  
 
Fmoc-AAPV-OH 9 
 
 
 
Synthesised as described in the general procedure for the synthesis of the N-Fmoc-
protected peptide, using Fmoc-Pro-OH (354.27 mg, 1.05 mmol) and Fmoc-Ala-OH 
(326.86 mg, 1.05 mmol), respectively, to afford 9 as a white solid (166.4 mg, 82%); 1H 
NMR (400 MHz, CDCl3) H 0.87, 0.90 (6H, d, J = 6.8 Hz, 2 x CH3 Val), 1.33, 1.34 (6H, 
d, J= 6.8 Hz, 2 x CH3 Ala), 1.93-2.27 (5H, m, CH() Val, CH2() Pro, CH2() Pro), 3.60-
3.80 (2H, m, CH2() Pro), 4.18 (1H, t, J= 7.0 Hz, CH () Val), 4.34-4.37 (2H, m, CH () 
Ala), 4.40-4.51 (2H, m, CH () Pro, Fmoc CH), 4.60-4.85 (2H, m, Fmoc CH2), 5.9 (1H, 
d, J= 7.6 Hz, NH), 7.25-7.77 (8H, Fmoc aromatic CH), 7.93 (1H, NH), 10.61 (1H, 
COOH); 13C NMR (400 MHz, CDCl3) C 17.3 (2C, 2 x CH3 Val), 18.5 (2C, 2 x CH3 Ala), 
25.0 (CH2() Pro), 28.0 (CH2() Pro), 31.2 (CH () Val), 37.5 (Fmoc CH), 47.0 (CH () 
Ala), 47.7 (CH2() Pro), 50.3 (CH () Ala), 57.5 (CH() Val), 60.4 (CH () Pro), 67.5 
(Fmoc CH2), 120.0, 125.1, 127.1,127.8 (8C, Fmoc aromatic CH), 141.3, 143.7 (4C, 
Fmoc aromatic C), 156.3 (CO carbamate), 164.2, 171.7, 172.9( 3C, CO),  174.2 
(COOH); HPLC: Rt = 17.8 min, column reverse phase C-4 protein, gradient mix: 0.0 min 
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[100% A], 15.0-25.0 min [100% B], 25.1-45.0 min [100% C], 45.1-55.0 min [100% A], 
flow: 1 mL min-1;  m/z (ESI +ve) 579 (M+H)+. 
 
Fmoc-GPLGV-OH 10 
 
 
 
 
Synthesised as described in the general procedure for the synthesis of the N-Fmoc-
protected peptide, using Fmoc-Gly-OH (312.16 mg, 1.05 mmol), Fmoc-Leu-OH (371.07 
mg, 1.05 mmol), Fmoc-Pro-OH (354.27 mg, 1.05 mmol), and Fmoc-Gly-OH(312.16 mg, 
1.05 mmol), respectively, to afford 10 as a white solid (114 mg, 49%); 1H NMR (400 
MHz, CDCl3) H 0.86-0.97 (12H, m, 2 x CH3 Leu, 2 x CH3 Val), 1.53-1.85 (3H, m, CH2 
() Leu, CH () Leu), 1.98-2.22 (5H, m, CH () Val, CH2 () Pro, CH2 () Pro), 3.5 (2H, 
m, CH2 () Pro), 3.61-3.86 (2H, m, CH2 () Gly), 4.0 (2H, s, CH2 () Gly), 4.12-4.27 (4H, 
m, CH () Val, CH () Leu, CH () Pro, Fmoc CH), 4.30-4.51 (2H, m, Fmoc CH2), 7.30-
7.78 (8H, m, Fmoc aromatic CH); 13C NMR (400 MHz, CDCl3) C 17.8 (2C, 2 x CH3 
Leu), 19.0 (2 x CH3 Val), 21.6 (CH2 () Leu), 23.0 (CH2 () Pro), 25.0 (CH2 () Pro), 29.0 
(CH () Leu), 30.2 (CH () Val), 39.5 (Fmoc CH), 43.0 (CH2 () Gly), 43.6 (CH2 () Gly), 
46.9 (CH2 () Pro), 52.2 (CH () Leu), 58.1 (CH () Val), 61.2 (CH () Pro), 67.3 (Fmoc 
CH2), 119.9, 125.1, 127.0, 127.7 (8C, Fmoc aromatic CH), 141.2, 143.7 (4C, Fmoc 
aromatic C), 157.2 (CO carbamate), 169.9, 170.5, 172.4, 173.4 ( 4C, 5 x CO),  173.8 
(COOH); HPLC: Rt = 18.7  min, column reverse phase C-4 protein, gradient mix: 0.0 
min [100% A], 15.0-25.0 min [100% B], 25.1-45.0 min [100% C], 45.1-55.0 min [100% 
A], flow: 1 mL min-1;  m/z (ESI +ve) 665 (M+H)+. 
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N’-cholesteryloxy-3-carbonyl-1,2-diaminoethane 5  
 
 
 
To a stirred solution of ethylene-1,2-diamine (150 mL) at room temperature, was added 
cholesteryl chloroformate (2 g, 4.45 mmol) in CHCl3 dropwise. After 18 h, the reaction 
was quenched with H2O (300 mL) and extracted with CH2Cl2 (3 x 150 mL). The organic 
extract was dried over MgSO4 and the solvent was evaporated in vacuo. The 
compound was purified by flash column chromatography on silica gel (CH2Cl2: MeOH: 
H2O: 92: 7: 1 v/v) to yield 5 as a white solid (1.71g, 86%); 1H NMR (400 MHz, CDCl3) H 
0.66 (3H, s, 18-CH3), 0.84 (3H, d, J = 6.4 Hz, 27-CH3), 0.85 (3H, d, J = 6.8 Hz, 26-CH3), 
0.90 (3H, d, J = 6.4 Hz, 21-CH3), 0.92 (3H, s, 19- CH3), 1.02-1.63 (21H, m, 1-CH2, 9-
CH, 11-CH2, 12-CH2, 14-CH, 15-CH2, 16-CH2, 17-CH, 20-CH, 22-CH2, 23-CH2, 24-CH2, 
25-CH), 1.76-2.04 (5H, m, 2-CH2, 7-CH2, 8-CH), 2.22-2.36 (2H, m, 4-CH2), 2.79-2.81 
(2H, m, 3’-CH2), 3.19-3.21 (2H, m, 4’-CH2), 4.52 (1H, m, 3-CH), 5.31 (1H, s, 6-CH); 13C 
NMR (400 MHz, CDCl3) C 11.8 (18-C),18.6 (21-C), 19.3 (19-C), 21.0 (11-C), 22.5 (26-
C), 22.8 (27-C), 23.7 (23-C), 24.2 (15-C), 27.9 (25-C), 28.2 (2C, 2-C, 16-C), 31.8 (2C, 
8-C, 7-C), 35.7 (20-C), 36.1 (22-C), 36.5 (10-C), 36.9 (1-C), 38.5 (24-C), 39.4 (4-C), 
39.6 (12-C), 39.8 (4’-CH2), 40.6 (3’-CH2), 42.2 (13-C), 49.9 (9-C), 56.0 (17-C), 56.6 (14-
C), 74.2 (3-C), 122.4 (6-C), 139.8 (5-C), 156.4 (CO carbamate); MS (ESI +ve) 473 (M + 
H)+. 
 
General Procedure for the synthesis of the N-Fmoc-protected peptide-cholesterol 
conjugate: To a solution of N-Fmoc-protected peptide, DMAP and HBTU in dry CHCl3 
(5 mL) was added N’-cholesteryloxy-3-carbonyl-1,2-diaminoethane 5 in dry CHCl3 (3 
mL). The mixture was stirred at room temperature under a nitrogen atmosphere for 18 
h. The reaction was quenched with 4% citric acid (4 mL) and washed with CHCl3 (3 x 
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20 mL). The organic extract was dried over MgSO4, filtered, and concentrated in vacuo 
to afford the desired N-Fmoc-protected peptide-cholesterol conjugate. 
 
Fmoc-AAPV-(N’-cholesteryloxy-3-carbonyl-1,2-diaminoethane) 13 
 
 
Synthesised as described in the general procedure for the N-Fmoc-protected peptide-
cholesterol conjugate, using N-Fmoc-protected peptide 9 (108.6 mg, 0.19 mmol), N’-
cholesteryloxy-3-carbonyl-1,2-diaminoethane 5 (88.2 mg, 0.19 mmol), DMAP (68.6 mg, 
0.56 mmol), and HBTU (72.6 mg, 0.19 mmol) to afford 13 as a pale yellow solid (131.4 
mg, 68%); 1H NMR (400 MHz, CDCl3) H 0.66 (3H, s, 18-CH3), 0.86 (3H, d, J = 6.8 Hz, 
27-CH3), 0.87 (3H, d, J = 6.8 Hz, 26-CH3), 0.89-1.02 (12H, m, 2 x CH3 Val, 19-CH3, 21-
CH3), 1.04-2.38 (41H, m, 2 x CH3 Ala, CH () Val, CH2 () Pro, CH2 () Pro, 1-CH2, 2-
CH2, 4-CH2, 7-CH2, 8-CH, 9-CH, 11-CH2, 12-CH2, 14-CH, 15-CH2, 16-CH2, 17-CH, 20-
CH, 22-CH2, 23-CH2, 24-CH2, 25-CH, 3’-CH2), 3.20-3.90 (2H, m, 4’- CH2), 4.19-4.85 
(7H, m, CH () Ala, CH () Val, CH () Pro, Fmoc CH, Fmoc CH2, 3-CH), 5.32 (1H, s, 
6-CH), 7.25-7.76 (8H, Fmoc aromatic CH); 13C NMR (400 MHz, CDCl3) C 11.8 (18-C), 
17.7 (2C, 2 x CH3 Val), 18.5 (2C, 2 x CH3 Ala), 19.4 (21-C), 21.0 (19-C), 21.3 (11-C), 
22.5 (26-C), 22.8 (27-C), 23.0 (CH2 () Pro), 23.8 (23-C), 24.2 (15-C), 25.1 (CH2 () 
Pro), 28.0 (25-C), 28.2 (16-C), 28.4 (2-C), 30.1 (CH () Val), 31.8 (8-C), 33.6 (7-C), 
35.7 (20-C), 36.1 (22-C), 36.5 (10-C), 36.9 (1-C), 38.9 (24-C), 39.5 (2C, 4-C, Fmoc 
CH), 39.6 (12-C), 39.9 (4’-CH2), 40.4 (3’-CH2), 42.2 (13-C), 47.1 (CH () Ala), 47.5 
(CH2 () Pro), 47.8 (9-C), 50.2 (CH () Ala), 56.1 (17-C), 56.6 (14-C), 57.5 (CH () Val), 
60.4 (CH () Pro), 67.0 (Fmoc CH2), 74.5 (3-C), 122.5 (6-C), 119.9, 125.1, 127.1, 127.8 
(8C, Fmoc aromatic CH), 139.7 (5-C), 142.1, 143.8 (4C, Fmoc aromatic C), 155.8, 
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156.7 (2C, 2 x CO carbamate), 171.3, 171.5, 172.1,172.5, (4C, 4 x CO); m/z (ESI +ve) 
1033 (M+H)+. 
 
Fmoc-GPLGV-(N’-cholesteryloxy-3-carbonyl-1,2-diaminoethane) 14 
 
 
Synthesised as described in the general procedure for the N-Fmoc-protected peptide-
cholesterol conjugate, using N-Fmoc-protected peptide 10 (105.0 mg, 0.16 mmol), N’-
cholesteryloxy-3-carbonyl-1,2-diaminoethane 5  (75.6 mg, 0.16 mmol), DMAP (58.6 
mg, 0.48 mmol), and HBTU (60.7 mg, 0.16 mmol) to yield 14 as a white solid (132.8 
mg, 74 %); 1H NMR (400 MHz, CDCl3) H 0.69 (3H, s, 18-CH3), 0.88 (3H, d, J = 6.8 Hz, 
27-CH3), 0.89 (3H, d, J = 6.8 Hz, 26-CH3), 0.91-1.01 (18H, m, 2 x CH3 Leu, 2 x CH3 
Val, 19-CH3, 21-CH3), 1.05-2.38 (38H, m, CH2 () Leu, CH () Leu, CH () Val, CH2 () 
Pro, CH2 () Pro, 1-CH2, 2-CH2, 4-CH2, 7-CH2, 8-CH, 9-CH, 11-CH2, 12-CH2, 14-CH, 
15-CH2, 16-CH2, 17-CH, 20-CH, 22-CH2, 23-CH2, 24-CH2, 25-CH, 3’-CH2), 3.25-3.93 
(6H, m, CH2 () Pro, CH2 () Gly, 4’- CH2), 4.05-4.48 (9H, m, CH2 () Gly, CH () Val, 
CH () Leu, CH () Pro, Fmoc CH, Fmoc CH2, 3-CH), 5.34 (1H, s, 6-CH), 7.31-7.78 
(8H, m, Fmoc aroatic CH); 13C NMR (400 MHz, CDCl3) C 11.8 (18-C), 17.7 (2 x CH3 
Leu), 18.7 (2 x CH3 Val), 19.3 (21-C), 21.0 (19-C), 21.3 (11-C), 21.5 (CH2 () Leu), 22.5 
(26-C), 22.8 (27-C), 23.0 (CH2 () Pro), 23.8 (23-C), 24.2 (15-C), 25.1 (CH2 () Pro), 
28.0 (25-C), 28.2 (16-C), 29.0 (2-C), 29.4 (CH () Leu), 29.7 (CH () Val), 31.8 (2C, 8-
C, 7-C), 35.8 (20-C), 36.1 (22-C), 36.5 (10-C), 36.9 (1-C), 38.6 (24-C), 39.5 (2C, 4-C, 
Fmoc CH), 39.7 (12-C), 39.8 (4’-CH2), 40.6 (3’-CH2), 42.3 (13-C), 43.7 (CH2 () Gly), 
44.3 (CH2 () Gly), 47.0 (CH2 () Pro), 49.9 (9-C), 50.0 (CH () Leu), 56.1 (17-C), 56.6 
(14-C), 59.1 (CH () Val), 61.5 (CH () Pro), 67.4 (Fmoc CH2), 74.3 (3-C), 122.5 (6-C), 
119.9, 125.0, 127.1, 127.8 (8C, Fmoc aromatic CH), 139.8 (5-C), 141.2, 143.6 (4C, 
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Fmoc aromatic C), 156.7, 157.4 (2C, 2 x CO carbamate), 169.8, 170.5, 172.2, 172.6, 
174.7 (5C, 5 x CO); m/z (ESI +ve) 1119 (M+H)+. 
 
General Procedure for the formation of the amine deprotection of N-Fmoc-
protected peptide-cholesterol conjugate: To a solution of N-Fmoc-protected peptide-
cholesterol conjugate in dry CH2Cl2 (4 mL) was added piperidine (1 mL). The reaction 
was stirred at room temperature under a nitrogen atmosphere for 4 h.  The crude 
mixture was concentrated in vacuo and purified using flash column chromatography 
((CH2Cl2: MeOH: NH3: 25: 7.3: 1): CH2Cl2 1:2, v/v) to afford the peptide-cholesterol 
conjugate as a white solid. 
 
H2N-AAPV-(N’-cholesteryloxy-3-carbonyl-1,2-diaminoethane) 15 
 
 
 
Synthesised as described in the general procedure for the peptide-cholesterol 
conjugate, using N-Fmoc-protected peptide-cholesterol conjugate 13 (97.7 mg, 0.095 
mmol) to afford 15 as a white solid (63.4 mg, 83%); 1H NMR (400 MHz, CDCl3) H 0.66 
(3H, s, 18-CH3), 0.86 (3H, d, J = 6.8 Hz, 27-CH3), 0.87 (3H, d, J = 6.8 Hz, 26-CH3), 
0.88-1.03 (12H, m, 2 x CH3 Val, 19-CH3, 21-CH3), 1.07-2.37 (41H, m, 2 x CH3 Ala, CH 
() Val, CH2 () Pro, CH2 () Pro, 1-CH2, 2-CH2, 4-CH2, 7-CH2, 8-CH, 9-CH, 11-CH2, 12-
CH2, 14-CH, 15-CH2, 16-CH2, 17-CH, 20-CH, 22-CH2, 23-CH2, 24-CH2, 25-CH, 3’-CH2), 
3.20-3.85 (2H, m, 4’- CH2), 4.21-4.80 (4H, m, CH () Ala, CH () Val, CH () Pro, 3-
CH), 5.36 (1H, s, 6-CH); 13C NMR (400 MHz, CDCl3) C 11.8 (18-C), 17.4 (2C, 2 x CH3 
Val), 18.6 (2C, 2 x CH3 Ala), 19.4 (21-C), 21.0 (19-C), 21.5 (11-C), 22.6 (26-C), 22.7 
(27-C), 23.0 (CH2 () Pro), 23.7 (23-C), 24.2 (15-C), 25.2 (CH2 () Pro), 27.9 (25-C), 
28.1 (16-C), 28.2 (2-C), 29.8 (CH () Val), 31.8 (8-C), 33.6 (7-C), 35.7 (20-C), 36.1 (22-
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C), 36.5 (10-C), 36.9 (1-C), 38.5 (24-C), 39.4 (4-C), 39.7 (12-C), 40.1 (4’-CH2), 40.4 (3’-
CH2), 42.2 (13-C), 46.2 (CH () Ala), 47.5 (CH2 () Pro), 47.7 (9-C), 50.2 (CH () Ala), 
56.1 (17-C), 56.6 (14-C), 58.5 (CH () Val), 60.9 (CH () Pro), 74.4 (3-C), 122.5 (6-C), 
139.7 (5-C), 156.7 (CO carbamate), 171.1, 172.0, 173.1,175.5, (4C, 4 x CO); m/z (ESI 
+ve) 811 (M+H)+. 
 
H2N-GPLGV-(N’-cholesteryloxy-3-carbonyl-1,2-diaminoethane) 16 
 
 
 
Synthesised as described in the general procedure for the peptide-cholesterol 
conjugate, using N-Fmoc-protected peptide-cholesterol conjugate 14 (102.9 mg, 0.092 
mmol) to afford 16 as a white solid (68.3 mg, 83%); 1H NMR (400 MHz, CDCl3) H 0.74 
(3H, s, 18-CH3), 0.93 (3H, d, J = 6.8 Hz, 27-CH3), 0.94 (3H, d, J = 6.8 Hz, 26-CH3), 
0.96-1.09 (18H, m, 2 x CH3 Leu, 2 x CH3 Val, 19-CH3, 21-CH3), 1.13-2.45 (38H, m, CH2 
() Leu, CH () Leu, CH () Val, CH2 () Pro, CH2 () Pro, 1-CH2, 2-CH2, 4-CH2, 7-CH2, 
8-CH, 9-CH, 11-CH2, 12-CH2, 14-CH, 15-CH2, 16-CH2, 17-CH, 20-CH, 22-CH2, 23-CH2, 
24-CH2, 25-CH, 3’-CH2), 3.21-3.95 (6H, m, CH2 () Pro, CH2 () Gly, 4’- CH2), 4.10-4.50 
(6H, m, CH2 () Gly, CH () Val, CH () Leu, CH () Pro, 3-CH), 5.38 (1H, s, 6-CH); 
13C NMR (400 MHz, CDCl3) C 11.8 (18-C), 17.8 (2 x CH3 Leu), 18.7 (2 x CH3 Val), 19.3 
(21-C), 21.0 (19-C), 21.4 (11-C), 22.6 (CH2 () Leu), 22.7 (26-C), 22.8 (27-C), 23.0 
(CH2 () Pro), 23.8 (23-C), 24.3 (15-C), 25.0 (CH2 () Pro), 28.0 (25-C), 28.2 (16-C), 
29.3 (2-C), 29.5 (CH () Leu), 29.7 (CH () Val), 31.8 (2C, 8-C, 7-C), 35.8 (20-C), 36.2 
(22-C), 36.6 (10-C), 37.0 (1-C), 38.6 (24-C), 39.5 (4-C), 39.7 (12-C), 40.6 (2C, 3’-CH2, 
4’-CH2), 42.3 (3C, 13C, 2 x CH2 () Gly), 46.6 (CH2 () Pro), 50.0 (2C, 9-C, CH () 
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Leu), 56.1 (17-C), 56.7 (14-C), 58.3 (2C, CH () Val, CH () Pro), 75.0 (3-C), 122.5 (6-
C), 139.8 (5-C), 156.8 (CO carbamate), 169.8, 171.0, 172.4, 172.6, 173.0 (5C, 5 x CO); 
m/z (ESI +ve) 897 (M+H)+. 
 
General Procedure for the synthesis of the PEGylated peptide-cholesterol 
conjugate: To a solution of peptide-cholesterol conjugate and DIPEA in dry CH2Cl2 (5 
mL) and under a nitrogen atmosphere, was added PEG2000-NHS ester in dry CH2Cl2 (3 
mL). The reaction was stirred at room temperature for 18 h.  The solvent was removed 
in vacuo and the crude mixture was purified using flash column chromatography 
((CH2Cl2: MeOH: H2O: 34.5: 9: 1): CH2Cl2 1:1, v/v) to yield the desired PEGylated 
peptide-cholesterol conjugate as a white solid. 
  
PEG2000-AAPV-(N’-cholesteryloxy-3-carbonyl-1,2-diaminoethane) 17 
 
 
 
Synthesised as described in the general procedure for the PEGylated peptide-
cholesterol conjugate, using peptide-cholesterol conjugate 15 (59.2 mg, 0.073 mmol), 
DIPEA (12.5 L, 0.073 mmol), and PEG2000-NHS ester (148.6 mg, 0.073 mmol) to 
obtain 17 as a white solid (109.6 mg, 55%); 1H NMR (400 MHz, CDCl3) H 0.68 (3H, s, 
18-CH3), 0.86 (3H, d, J = 6.8 Hz, 27-CH3), 0.87 (3H, d, J = 6.8 Hz, 26-CH3), 0.88-1.03 
(12H, m, 2 x CH3 Val, 19-CH3, 21-CH3), 1.06-2.37 (41H, m, 2 x CH3 Ala, CH () Val, 
CH2 () Pro, CH2 () Pro, 1-CH2, 2-CH2, 4-CH2, 7-CH2, 8-CH, 9-CH, 11-CH2, 12-CH2, 
14-CH, 15-CH2, 16-CH2, 17-CH, 20-CH, 22-CH2, 23-CH2, 24-CH2, 25-CH, 3’-CH2), 3.38 
(3H, s, CH3O), 3.63 (173H, s, PEG CH2),  3.24-3.85 (2H, m, 4’- CH2), 4.29-4.74 (4H, m, 
CH () Ala, CH () Val, CH () Pro, 3-CH), 5.36 (1H, s, 6-CH); 13C NMR (400 MHz, 
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CDCl3) C 11.8 (18-C), 17.3 (2C, 2 x CH3 Val), 18.6 (2C, 2 x CH3 Ala), 19.2 (21-C), 19.5 
(19-C), 21.0 (11-C), 22.5 (26-C), 22.7 (27-C), 23.0 (CH2 () Pro), 23.7 (23-C), 24.2 (15-
C), 25.2 (CH2 () Pro), 27.9 (25-C), 28.1 (16-C), 28.2 (2-C), 29.8 (CH () Val), 31.5 (8-
C), 31.7 (7-C), 35.7 (20-C), 36.1 (22-C), 36.5 (10-C), 36.8 (1-C), 38.5 (24-C), 39.4 (4-
C), 39.7 (12-C), 40.0 (4’-CH2), 40.4 (3’-CH2), 42.2 (13-C), 47.4 (CH () Ala), 48.1 (CH2 
() Pro), 48.8 (9-C), 49.9 (CH () Ala), 56.1 (17-C), 56.6 (14-C), 58.4 (CH () Val), 60.9 
(CH () Pro), 70.5 (PEG CH2), 74.3 (3-C), 122.5 (6-C), 139.7 (5-C), 156.6 (CO 
carbamate), 171.1, 171.5, 172.0,172.4, 172.6, 173.0  (6C, 6 x CO); HPLC: Rt = 25.6 
min, column reverse phase C-4 protein, gradient mix: 0.0 min [100% A], 15.0-25.0 min 
[100% B], 25.1-45.0 min [100% C], 45.1-55.0 min [100% A], flow: 1 mL min-1; m/z 
(MALDI +ve): 2753 (M+Na)+. 
 
PEG2000--GPLGV-(N’-cholesteryloxy-3-carbonyl-1,2-diaminoethane) 18 
 
 
Synthesised as described in the general procedure for the PEGylated peptide-
cholesterol conjugate, using peptide-cholesterol conjugate 16 (68.3 mg, 0.076 mmol), 
DIPEA (13.1 L, 0.076 mmol), and PEG2000-NHS ester (155.1 mg, 0.076 mmol) to 
obtain 18 as a white solid (100 mg, 47%); 1H NMR (400 MHz, CDCl3) H 0.66 (3H, s, 
18-CH3), 0.84 (3H, d, J = 6.8 Hz, 27-CH3), 0.86 (3H, d, J = 6.8 Hz, 26-CH3), 0.89-1.02 
(18H, m, 2 x CH3 Leu, 2 x CH3 Val, 19-CH3, 21-CH3), 1.10-2.33 (38H, m, CH2 () Leu, 
CH () Leu, CH () Val, CH2 () Pro, CH2 () Pro, 1-CH2, 2-CH2, 4-CH2, 7-CH2, 8-CH, 9-
CH, 11-CH2, 12-CH2, 14-CH, 15-CH2, 16-CH2, 17-CH, 20-CH, 22-CH2, 23-CH2, 24-CH2, 
25-CH, 3’-CH2), 3.38 (3H, s, CH3O), 3.64 (173H, s, PEG CH2), 3.20-3.83 (6H, m, CH2 
() Pro, CH2 () Gly, 4’- CH2), 4.10-4.50 (6H, m, CH2 () Gly, CH () Val, CH () Leu, 
CH () Pro, 3-CH), 5.34 (1H, s, 6-CH); 13C NMR (400 MHz, CDCl3) C  11.8 (18-C), 17.8 
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(2C, 2 x CH3 Leu), 18.7 (2C, 2 x CH3 Val), 19.3 (21-C), 21.0 (19-C), 21.3 (11-C), 22.5 
(CH2 () Leu), 22.8 (26-C), 23.0 (27-C), 23.2 (CH2 () Pro), 23.8 (23-C), 24.3 (15-C), 
25.0 (CH2 () Pro), 28.0 (25-C), 28.2 (16-C), 28.9 (2-C), 29.6 (CH () Leu), 30.3 (CH () 
Val), 31.8 (2C, 8-C, 7-C), 35.8 (20-C), 36.1 (22-C), 36.5 (10-C), 37.0 (1-C), 38.6 (24-C), 
39.5 (4-C), 39.7 (12-C), 40.0 (2C, 3’-CH2, 4’-CH2), 42.3 (3C, 13C, 2 x CH2 () Gly), 47.5 
(CH2 () Pro), 50.0 (2C, 9-C, CH () Leu), 56.1 (17-C), 56.6 (14-C), 59.0 (3C, CH () 
Val, CH () Pro, CH3O), 70.5 (PEG CH2), 74.2 (3-C), 122.4 (6-C), 139.8 (5-C), 156.6 
(CO carbamate), 169.4, 170.5, 172.0, 172.5, 173.0, 173.3, 174.2 (7C, 7 x CO); HPLC: 
Rt = 25.5 min, column reverse phase C-4 protein, gradient mix: 0.0 min [100% A], 15.0-
25.0 min [100% B], 25.1-45.0 min [100% C], 45.1-55.0 min [100% A], flow: 1 mL min-1; 
m/z (MALDI +ve): 2838 (M+Na)+. 
 
PEG2000-(N’-cholesteryloxy-3-carbonyl-1,2-diaminoethane) 19 
 
 
 
To a stirred solution of N’-cholesteryloxy-3-carbonyl-1,2-diaminoethane 5 (60 mg, 0.127 
mmol) and DIPEA (21.8 L, 0.127 mmol) in dry CH2Cl2 (5 mL) at room temperature and 
under a nitrogen atmosphere, was added PEG2000-NHS ester (258.5 mg, 0.127 mmol) 
in dry CH2Cl2 (3 mL). After 18 h, the crude mixture was concentrated in vacuo and 
recrystallized in cold Et2O to afford 19 as a white solid (298 mg, 98%); 1H NMR (400 
MHz, CDCl3) H 0.68 (3H, s, 18-CH3), 0.86 (3H, d, J = 6.4 Hz, 27-CH3), 0.87 (3H, d, J = 
6.4 Hz, 26-CH3), 0.91 (3H, d, J = 6.4 Hz, 21-CH3), 1.00 (3H, s, 19- CH3), 1.05-1.62 
(21H, m, 1-CH2, 9-CH, 11-CH2, 12-CH2, 14-CH, 15-CH2, 16-CH2, 17-CH, 20-CH, 22-
CH2, 23-CH2, 24-CH2, 25-CH), 1.78-2.04 (5H, m, 2-CH2, 7-CH2, 8-CH), 2.06-2.15 (2H, 
m, 4-CH2), 2.25-2.38 (2H, m, 3’-CH2), 3.25-3.35 (2H, m, 4’-CH2), 3.38 (3H, s, CH3O), 
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3.64 (173H, s, PEG CH2), 4.48 (1H, m, 3-CH), 5.36 (1H, s, 6-CH); 13C NMR (400 MHz, 
CDCl3) C 11.8 (18-C), 18.7 (21-C), 19.3 (19-C), 21.1 (11-C), 22.5 (26-C), 22.8 (27-C), 
23.8 (23-C), 24.2 (15-C), 28.0 (25-C), 28.2 (2C, 2-C, 16-C), 31.8 (2C, 8-C, 7-C), 35.7 
(20-C), 36.1 (22-C), 36.5 (10-C), 37.0 (1-C), 38.6 (24-C), 39.5 (4-C), 39.7 (12-C), 41.0 
(2C, 3’-CH2, 4’-CH2), 42.3 (13-C), 50.0 (9-C), 56.1 (17-C), 56.6 (14-C), 59.0 ( CH3O), 
70.5 (PEG CH2), 74.2 (3-C), 122.4 (6-C), 139.8 (5-C), 170.8, 172.4 (2C, 2 x CO); 
HPLC: Rt = 25.5 min, column reverse phase C-4 protein, gradient mix: 0.0 min [100% 
A], 15.0-25.0 min [100% B], 25.1-45.0 min [100% C], 45.1-55.0 min [100% A], flow: 1 
mL min-1; m/z (MALDI +ve): 2415 (M+Na)+. 
 
6.3  Enzyme Activity Assay and degradation Study 
 
6.3.1 Preparation of enzyme stock solutions 
 
Lyophilized powder of HLE was resuspended in 10 mM HEPES, 154 mM NaCl, 0.1 mM 
EDTA, pH 7.4 to a final concentration of 1.03 M. Aliquots of the stock solution were 
stored at -20 C 
 
MMP-2 in the original vial (1.52 M) were diluted in 25 mM HEPES, 10 mM CaCl2, 10 
M ZnCl2, pH 8.0 to prepare a stock solution of 15.2 nM. Aliquots of the stock solution 
were stored at -20 C and the remaining original MMP-2 was stored at -80 C. 
 
6.3.2 Determination of enzyme activity 
 
MeO-suc-AAPV-pNA was employed as a substrate for the determination of HLE 
activity. MeO-Suc-AAPV-pNA solution (500 L, 0.51 mM) dissolved in 10 mM HEPES, 
154 mM NaCl, 0.1 mM EDTA, pH 7.4, were mixed with HLE (100 L, 1.03 M). The 
release of the pNA, as a result of enzyme reaction, was monitored at 410 nm for 2 min. 
The unit of HLE was defined based on pNA calibration curved, previously obtained, e.g. 
1 unit releases 48 nmol of pNA per min at room temperature. The enzyme activity unit 
varies from batch-to-batch.   
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Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 was employed as a substrate for the 
determination of MMP-2 activity. The stock solution of Mca-Pro-Leu-Gly-Leu-Dpa-Ala-
Arg-NH2 (2.7 µL, 0.92 mM) in DMSO was diluted in 25 mM HEPES, 10 mM CaCl2, 10 
M ZnCl2, pH 8.0 to a final concentration of 0.05 mM in a 96-well microtiter plate. MMP-
2 (50 µL, 15.2 nM) was added to the solution and the fluorescence intensity of Mca-
Pro-Leu-OH, a cleavage product from the enzyme cleavage, was monitored at ex = 
328 nm and em = 393 nm for 15 min. The unit of MMP-2 was defined based on Mca-
Pro-Leu-OH calibration curved, previously obtained. 
 
6.3.3 Degradation of MeO-suc-AAPV-pNA and PEG2000-AAPV-pNA by HLE  
monitored by UV spectroscopy 
 
MeO-suc-AAPV-pNA (0.12 mM) and PEG2000-AAPV-pNA (0.20 mM) prepared in 10 mM 
HEPES, 154 mM NaCl, 0.1 mM EDTA, pH 7.4, was added HLE (10 µL, 1.03 M). The 
absorbance of the released pNA was then monitored at 410 nM for 60 min. 
 
6.3.4 Cleavage of PEG2000-AAPV-pNA and PEG2000-AAPV-C18 conjugates by HLE  
monitored by HPLC 
 
PEG2000-AAPV-pNA (0.20 mM) and PEG2000-AAPV-C18 (0.18 mM) prepared in 10 mM 
HEPES, 154 mM NaCl, 0.1 mM EDTA, pH 7.4, were mixed with HLE (200 µL, 1.03 M) 
and the mixtures were incubated at 37 C for 1 to 2 h. The enzyme was denatured by 
freezing the mixtures in nitrogen (liq). Analytical HPLC was performed using reverse 
phase protein C4 column, ELSD detector and the following gradient mix: 0.0-10.0 min 
[100% A], 25.0 min [30% A and 70% B], 40.0-45.0 min [100% B], 46.0-55.0 min [100% 
C], 56.0-65.0 min [100% A]; flow rate 1.5 ml min-1 
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6.4 Preparation and characterization of pDNA nanoparticles  
 
6.4.1  Preparation of pEGFPLuc DNA 
 
Transformed E. coli containing pEGFPLuc (pDNA, 6.4 kb) was grown in sterilised LB 
medium (5 mL) with kanamycin (5 L) overnight at 37 C with shaking. Next day, the 
culture was transferred to sterilised LB medium (500 mL) with kanamycin (500 L) and 
was grown at 37 C with shaking overnight. Isolation of pDNA was carried out using 
E.Z.N.A. Endo-Free Plasmid Kit (Omega Bio-Tek) for preparation of plasmid with low 
endotoxin levels. The contamination of endotoxin, lipopolysaccharides (LPS) released 
from E. coli cell membrane during lysis step of plasmid purification, leads to low 
transfection efficiency in vitro and inducing inflammatory reaction in vivo. With the use 
of this kit, endotoxins are effectively removed from lysate with endo-toxin removal 
(ETR) buffer. Briefly, the culture was transferred to 4x 250 mL GSA centrifuge tubes. 
The cell pellets were harvested by centrifuging at 5,000 rpm for 10 min and the medium 
was removed. Resuspension buffer with RNase A (2.5 mL) was added to bacterial 
pellet and vortexed until the re-suspension was complete. Lysis buffer (2.5 mL) was 
added, mixed gently by inverting and rotating the tube 10 times and incubated at room 
temperature for 2 min. Ice-cold precipitation buffer (1.25 mL) was added, mixed gently 
and thoroughly by inverting and rotating the tube 7 times and incubated at room 
temperature for 2 min. The lysate was immediately poured into the barrel of the Lysate 
Clearance Filter Syringe and left for 2 min. The end cap of the syringe was removed 
and the plunger was gently inserted into the barrel to expel the clear lysate into a 15-
mL tube. The equal volume of ETR binding buffer was added to the lysate and mixed 
gently by inverting the tube 10 times. pDNA was then purified with HiBind DNA midi 
column. Equilibration buffer (1 mL) was added to HiBind DNA midi column and 
centrifuged at 3,800 rpm for 3 min. The flow-through liquid was discarded. The lysate 
(3.5 mL) was added to the column and centrifuged at 3,800 rpm for 3 min. The process 
was repeated until all the lysate was passed through the column. The flow-through 
liquid was discarded. ETR wash buffer (2mL) was added to the column and centrifuged 
at 3,800 rpm for 3 min. Buffer HB (3 mL) was added to the column and centrifuged at 
3,800 rpm for 3 min. The flow-through liquid was discarded. 2x DNA wash buffer (3.5 
mL) were added to the column and centrifuged at 3,800 rpm for 3 min. The flow-
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through liquid was discarded. The empty column was centrifuged at 3,800 rpm for 10 
min to dry the column. The HiBind DNA midi column was placed over a new 15-mL 
tube and endo-free elution buffer (10 mM Tris, pH 8.5) (0.5 mL) was added and the 
column was left for 2 min. pDNA was eluted by centrifuging at 3,800 rpm for 5 min. 
pDNA concentration was determined using Nanodrop ND-1000, which was found to be 
0.5-0.6 g/L. The pDNA quality was also determined by agarose gel electrophoresis.  
 
6.4.2 Preparation of pDNA Nanoparticles 
 
DODAG, DOPC, Chol and the synthesised PEGylated peptide-lipid conjugates were 
prepared as stock solutions in CHCl3 and stored at -20 C. Appropriate volumes of each 
lipid stock were combined in a round bottom flask (5 mL) containing CHCl3 (500 L). 
The solvent was slowly removed in vacuo to form an even lipid film which was then 
purged with nitrogen (g) to remove residual traces of CHCl3. The film was re-hydrated 
with 4mM HEPES (pH 7) at a defined volume to obtain total lipid concentration of 1 mg 
mL-1. The solution was subsequently subjected to sonication at 40 C for 40 min. pDNA 
nanoparticles were prepared by mixing the appropriate volume of pDNA with the 
resulting liposome solutions under heavy vortex to obtain the desired lipid: pDNA w/w.  
 
6.4.3  Determination of pDNA encapsulation efficiency  
 
Propidium Iodide (PI) assay: The pDNA nanoparticles were prepared, as described 
previously, at 1:1, 2:1, 4:1, 8:1, 12:1 and 16:1 lipid: pDNA w/w. After 10 min incubation 
at room temperature, the nanoparticles were diluted in 4mM HEPES buffer to a total 
volume of 100 L. PI solution (100 L, 2.5 µM) was added and the mixtures were 
incubated at 37 C for 5 min. The fluorescence intensity of each mixture was measured 
at λex = 535 nm, λem = 617 nm using a Varioskan flash microplate reader. The 
fluorescence intensities of empty liposome (with no pDNA) incubated with PI solution 
and PI solution in buffer were employed as background measurements. 
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% pDNA encapsulation = [1-(Fnanoparticles/ Fcontrol free pDNA)] x 100 
 
Where Fnanoparticles and Fcontrol free pDNA represent measured fluorescence intensities of the 
nanoparticles and free pDNA incubated with PI solution, respectively.  
 
Agarose gel electrophoresis: The nanoparticles were prepared, as described 
previously, at 1:1, 2:1, 4:1, 8:1, and 12:1 lipid: pDNA w/w. After 10 min incubation at 
room temperature, the nanoparticles were diluted in 4mM HEPES buffer to a total 
volume of 50 L. 0.8% Agarose gel was prepared in 1X Tris-acetate-EDTA (TAE) buffer 
and heated in a microwave on high power (800W) for 2 min until completely dissolved. 
The gel solution was cooled down in the water bath at 50C for 20 min. SYBR safe 
DNA gel stain (10 L of 10000X) was added and the gel solution was swirled to mix. 
The solution was then poured slowly into the tray (137 x 120 mm, gel thickness 1 mm) 
and the bubbles were removed using disposable pipette before the comb (2mm x 24 
wells) was inserted. After left to solidify for 35 min, the gel was placed into the buffer 
tank containing 1X TAE buffer and SYBR safe DNA gel stain (5 L of 10000X). The 
nanoparticles solutions (20 L, 0.4 g pDNA) mixed with 6X orange DNA loading dye 
(1 L) were loaded into each well. O’ GeneRuler™ Ladder mix was used as the DNA 
marker. The electrophoresis was performed at 65 mV for 180 min and the gel was 
visualized under UV light using Alliance 4.7 UVITEC Cambridge. 
 
6.4.4 Size and zeta potential measurement 
 
Liposomes and nanoparticles sizes were measured by dynamic light scattering using 
Coulter Delta N4 plus 440SX particle analyser. All measurements were performed at 90 
degree and 25 C. The mean diameter was determined from the calculated unimodal 
size distribution of the particles. The zeta potential measurements were performed on a 
Nanozeries Nano-ZS zetasizer equipped with a 4 mW He−Ne laser (633 nm) and 
avalanche photodiode detector.  The samples (total lipid concentration of 0.5 mg mL-1) 
were prepared in 4 mM HEPES buffer, pH 7. 
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6.5  In vitro study of pDNA nanoparticles 
 
6.5.1 Cell culture and maintenance 
 
MCF-7 and HT-1080 cell lines were grown in a 75 mL tissue culture flask containing 
DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and 
streptomycin (complete medium), at 37 C in 5% CO2 atmosphere. The cells were 
grown until 80% confluency. The media was removed by aspiration and washed with 
PBS (2 x 5 mL) before trypsin-EDTA (2 mL) was added. The cells were then incubated 
for 10 min at 37 C with 5% CO2. The detached cells were diluted with complete midia 
(8 mL) and the cell suspension (2 mL) was transferred to a new 75 mL tissue culture 
flask containing fresh complete media (8 mL). Both cell lines were used up to the 
passage numbers of 30. After that the cells were discarded and new cell batches were 
defrosted. 
 
6.5.2 Determination of MMP-2 level in cell culture media using MMP-2 human  
ELISA assay kit  
 
HT1080, MCF-7, HEK293T, DU145, and Hela cells were seeded at 4 x 104, 6 x 104, 4 x 
104, 4 x 104, and 6 x 104 cells per well, respectively, in 24-well plates (500 L of 
complete medium). The cells were grown until 60% confluency for HT1080 and 80% 
confluency for MCF-7, HEK293T, DU145, and Hela at 37C in 5% CO2 atmosphere. 
The media was removed and replaced with fresh complete media (300 L) and the 
cells were incubated at 37C with 5% CO2 for further 24 h. The cell supernatants were 
collected and centrifuged (5000 rpm for 2 min) to separate cellular debris. The 
determination of MMP-2 level in the cell culture media was carried out using MMP-2 
human Elisa assay kit (Invitrogen). In brief, incubation buffer (50 L) was added to 
microtiter wells precoated with MMP-2 antibody. MMP-2 human standard was 
reconstituted in standard diluents buffer and serial dilutions were made according to the 
manufacturer’s protocol. The collected cell supernatants were diluted 5-fold in the 
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standard diluent buffer. After that the diluted MMP-2 standards and the diluted cell 
supernatants (50 L) were added to each microtiter well, and the plate was incubated 
at the room temperature for 2 h. The mixture in each well was then removed by 
aspiration and the wells were washed with wash buffer (4 x 400 L). A biotinylated 
secondary detection antibody (100 L) was added to each well and the plate was 
incubated at room temperature for 1 h. The solution was removed by aspiration and the 
wells were washed with wash buffer (4 x 400 L). Streptavidin-peroxydase solution 
(100 L) was added to each well to bind to the biotinylated antibody. The plate was 
incubated at the room temperature for 30 min, and the solution was removed by 
aspiration, and the wells were washed with wash buffer (4 x 400 L). Substrate solution 
(100 L) was added to the wells and the plate was incubated in the dark at room 
temperature for further 30 min. Stop solution (100 L) was then added to the wells and 
the absorbance of each well was recorded at 450 nm. The concentrations of MMP-2 in 
the supernatants were calculated from the calibration curve constructed with the MMP-
2 human standard. 
 
6.5.3 MTS cell proliferation assay  
 
MCF-7 cells were seeded in 48-well plates (3.5 x 104 cells per well, 250 L of complete 
medium) for 72 hours prior to the assay. The cells were incubated at 37 C in a 
humidified, 5% CO2 incubator until 80% confluency. The media was then removed and 
replaced with fresh media. The nanoparticles with PEG2000-AAPV-lipid conjugates were 
added to each well at three lipid doses (8, 12 and 16 g/well; 1 ug pDNA) and the cells 
were incubated at 37C in 5% CO2 atmosphere for 4, 8 and 24 h. The cell proliferation 
assay was performed using the CellTiter 96 AQueous One Solution Cell Proliferation 
Assay (Promega, USA). In brief, the media was removed, after each uptake period, and 
the cells were washed with PBS (2 x 250 L). Fresh media (100 L) was added to each 
well, followed by the addition of CellTiter 96 AQueous One Solution Reagent (20 L). 
After 2 h incubation, the lysates were transferred to 96-well plates and the absorbance 
of each well was recorded at 490 nm using a microplate reader. 
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HT1080 cells were seeded in 48-well plates (2.5 x 104 cells per well, 250 L of 
complete medium) for 24 hours prior to the assay. The cells were grown until 60% 
confluency at 37C in a humidified, 5% CO2 incubator. The media was then removed 
and replaced with fresh media. The nanoparticles with PEG2000-GPLGV-lipid conjugates 
were added to each well at three lipid doses (8, 12 and 16 g/well; 1 ug pDNA) and the 
cells were incubated at 37C in 5% CO2 atmosphere for 4, 8 and 24 h.  The cell 
proliferation assay was carried out as described above. 
 
6.5.4 Lactate dehydrogenase (LDH) cytotoxicity assay 
 
MCF-7 cells were seeded as described in the MTS cell proliferation assay. The cells 
were grown until 80% confluency, and the media was then removed and replaced with 
fresh media.  The nanoparticles with PEG2000-AAPV-lipid conjugates were added to 
each well at three lipid doses (8, 12 and 16 g/well; 1 ug pDNA) and the cells were 
incubated at 37C in 5% CO2 atmosphere for 4, 8 and 24 h. The LDH assay was 
performed using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, 
USA). Briefly, the cell supernatants (150 L) were transferred to microcentrifuge tubes 
and the tubes were spun down in a centrifuge (2000 rpm, 10 min) to separate cellular 
debris. The remaining supernatants were removed by aspiration and the cells were 
washed with PBS (2 x 250 L), and the lysis buffer (100 L) was added to each well. 
The plate was incubated at 37C for 30 min. The cell supernatants, after centrifuged, 
were transferred to a new 96-well plate and the cell lysates (50 L) were transferred to 
the other half of the plate. The LDH substrate mix was added to the wells and the plate 
was incubated in the dark at room temperature. After 30 min incubation, the stop 
solution (50 L) was added and the absorbance of each well was measured at 490 nm 
using a microplate reader. % cell death from cytotoxicity was calculated as followed: % 
cell death = % LDH release from the cells incubated with the nanoparticles - % LDH 
release from control cells 
 
HT1080 cells were seeded as described in the MTS cell proliferation assay. The cells 
were grown until 60% confluency at 37C in a humidified, 5% CO2 incubator. The media 
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was then removed and replaced with fresh media. The nanoparticles with PEG2000-
GPLGV-lipid conjugates were added to each well at three lipid doses (8, 12 and 16 
g/well; 1 ug pDNA) and the cells were incubated at 37C in 5% CO2 atmosphere for 4, 
8 and 24 h. The LDH cytotoxicity assay was carried out as described above.  
 
6.5.5 pDNA transfection 
 
HLE experiment: MCF-7 cells were seeded at 6 x 104 per well in 24-well plates (500 
L of complete medium) for 72 hours prior to transfection, respectively.  The cells were 
grown until 80% confluency at 37C in a humidified, 5% CO2 incubator. The media was 
then removed and replaced with fresh media. Two sets of pDNA nanoparticles 
containing PEG2000-AAPV-lipid conjugate and control PEG2000-lipid conjugate were 
prepared at 12:1 lipid: pDNA w/w, as described previously. HLE (10 L, 1.03 M) was 
added to the first set and incubated at room temperature for 10 min, while the other set 
contained no HLE. The mixtures were added to each well (1g pDNA per well) and the 
plates were then incubated at 37C in 5% CO2 atmosphere for 6 h. The media was 
removed, the cells were washed with PBS (2 x 500 L) and then fresh media was 
added (500 L). After further incubation at 37C for 24 h, the cells were washed with 
PBS (2 x 500 L) and 1 x cell culture lysis reagent (80 L) was added to each well. One 
freeze-thaw cycle was carried out to ensure the complete lysis. The cells were scraped 
from the wells and the lysates were centrifuged (5000 rpm, 2 min) to separate cellular 
debris. The supernatants were then analysed for luciferase gene expression  
 
In initial biological test, in collaboration with Dr. Mathieu Mevel, 50 mol% 
DODAG/DOPE lipoplexes containing PEG2000-AAPV-cholesterol and control PEG2000-
lipid were divided into two sets: HLE-treatment and non-treatment, as described above. 
The mixture was incubated with OVCAR-3 cells in complete growth media at 37C in 
5% CO2 atmosphere for 24 h. The media was removed, the cells were washed with 
PBS (2 x 500 L) and then fresh media was added (500 L). The cells were then 
incubated for a further 24 h before luciferase assay analysis.  
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MMP-2 experiment: MCF-7 and HT1080 cells were seeded as described above. The 
cells were grown until 80% confluency for MCF-7 and 60% confluency for HT1080, at 
37C in a humidified, 5% CO2 incubator. The media was then removed and replaced 
with fresh media. pDNA nanoparticles containing PEG2000-GPLGV-lipid conjugate and 
control PEG2000-lipid conjugate were prepared at 12:1 lipid: pDNA w/w, as described 
previously, and added to each well (1 g pDNA per well). The plates were incubated at 
37C in 5% CO2 atmosphere for 24h. The media was removed, the cells were washed 
with PBS (2 x 500 L) and the fresh media was added (500 L). The cells were 
incubated for a further 24 h before luciferase assay was carried out.  
 
6.5.6 Luciferase reporter assay 
 
The luciferase assay system (Promega, USA) was used to measure luciferase gene 
expression. The assay was performed on a Berthold Lumat LB 9507 luminometer. The 
transfection efficiency was measured in relative light units (RLU) and normalised to 
total protein content determined with bicinchoninic acid (BCA) protein assay kit (Pierce, 
Thermo Scientific). The data was reported as RLU/mg protein. 
 
6.5.7 Total protein assay 
 
Total protein assay was carried out using bicinchoninic acid (BCA) protein assay. BCA 
assay is a highly sensitive and selective assay for the detection and quantitation of total 
protein. The assay is based on the reduction reaction of Cu2+ to Cu1+ by protein in the 
alkaline medium. In the first step, Cu2+ chelates to the protein in the alkaline 
environment to form a blue-coloured complex. Two molecules of BCA then chelates 
with Cu1+ to form a purple-coloured complex, giving a strong absorbance at 562 nm.  
To carry out this assay, briefly, BCA assay reagent (200 L) was added to the cell 
lysate supernatant (20 L) in a 96-well plate. The mixtures were incubated at 37C for 
30 min and the absorbance of each well was recorded at 570 nm using a microplate 
reader. The protein content was calculated based on the calibration curve of known 
concentration of Bovine serum albumin standard, previously obtained.  
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6.5.8 Fluorescence Microscopy  
 
HLE experiment: MCF-7 cells were seeded in a 6-well plate (1.2 x 105 cells per well, 2 
mL of complete medium) containing microscope coverslips (1 mm, thickness) for 72 
hours prior to the fluorescent labelling. The cells were grown until 80% confluency at 37 
C in a humidified, 5% CO2 incubator. The media was then removed and replaced with 
fresh media. Preparation of fluorescent liposomes was achieved by incorporation of 1 
mol% DOPE-Rhodamine into liposome formulation. Two sets of fluorescently labelled 
liposomes with PEG2000-AAPV-lipid conjugate and PEG2000-lipid conjugate (48 g of 
total lipid) were prepared. HLE (10 L, 1.03 M) was added to the first set and 
incubated at room temperature for 10 min, while the other set contained no HLE. The 
mixtures were added to each well and the plates were incubated at 37C in 5% CO2 
atmosphere for 6h. The media was then removed and the cells were washed with PBS 
(2 x 2 mL). The cells were treated with paraformaldehyde (1 mL, 4% v/v) and incubated 
at 37 C for 20 min. The cells were then washed with PBS (2 x 2 mL) and incubated 
with glycine solution (1 mL, 20 mg mL-1) at 37 C for 20 min. The cells were washed 
with PBS (2 x 2 mL) and stained with DAPI (1 mL, 100 nM) at 37 C for 5 min. The cells 
were washed with PBS (2 x 2 mL) one final time, then the coverslips were removed 
from the wells, and mounted face-down on microscope slides using PBS: glycerol (10 
L, 1: 1 v/v). Microscopy images were obtained on a Nickon Eclipse E600 microscope 
 
MMP-2 experiment: HT1080 cells were seeded in 6-well plates (8 x 104 cells per well, 
2 mL of complete medium) containing microscope coverslips (1 mm, thickness) for 24 
hours prior to the fluorescent labelling. The cells were grown until 60% confluency at 37 
C in a humidified, 5% CO2 incubator. The media was then removed and replaced with 
fresh media. Fluorescently labelled liposomes with PEG2000-GPLGV-lipid conjugate and 
PEG2000-lipid conjugate (48 g of total lipid) were prepared and added to the wells. The 
plates were incubated at 37 C in 5% CO2 atmosphere for 24 h. The coverslips were 
fixed and mounted as described above. Microscopy images were taken on an Olympus 
251 scope and confocal images were obatained using an upright Leica instrument. 
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6.6 Serum aggregation analysis of pDNA nanoparticles 
 
6.6.1 Stability in transfection medium (10% serum)  
 
pDNA nanoparticles were prepared at 12:1 lipid: pDNA w/w, as described previously. 
The same volumes of the nanoparticles as employed in transfection were diluted with 
complete media (500 L). The particles sizes were recorded immediately using 
dynamic light scattering. The mixtures were incubated at 37 C and their sizes were 
measured at 30 min intervals over 4 h.  
 
6.6.2 Stability in 80% serum: Turbidity assay 
 
pDNA nanoparticles were prepared at 12:1 lipid: pDNA w/w, as described previously. 
FBS (400 L) were added to the nanoparticle solutions (100 L) and the absorbance of 
the mixtures was recorded immediately at 600 nm using UV spectrometer. The 
mixtures were incubated at 37 C and their absorbance was measured at 30 min 
intervals over 4 h.  
 
6.7 Preparation and characterization of siRNA nanoparticles 
 
6.7.1 Preparation of siRNA stock solutions 
 
Upon receipt, the siRNA tube was briefly centrifuged to ensure that the dried siRNA 
was at the bottom of the tube. The siRNA was resuspended in the Nuclease-free water 
to a final concentration of 50 M. When handling, gloves should be worn and RNase-
free reagents, tubes, and barrier pipette tips should be used to minimize the 
degradation of the siRNA by exogenous ribonucleases. Once reconstituted, the siRNA 
was ready to use and the resuspended siRNA was stored at -20 C.  
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6.7.2 Preparation of siRNA nanoparticles 
 
siRNA nanoparticles were prepared by mixing an appropriate volume of siRNA with the 
liposome solutions under heavy vortex to obtain the desired lipid: siRNA charge ratios. 
 
6.7.3 Determination of siRNA encapsulation efficiency 
 
Propidium Iodide (PI) assay: The nanoparticles were prepared, as described 
previously, at 0.5:1, 2:1, 4:1, and 8:1 lipid: siRNA charge ratios. The propidium iodide 
assay was carried out as described in 6.4.3, propidium iodide (PI) assay section. The 
fluorescence intensities of empty liposome (without siRNA) incubated with PI solution 
and PI solution in buffer were employed as background measurements. 
 
% siRNA encapsulation = [1-(Fnanoparticles/ Fcontrol free siRNA)] x 100 
 
Where Fnanoparticles and Fcontrol free siRNA represent measured fluorescence intensity of 
nanoparticles and free siRNA incubated with PI solution.  
 
Agarose gel electrophoresis: The nanoparticles were prepared, as described 
previously, at 0.5:1, 2:1, 4:1, and 8:1 lipid: siRNA charge ratios. After 10 min incubation 
at room temperature, the nanoparticles were diluted in 4mM HEPES buffer to a total 
volume of 100 L. 1% Agarose gel was prepared in 1X Tris-borate-EDTA (TBE) buffer 
and heated in a microwave on high power (800W) for 2 min until completely dissolved. 
The gel solution was cooled down in the water bath at 50C for 20 min. SYBR green II 
RNA gel stain (5 L of 10000X) was added and the gel solution was swirled to mix. The 
solution was then poured slowly into the tray before the comb (2mm x 24 wells) was 
inserted. After left to solidify for 35 min, the gel was placed into the buffer tank 
containing 1X TBE buffer and SYBR green II RNA gel stain (5 uL of 10000X). The 
nanoparticles solutions (10 L, 0.06 g siRNA) mixed with 6X orange DNA loading dye 
(1 L) were loaded into each well. Free siRNA was used as siRNA marker. The 
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electrophoresis was performed at 65 mV for 30 min and the gel was visualized under 
UV light using Alliance 4.7 UVITEC Cambridge. 
 
6.7.4 Size and zeta potential measurements 
 
siRNA nanopartlces were prepared, as described previously, at 4:1 lipid: siRNA 
charged ratio. Size and zeta potential measurements were performed as described in 
6.4.4. 
 
6.8 In vitro siRNA knockdown of transient luciferase expression 
 
6.8.1 pDNA Transfection  
 
MCF-7 and HT1080 cells were seeded at 3.5 x 104 and 2.5 x 104 cells per well  in 48-
well plates (250 L of complete media) for 72 and 24 hours prior to transfection, 
respectively.  The cells were grown until 80% for MCF-7 and 60% confluency for 
HT1080, at 37C in a humidified, 5% CO2 incubator. The media was then removed and 
replaced with fresh media. The transfection of pEGFPLuc DNA was carried out using 
jetPEI. According to the manufacturer’s protocol, briefly, pDNA (0.5 g) and jetPEI 
(1 L) were diluted separately in NaCl buffer (150 mM, 25 L). jetPEI solution was 
added to pDNA solution, the mixture was vortexed, and incubated at room temperature 
for 30 min. The mixture (50 L) was then added to the wells and the cells were 
incubated at 37C in 5% CO2 atmosphere for 2 h. The media was removed and the 
cells were washed with PBS (2 x 250 L) before being used for siRNA knockdown 
experiment. 
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6.8.2 Optimisation of anti-luciferase siRNA concentrations for luciferase  
knockdown 
 
Non-PEGylated liposomes were prepared to encapsulate siRNA, anti-luciferase and 
negative siRNA, at 10, 20, 30, and 50 nM and 10, 20, 30, and 50 M (4:1 lipid: siRNA 
charge ratios). The mixtures were added to each well of the transfected cell lines, MCF-
7 and HT1080 in 6.8.1, (250 L of OptiMEM). MCF-7 cells were incubated for 6 h and 
HT1080 cells were incubated for 24 h at 37C in 5% CO2 atmosphere. The media was 
removed, the cells were washed with PBS (2 x 250 L) and fresh media was added 
(250 L). The cells were incubated for a further 36 h before analysis for luciferase 
activity.  
 
% luciferase knockdown = [1-(luciferase activityanti-luciferase siRNA/ luciferase activitynonspecific 
siRNA)] x 100 
 
6.8.3 Transient luciferase knockdown using anti-luciferase siRNA 
 
HLE experiment: Two sets of liposomes containing PEG2000-AAPV-lipid conjugate and 
control PEG2000-lipid conjugate were prepared to encapsulate siRNA, anti-luciferase 
siRNA and negative siRNA, at 4:1 lipid: siRNA charge ratios. HLE (10 L, 1.03 M) was 
added to the first set and incubated at room temperature for 10 min, while the other set 
contained no HLE. The mixtures were added to the wells of the transfected MCF-7 in 
6.8.1 (30 M siRNA per well, 250 L of complete media) and the plates were then 
incubated at 37C in 5% CO2 atmosphere for 6h.The media was then removed, the 
cells were washed with PBS (2 x 250 L) and the fresh media was added (250 L). The 
cells were incubated for a further 36 h before analysis for luciferase activity.  
 
MMP-2 experiment: The liposomes containing PEG2000-GPLGV-lipid conjugate and 
control PEG2000-lipid conjugate were prepared to encapsulate siRNA, anti-luciferase 
siRNA and negative siRNA, at 4:1 lipid: siRNA charge ratios. The mixtures were added 
to the wells of the transfected HT1080 in 6.8.1 (30 M siRNA per well, 250 L of 
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complete media) and incubated at 37C in 5% CO2 atmosphere for 24 h. The media 
was removed, the cells were washed with PBS (2 x 250 L) and the fresh media was 
added (250 L). The cells were incubated for a further 36 h before analysis for 
luciferase activity. 
 
6.9 In vitro siRNA knockdown of luciferase expression in stably transfected cell  
lines  
 
6.9.1 Preparation of stably transfected luciferase cell lines 
 
MCF-7 and HT1080 cells were seeded at 1.2 x 105 and 8 x 104 in 6-well plates (2 mL of 
complete growth media) for 72 and 24 hours prior to transfection, respectively.  The 
cells were grown until 80% confluency for MCF-7 and 60% confluency for HT1080, at 
37C in 5% CO2 atmosphere. The media was removed and replaced with fresh media. 
The transfection of pUbC-Luc-S/MAR DNA was carried out using jetPEI. Briefly, 
pDNA (3 g) and jetPEI (6 L) were diluted separately in NaCl buffer (150 mM, 100 
L). jetPEI solution was added to pDNA solution, vortexed, and incubated at room 
temperature for 30 min. The mixture (200 L) was added to the wells and incubated at 
37C in 5% CO2 atmosphere for 2 h. The media was removed, washed with PBS (2 x 2 
mL) and the fresh media was added (2 mL). The cells were incubated for a further 48 h. 
The media was removed and washed with with PBS (2 x 2 mL). The fresh media 
containing G418, a selection drug, (1 mg/mL) was added (2 mL) to each well and the 
plate was maintained at 37C in 5% CO2 atmosphere. The antibiotic-containing media 
should be replaced every 3-4 days. The drug-resistant colonies of MCF-7 appeared in 4 
weeks and for HT1080 the drug-resistant colonies appeared in 2 weeks, after 
transfection. The media was removed and washed with PBS (2 x 2 mL). The large end 
of pipette tip (1000 L) was snipped off, dipped into Vaseline and stuck around the 
colonies. Trypsin-EDTA (300 L) was added to detach the cells and the individual 
colonies were transferred into a new 6-well plate containing complete media. The cells 
were incubated at 37C in 5% CO2 atmosphere and the media were replaced every 3-4 
days. When confluency, the cells were trypsinized and transferred to a 75 mL tissue 
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culture flask containing complete media. The cell lines were analysed for luciferase 
expression before they were used for siRNA knockdown experiment. 
 
6.9.2. Luciferase knockdown in stably transfected cell line using anti-luciferase  
siRNA  
 
HLE experiment: MCF-7-luc was seeded in 48-well plates (3.5 x 104 cells per well, 250 
L of complete growth media) for 72 hours prior to transfection. The cells were grown 
until 80% confluency at 37C in 5% CO2 atmosphere. The media was then removed 
and replaced with fresh media.The luciferase knockdown using anti-luciferase siRNA 
was carried out as described in 6.8.3, HLE experiment section. 
 
MMP-2 experiment: HT1080-luc was seeded in in 48-well plates (2.5 x 104 cells per 
well, 250 L of complete media) for 24 h prior to transfection. The cells were grown until 
60% confluency at 37C in 5% CO2 atmosphere. The media was then removed and 
replaced with fresh media.The luciferase knockdown using anti-luciferase siRNA was 
carried out as described in 6.8.3, MMP-2 experiment section.
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